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ABSTRACT 
Plasmids confer genes encoding clinically relevant antibiotic resistance. It was hypothesised 
that the AcrAB-TolC multidrug resistance efflux pump was required for clinically relevant 
levels of carbapenem resistance. However, carbapenemase-producing Salmonella TolC 
mutants were less susceptible to carbapenems. In the presence of the efflux inhibitor phe-arg-
β-naphthylamide (PAβN), wildtype bacteria and 36/86 non-replicate clinical isolates of 
carbapenem-producing Enterobacteriaceae were ≥4-fold less susceptible to ertapenem. 
Experimental data suggested that OmpF repression conferred the increased carbapenem MICs. 
Two blaKPC-encoding plasmids have been isolated in the UK; pKpQIL-UK was found in K. 
pneumoniae, but its variant, pKpQIL-D2 was also found in other species. Therefore, it was 
hypothesised that a region of pKpQIL-D2 either conferred a broader plasmid host range 
and/or a fitness benefit to the host bacterium. Fitness studies measuring growth rates, ability 
to form biofilm, conjugation frequency and plasmid persistence showed that both plasmids 
affected the host bacterium but in different ways. Compared to pKpQIL-UK, pKpQIL-D2 did 
not confer a significant fitness advantage to its host under the conditions tested. RNA-
sequencing showed both plasmids affected a different set of genes related to metabolism. The 
understanding of the factor(s) contributing to the persistence and dissemination of successful 
plasmids may help to control antibiotic resistance. 
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CHAPTER ONE: INTRODUCTION 
1.1 Bacteria 
The earliest evidence for the existence of bacteria dates back to about 3.5 billion years 
(Schopf, 1993). Besides being ubiquitous, these microscopic organisms share an intimate 
relationship with humans.  Newly born infants are colonised with a normal flora within days 
of birth (Hall et al., 1990). The presence of a normal flora has been suggested to benefit the 
host in many ways, such as modulation of host gene expression important in intestinal 
functions (Hooper et al., 2002), provision of vitamins (Hill, 1997), absorption of minerals 
(Younes et al., 2001), intestinal epithelial cell differentiation (Gordon et al., 1997), 
development of the immune system (Umesaki et al., 1993) and preventing colonisation of the 
host by harmful bacteria (Bernet et al., 1994). Although many bacteria benefit their hosts, 
there are also others which cause diseases. 
 Bacteria can be broadly differentiated into two groups based on the way they are 
coloured by Gram’s stain i.e. Gram-positive and -negative bacteria (Moyes et al., 2009). As a 
result of differences in the cell wall of bacteria, Gram-positive bacteria are stained purple 
while Gram-negative bacteria will be stained pink (Moyes et al., 2009). The Gram-positive 
bacterium has a thicker, multi-layered peptidoglycan cell wall (Figure 1.1a). In comparison, a 
Gram-negative bacterium has a thinner, mostly single-layered peptidoglycan cell wall (Figure 
1.1b) (Cabeen and Jacobs-Wagner, 2005). The Gram-negative bacterium also carries an outer 
membrane which is lacking among Gram-positive bacteria (Cabeen and Jacobs-Wagner, 
2005).  
The Enterobacteriaceae family consists of Gram-negative rod shaped bacteria and 
includes Klebsiella pneumoniae, Escherichia coli and Salmonella enterica. Many of these 
bacteria are commonly found as normal flora in human intestine and are capable of being 
2 
 
 
 
  
  
(b) 
Thin 
peptidoglycan 
cell wall 
  
Cytoplasmic 
membrane 
  
Outer 
membrane 
  
Periplasmic 
space 
Porin 
 
Efflux pump 
β-lactamase
Thick 
peptidoglycan 
cell wall 
(a) 
  
Cytoplasmic 
membrane 
 
 
 
Teichoic acid
Figure 1.1 Differences between Gram-positive and Gram-negative bacteria cell 
wall 
(a) The cell wall of a Gram-positive bacterium is made up of multiple layer of 
peptidoglycan polymer. Teichoic acids are found embedded in the cell wall to increase its 
rigidity. (b) Gram-negative bacterium possesses a thinner peptidoglycan in the space 
between the outer membrane and cytoplasmic membrane called the periplasmic space. 
The porin in the outer membrane acts as a non-specific channel for passive exchange of 
solutes between the extracellular environments with the bacterial cell. The efflux pump 
functions to extrude compounds in the cell to the external environment. β-lactamase 
enzymes inactivate β-lactam antibiotics allowing the bacterium to be resistant to the 
antibiotic. 
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opportunistic pathogen which cause nosocomial- and community-acquired infections 
(Nordmann et al., 2012a, Hurrell et al., 2009). Opportunistic pathogen refers to organisms 
which are living within a host (e.g. human) or originate from the environment and which are 
able to cause diseases upon successfully infecting their host (Brown et al., 2012). 
Among the more notable of the bacteria which cause mortality and morbidity in both 
the clinical and community settings include E. coli, K. pneumoniae, Enterobacter spp. and 
Proteus spp. (Boucher et al., 2009, ECDC, 2013a). Being ubiquitous among humans and 
vertebrates, E. coli and K. pneumoniae are also the leading causative agents of urinary, 
respiratory and bloodstream infections worldwide (WHO, 2014). Salmonella is the leading 
cause of food borne outbreaks and the most frequent cause of enteric infection after 
Campylobacter in the EU (ECDC, 2015). In Europe, it was reported that about 3.2 million 
patients have at least one healthcare-associated infection annually (ECDC, 2013a). These 
include respiratory tract infections, surgical site infections, urinary tract infections and 
bacteraemia (ECDC, 2013a). The need to treat infection caused by pathogenic bacteria has 
driven medical research that has resulted in the discovery and development of various 
antibacterial compounds.  
1.1.1 Salmonella Typhimurium as a Model Organism 
Salmonella Typhimurium is a motile rod shaped Gram-negative bacterium and a member of 
the Enterobacteriaceae family. This facultative anaerobic bacterium is an important cause of 
food-borne diarrhoeal diseases (Fàbrega and Vila, 2013). Phylogenetic analyses using various 
genetic markers such as 16S RNA, rpoB and initiation factor 2, have shown that members of 
the Enterobacteriaceae family share high genetic similarities (Drancourt et al., 2001, 
Hedegaard et al., 1999, Moran et al., 2005, Roggenkamp, 2007). These analyses have also 
shown close phylogenetic relationship between E. coli and S. Typhimurium (Hedegaard et al., 
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1999, Roggenkamp, 2007). About 72% of the genes in S. Typhimurium are homologous to 
that found in E. coli and K. pneumoniae, and these protein share on average, about 89% 
sequence identity (McClelland et al., 2001). Being the most studied laboratory organism for 
decades, E. coli has been the reference and model organism for studying various biochemical 
pathways and biological processes in other organisms (Keseler et al., 2005, Holden, 2002, 
Salgado et al., 2004). Although widely studied, there is a lack of suitable infection model 
available for this bacterium (Allen et al., 2006, Savkovic et al., 2005, Zhang et al., 2008). 
Similar to E. coli, S. Typhimurium is a highly tractable organism which has simple nutritional 
requirements, rapid growth rates and it is easy to genetically manipulate this bacterium (Garai 
et al., 2012). Due to the availability of various in vitro and in vivo infection models, S. 
Typhimurium is also an ideal model organism especially in studying host-pathogen 
interactions and bacterial pathogenesis (Garai et al., 2012).  
1.2 β-lactam Antibiotics 
One of the first antimicrobials to be discovered was penicillin in the late 1920s, which was 
found to exhibit a potent antibacterial effect (Fleming, 1929). For the next few decades, a 
range of novel antibacterial compounds of different classes were discovered, such as 
streptomycin, tetracycline, chloramphenicol, neomycin, gentamicin, erythromycin, 
vancomycin and rifampicin (Hopwood et al., 2007). The term ‘antibiotic’, which means 
‘against life’ was coined by Salman Waksman no less than a decade after the discovery of 
penicillin to describe substances produced by microorganisms which possess growth 
inhibitory effect on other microorganisms (Waksman, 1973). At present, the definition of 
‘antibiotic’ has been expanded to include semi- and fully-synthetic antibacterial agents, and is 
generally used to refer to compounds used clinically to treat human infections. This 
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distinguishes antibiotics from biocides which are antimicrobial but not suitable for systemic 
use in humans (Yoneyama and Katsumata, 2006).  
In 2009, antibiotics sales generated an estimated revenue of USD 42 billion globally 
(Hamad, 2010). Although there are a plethora of antibiotic classes being marketed, the β-
lactam antibiotics are the largest class of antibiotic being manufactured and has the highest 
share in terms of sales, as they are widely used to treat Gram-positive and -negative bacterial 
infections (ECDC, 2013a, Hamad, 2010, Kresse et al., 2007, Woo et al., 2003). In most 
European countries, β-lactam antibiotics comprised of more than 50% of the antibiotics 
prescribed in the community and hospital settings (Figure 1.2) (ECDC, 2013a). 
 The β-lactam class of antibiotics encompasses several sub-classes such as penicillins 
(Fleming, 1929), cephalosporins (Burton and Abraham, 1951), clavams (Brown et al., 1976), 
carbapenems (Kahan et al., 1979) and monocyclic β-lactams (also known as monobactams 
(Aoki et al., 1976). These antibiotics are produced by fungi and prokaryotes, e.g. Penicillium 
spp., Aspergillus nidulans, Cephalosporium spp. and Streptomyces spp. (Demain and Elander, 
1999). A common chemical structure i.e. the four-membered lactam ring, also termed β-
lactam ring is shared among the sub-classes and plays an essential role in this antibacterial 
activity (Figure 1.3) (Demain and Elander, 1999, Donetz et al., 1984). Modification of 
chemical groups attached to the lactam ring results in changes in the antibacterial activity and 
stability of the antibiotic against inactivating enzymes as well as pharmacological properties 
(Yoshida, 1980, Chantot et al., 1992, Nayler, 1971). 
Due to their high clinical efficacy and low toxicity, β-lactam antibiotics play a major 
role in both clinical and veterinary medicine (Hornish and Kotarski, 2002, Timmerman et al., 
2006). Therefore, β-lactam antibiotics are often the first choice for treating bacterial infections 
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Antibiotic usage in the (a) hospital and (b) community setting, according to individual 
European countries [Source: ECDC (2013)]. ‘DDD’ refers to the ‘defined daily dose’ 
of an antibiotic. 
Figure 1.2 Distribution of antibiotic usage in Europe 
(a) 
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Figure 1.3 Structures of β-lactam antibiotics 
Core structure of (a) penicillin, (b) cephalosporin and (c) carbapenem. R is the side chain 
which differs among the individual members of the sub-class of the β-lactam antibiotics 
[Source: Demain & Elander (1999) and Hamilton-Miller & Brumfitt (1974)]. 
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and are the most widely prescribed antibiotics in hospitals (Jovetic et al., 2010, Nicolau, 2008, 
Plüss-Suard et al., 2011, Liew et al., 2011). Broad-spectrum penicillins and cephalosporins 
are also used for growth promotion, disease and prophylactic treatments for animals, although 
this is country dependent (Timmerman et al., 2006, Phillips et al., 2004, Graham et al., 2007, 
Paphitou, 2013).  
1.2.1 Mechanism of Action of β-lactams  
All Gram-positive and -negative bacterial cells are separated from their surroundings by a cell 
wall made up of peptidoglycan which is important for preventing the cell from lysis due to the 
higher internal osmotic pressure of the cell relative to the external environment (Scheffers and 
Pinho, 2005). Peptidoglycans are made up of glycan chains which consist of N-
acetylglucosamine (GlcNAc) and N-acetylmuramic acid (MurNAc) subunits. Through 
transglycosylation reaction, these subunits are joined together by β-1,4-glycosidic bonds to 
form long polymer chains (Figure 1.4a) (Holtje, 1998). Peptide cross-links are formed 
between the glycan polymers through a reaction called transpeptidation, this allows the 
formation of a three dimensional structure that gives rise to the bacterial cell wall (Figure 1.4b) 
(Holtje, 1998, Scheffers and Pinho, 2005).  
Both the transglycosylation and transpeptidation reactions are required for the 
development of the peptidoglycan cell wall. The reactions are catalysed by transglycosylase 
and transpeptidase enzymes (Scheffers and Pinho, 2005). Such enzymatic activities can be 
found on a group of proteins called penicillin-binding proteins (PBPs), identified for their 
binding affinity towards penicillin, from which they have been given the name (Blumberg and 
Strominger, 1974). The types of PBPs found in a particular bacterial cell vary across species 
(Georgopapadakou, 1993). Some PBPs, such as PBP2 and PBP3 are monofunctional, hence 
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(a) The peptidoglycan cell wall of bacteria is made up of glycan polymers which 
consist of N-acetylglucosamine (GlcNAc) and N-acetylmuramic acid (MurNAc) 
monomers linked together by β-1,4-glycosidic bonds through a process called 
transglycosylation. The glycan polymers are arranged in a three-dimensional structure 
via the peptide cross-links. (b) The cross-linking of the glycan chains occurs via 
transpeptidation catalysed by penicillin-binding proteins which forms the peptide 
cross-link between the peptide side chains of the GlcNAc and MurNAc monomers. 
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they are only capable of catalysing the transpeptidation reaction (Ghuysen, 1997, Goffin et al., 
1996), whereas PBP1A and PBP1B are bifunctional, acting both as a transpeptidase and 
transglycosylase (Ishino et al., 1980, Nakagawa et al., 1979). 
The PBPs’ important role in maintaining cell integrity has been shown in many studies 
(Nelson and Young, 2000, Spratt, 1975, Wei et al., 2003). As the name of these enzymes 
suggest, they are the targets of β-lactam antibiotics. The antibiotic inhibits the 
transpeptidation step of bacterial cell wall synthesis (Tipper and Stroming, 1965). Naturally, 
the peptide stem of two peptidoglycan monomer would undergo transpeptidation to form the 
peptide cross-link. But in the presence of β-lactam antibiotics, the compound act as 
competitive substrates for the PBPs. During transpeptidation, the antibiotics are covalently 
linked to the PBPs and render the transpeptidase enzyme inactive (Tipper and Stroming, 1965, 
Holtje, 1998). These antibiotics have been shown to affect cell growth via binding to PBPs 
which may lead to cell death (Lleo et al., 1987, Tuomanen et al., 1986).  
1.2.2 Carbapenems 
All β-lactam antibiotics share a similar mechanism of action by inhibiting bacterial cell wall 
biosynthesis. However, among all the β-lactam antibiotics, carbapenems are known to have a 
better efficacy against a broader spectrum of bacteria. The United States Food and Drug 
Administration (FDA) approved carbapenems are imipenem, meropenem, ertapenem and 
doripenem, with the latter being the newest member to this sub-class of β-lactam antibiotics 
(Hilas et al., 2008).  
 Unlike most other β-lactam antibiotics for which their antibacterial activities are 
restricted by bacterial growth rate, carbapenem killing activity is growth-independent (Cozens 
et al., 1989, Eng et al., 1991). Carbapenems also outrank other β-lactam antibiotics in terms of 
bacterial cell penetration and stability against most β-lactamases (Franceschini et al., 2002, 
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Iaconis et al., 1997, Yang et al., 1995). Carbapenems also retain antibacterial activity against 
various genera of bacteria producing a range of extended-spectrum β-lactamases (Schwaber et 
al., 2005). Due to its low toxicity, high efficacy and ultra-broad spectrum activity against 
many Gram-positive, -negative and anaerobic bacteria, carbapenems are often regarded as the 
last line of defence we have for severe bacterial infections (Papp-Wallace et al., 2011). Hence, 
these antibiotics are not easily prescribed to patients to avoid the selective pressure on 
carbapenem resistant bacteria (Fong et al., 2012, Mohr, 2008). However, when an infection is 
caused by extended-spectrum β-lactamase (ESBL) producing bacteria, carbapenems are often 
the first line of treatment options employed (Colardyn, 2005, Moellering et al., 1989, Mohr, 
2008, Hawkey and Livermore, 2012).  
Carbapenems mainly differ from each other in the side chains they have. Compared to 
other β-lactam antibiotics (Figure 1.3), all carbapenems have a unique hydroxyethyl group 
(Figure 1.5; Orange circle) which provides better stability against β-lactamases (Hammond, 
2004). Meropenem and ertapenem possess a C1 methyl group which confers stability to renal 
dehydropeptidase (DHP-I) (Figure 1.5a & c; Red circles) (Drusano, 1997, Blumer, 1997, 
Musson et al., 2003). The lack of this methyl group causes imipenem to be easily degraded by 
this enzyme (Figure 1.5b). Hence, imipenem is prescribed with cilastatin (DHP-I inhibitor) 
(Blumer, 1997). The presence of the C2 moiety confers meropenem with enhanced activity 
against Enterobacteriaceae, including P. aeruginosa (Figure 1.5a; Blue circle). The side chain 
in this position also results in the difference in activity between meropenem and imipenem 
where the latter is more active against Staphylococcus spp. (Drusano, 1997). The benzoate 
side chain in ertapenem (Figure 1.5c; Green circle) increases its protein binding ability which 
leads to a longer half life (4 hours) when compared to meropenem (1 hour) and imipenem (1 
hour) (Hammond, 2004). 
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Figure 1.5 Structures of carbapenem antibiotics 
Structure of (a) meropenem, (b) imipenem and (c) ertapenem. Unlike other β-lactam 
antibiotics, carbapenems have a unique hydroxyethyl group which allows better stability 
against β-lactamases (Orange circle). The methyl group (Red circle) in meropenem and 
ertapenem confers stability to renal dehydropeptidase-I. The C2 moiety (Blue circle) in 
meropenem confers enhanced activity against Gram-negative bacteria, including P. 
aeruginosa. The benzoate group in ertapenem (Green circle) confers ertapenem with a 
longer half life [Source: Demain & Elander (1999) and Hamilton-Miller & Brumfitt 
(1974)]. 
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1.3 Antibiotic Resistance 
The introduction of antibiotics into clinical therapy has successfully reduced the mortality rate 
associated to bacterial infections (IDSA, 2011). Antibiotic resistance is an evolutionary 
process of bacteria to overcome the inhibitory effects of antibiotics since their introduction 
into clinical therapy. This was supported by a study showing most clinical isolates collected 
from various continents before the antibiotic era were antibiotic susceptible (Hughes and 
Datta, 1983). However, a more recent study has provided evidence of antibiotic resistance 
existing long before the history of mankind when β-lactam, glycopeptides and tetracycline 
resistance genes were identified in 30,000-year old Beringian permafrost sediment (D'Costa et 
al., 2011). Since its introduction, the therapeutic effects of antibiotics have been countered by 
the emergence and expansion of antibiotic resistant bacteria (Hopwood et al., 2007).  
 Unlike the number of methicillin-resistant Staphylococcus aureus (MRSA) which is 
stabilising or showing downward trends in the EU, the reports of multidrug-resistant K. 
pneumoniae and E. coli have been increasing in one third of the EU countries (ECDC, 2013a). 
Non-susceptibility (i.e. intermediate and resistant) to third-generation cephalosporins and 
carbapenem in Enterobacteriaceae was reported to be 33.4% and 7.6%, respectively. In both 
cases, K. pneumoniae showed the highest percentage of non-susceptibility among the isolates 
tested (ECDC, 2013a). In 2014, the World Health Organisation (WHO) reported the detection 
of third generation cephalosporin resistant E. coli in 86 (44%) of its Member States. Similarly, 
resistance to third generation cephalosporin and carbapenem in K. pneumoniae was reported 
in 87 (45%) and 71 (37%) of WHO Member States, respectively (WHO, 2014). In these data, 
the countries which were included in the figures were only considered to have significant 
antibiotic resistant bacteria when studies were available showing more than 30% of the tested 
isolates were resistant. This depicts the dire situation where the standard intravenous 
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treatments with cephalosporins have been rendered ineffective and the last line therapy with 
carbapenem is also being threatened (WHO, 2014).  
1.3.1 Burden of Antibiotic Resistance  
With infectious disease being one of the leading causes of death around the world, the 
presence of antibiotic resistant bacteria further increases the burden of infectious diseases. In 
2007, 25,000 deaths per year in the European Union (EU) were estimated to be due to 
infections caused by antibiotic resistant bacteria (ECDC and EMEA, 2009). Of note, about 
67 % of this value is due to infection with Gram-negative bacteria. As only five antibiotic 
resistant bacteria, i.e. methicillin-resistant S. aureus (MRSA), vancomycin-resistant 
Enterococcus faecium, carbapenem-resistant Pseudomonas aeruginosa, third-generation 
cephalosporin resistant E. coli and K. pneumoniae, were taken into account in the survey, the 
total number of deaths by antibiotic resistant bacteria is underestimated. In the same report, 
the estimated financial cost related to infections caused by the antibiotic resistant bacteria 
amounted to EUR 1.5 billion annually. The cost included outpatient care cost (~EUR 10 
million/annum), productivity losses due to absence of work (~EUR 150 million/annum), and 
productivity losses due to deaths (~EUR 450 million/annum). The infections were also 
associated with an extra 2.5 million days of hospitalisation. 
 In the US, the medical cost of a single patient infected with an antibiotic-resistant 
bacterial infection in a Chicago teaching hospital was estimated to be between USD 18,588 to 
USD 29,069 in 2000 (Roberts et al., 2009). The studies also estimated the mortality rate 
associated with antibiotic resistant infections to be 6.5% and the societal cost to be between 
USD 10.7 to 15.0 million per annum. Patients with antibiotic-resistant infections also had 
between 6.4 to 12.7 excess days of hospitalisation per annum. Extrapolation of these data 
indicates the excess healthcare and societal cost associated with antibiotic-resistant infections 
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in the US to be approximately USD 20 billion and USD 35 billion per annum, respectively, 
with an excess of 8 million hospitalisation days per annum (Bush et al., 2011). Every year, 
there are approximately 2 million healthcare-associated infections with a majority of the 
infections contributed by antibiotic-resistant bacteria and resulting in almost 99,000 deaths in 
the US (Klevens et al., 2007). 
 In 2006, a national survey showed 300,000 of the infections reported in the United 
Kingdom (UK) annually were healthcare-associated infections and the cost for the treatment 
of the patients amounted to over GBP 1 billion per annum (NAO, 2009). The estimated 
number of excess deaths attributed to MRSA and third-generation cephalosporin resistant E. 
coli in the UK was 1,600 cases in the 2007 (de Kraker et al., 2011). In the same study, the 
excess number of days of hospitalisation and excess cost due to these antibiotic-resistant 
bacteria were approximately 73,000 days and EUR 17 million (de Kraker et al., 2011). 
 With these data combined, it can be seen that antibiotic-resistant bacteria cause a 
significant burden to the society. Moreover, studies have shown association of higher death 
rates with infections caused by antibiotic-resistant bacteria in certain clinical situations such 
as bloodstream infection and infection during liver transplant (Esterly et al., 2012, Kalpoe et 
al., 2012). In particular, carbapenem-resistant Enterobacteriaceae associated infections have 
been shown to cause significantly higher mortality compared to infections caused by the 
corresponding susceptible species (Falagas et al., 2014). If the antibiotic resistance 
phenomenon is left unchecked, it is estimated that by 2050, there will be about 10 million 
deaths per annum associated to antibiotic resistant infections (O'Neill, 2014). 
1.3.2 Antibiotic Resistance Mechanisms 
Bacteria employ a myriad of mechanisms to survive the stresses imposed by the presence of 
antibiotics (Fisher et al., 2005). As the target of all β-lactam antibiotics is essentially the PBPs 
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involved in cell wall synthesis (Blumberg and Strominger, 1974), alteration of the target 
proteins resulting in lower affinity towards the antibiotics can confer the host cell with 
resistance to the antibiotics. This has been reported in various bacteria such as Neisseria 
gonorrhoeae (Ropp et al., 2002), Neisseria meningitidis (Antignac et al., 2001) and 
Haemophilus influenzae (Matic et al., 2003). 
 In addition to the cytoplasmic membrane and peptidoglycan cell wall that Gram-
positive bacteria have, Gram-negative bacteria also possess an outer membrane which is 
impermeable to hydrophobic compounds (Nikaido, 2003). Hence, Gram-negative bacteria 
possess hydrophilic protein channels also called porins which allow non-specific exchange of 
small hydrophilic solutes such as glucose, sucrose, amino acids and some antimicrobial 
compounds across the outer membrane (Lugtenberg and Van Alphen, 1983, Yoshimura and 
Nikaido, 1985). The major porins found in Gram-negative bacteria are from the outer 
membrane protein F (OmpF) and OmpC families (Pages et al., 2008). These porins are non-
specific to the solutes which pass through them. However, they are more efficient in allowing 
the diffusion of cation compounds (Nikaido and Rosenberg, 1983). Both porins can be 
transcriptionally and post-transcriptionally regulated in response to external signals which 
include medium osmolarity, pH, nutrient limitation and temperature (Nikaido, 2003, Pages et 
al., 2008). In general, OmpF has a larger pore size compared to OmpC (Nikaido and 
Rosenberg, 1983). In E. coli, the pore sizes of OmpF and OmpC are 1.2 nm and 1.1 nm, 
respectively (Pratt et al., 1996). Hence the repression of OmpF and the increase expression of 
OmpC will impair the influx of larger solutes across the bacterial outer membrane (Nikaido 
and Rosenberg, 1983). 
Two major types of porins i.e. OmpK35 (OmpF homologue) and OmpK36 (OmpC 
homologue) are found in K. pneumoniae (Albertí et al., 1995, Hernandez-Alles et al., 1995). 
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The artificial expression of OmpK35 porin in an antibiotic-resistant K. pneumoniae strain 
lacking both of the major porins was shown to reduce the minimum inhibitory concentration 
(MIC) values of carbapenems, fluoroquinolones, second-, third- and fourth-generation 
cephalosporins (Domenech-Sanchez et al., 2003). The expression of OmpK36 in the same 
study also resulted in a decrease in the MIC values of a range of antibiotics tested but to a 
lesser extent when compared to the effects of OmpK35 expression. As most non-ESBL 
producing strains of K. pneumoniae express both of the major porins whereas the ESBL 
producing strains of this bacterium only expresses the OmpK36 porin, the possibility of an 
interplay between the expression of ESBL and the selective loss of porin expression to result 
in an increase in antibiotic resistance of the bacteria cannot be excluded (Hernandez-Alles et 
al., 1999, Martínez-Martínez et al., 2002). 
 The sub-inhibitory intracellular concentrations of antibiotics resulting from the 
restricted entry of antibiotics imposed by down-regulation of porin expression can also be 
achieved by the up-regulation of efflux pumps (Nikaido, 2001). Efflux pumps can be 
categorised into five families, i.e. major facilitator superfamily (MFS) (Marger and Saier Jr, 
1993), adenosine triphosphate (ATP)-binding cassette (ABC) superfamily (Schneider and 
Hunke, 1998), small multidrug resistant (SMR) family (Paulsen et al., 1996), resistance-
nodulation-cell division (RND) superfamily (Saier et al., 1994), and multidrug and toxic 
compound extrusion (MATE) family (Brown et al., 1999). Efflux is an active process which 
utilises energy in the form of ion or proton gradient or ATP for active transportation of 
compounds across the cell barrier (Kumar and Schweizer, 2005). 
 Amongst the best characterised efflux pumps are the AcrAB-TolC system of E. coli 
and the MexAB-OprM system of P. aeruginosa (Nikaido, 1998, Poole, 2000). Both are 
pumps of the RND superfamily and they are comprised of a tripartite system which includes 
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an inner membrane transporter protein (AcrB and MexB), efflux adaptor protein (AcrA and 
MexA) and the outer membrane protein (TolC and OprM) spanning both the inner and the 
outer membrane of Gram-negative bacteria (Symmons et al., 2009). Through kinetic studies, 
the E. coli AcrAB-TolC has been shown to have a high efflux capacity for penicillins (Lim 
and Nikaido, 2010). This tripartite pump system has been found to be a major efflux system 
among members of the Gram-negative Enterobacteriaceae (Poole, 2005). Other studies in K. 
pneumoniae and S. Typhimurium have also implicated this efflux system with resistance to β-
lactam antibiotics (Nikaido et al., 1998, Pages et al., 2009).  
 Among the 12 predicted RND efflux systems on the genome of P. aeruginosa, a 
clinically important nosocomial bacterium, MexAB-OprM is the efflux system which has 
been studied most extensively (Stover et al., 2000, Gillis et al., 2005). The MexAB-OprM 
efflux pump has been associated with carbapenem resistance in one study where clinical 
isolates with the loss of OprD porin expression showed increased resistance to meropenem 
(Pai et al., 2001). The porin has been shown to act as a channel allowing diffusion of 
carbapenem across the cell barrier of P. aeruginosa (Wolter et al., 2004). However, another 
study found no correlation between OprD or MexAB-OprM expression and carbapenem 
resistance (El Amin et al., 2005).  
 Shortly after the introduction of penicillin into clinical use, the first β-lactamase 
enzyme, termed penicillinase was isolated (Abraham and Chain, 1940). The β-lactamase 
enzymes are one of the major mechanisms of resistance in Gram-negative bacteria and have 
been classified into four classes on the basis of protein sequence (Ambler Class A to D) and 
by their substrate and inhibitor profile (Group 1 to 3) (Bush et al., 1995, Ambler, 1980). The 
enzymes of clinical relevance can be generally differentiated into ESBLs, AmpC β-lactamases 
and carbapenemases. Although there is no specific definition of an ESBL, it is normally a β-
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lactamase which can hydrolyse penicillins, cephalosporins (first-, second- and third-
generations), and aztreonam; but is susceptible to β-lactamase inhibitors (Paterson and 
Bonomo, 2005). The ESBL-producing Gram-negative bacteria are becoming increasingly 
prevalent worldwide, albeit showing different antibiotic susceptibility depending on 
geographical locations (Reinert et al., 2007, Nijssen et al., 2004, Kallen et al., 2011). As 
ESBLs show no significant activity against carbapenems (Paterson and Bonomo, 2005), these 
antibiotics are often the preferred choice of therapy for ESBL-producing Gram-negative 
bacterial infections (Rupp and Fey, 2003). AmpC β-lactamases have similar activities to 
ESBLs but are resistant to inhibitors such as clavulanic acid (Bush et al., 1995). Lastly, the 
carbapenemases consist of various enzymes which are mostly resilient to β-lactamase 
inhibitors and possess varying hydrolytic ability against all β-lactam antibiotics including 
carbapenems (Queenan and Bush, 2007, Thomson, 2010).  
 Although each mechanism can individually confer resistance to β-lactam antibiotics, 
bacteria sometimes employ a combination of these mechanisms to achieve extremely high 
level of resistance to the antimicrobial compound, such as the mutations in PBP3 and elevated 
expression of AcrAB efflux pump in H. influenzae (Kaczmarek et al., 2004). Similarly, the 
production of β-lactamases (e.g. CTX-M-15) and deficiencies in porins (OmpK35 and 
OmpK36) confer high carbapenem resistance in K. pneumoniae (Jacoby et al., 2004, Poulou 
et al., 2013, Ruiz et al., 2012), and over-expression of MexAB-OprM efflux pump in the 
absence of OprD porin confers P. aeruginosa with carbapenem resistance (Pai et al., 2001).  
1.3.3 Carbapenemase-mediated Antibiotic Resistance 
Infectious disease is one of the leading causes of death worldwide, with pneumonia and 
diarrhoeal disease as the main global causes of deaths (WHO, 2011). The efforts in place to 
overcome infectious disease have been hampered by the worldwide emergence of antibiotic 
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resistant bacteria (Arias and Murray, 2009). Few antibiotics remain active for the treatment of 
severe and life-threatening infections by Gram-negative bacteria (Spellberg et al., 2004, 
Piddock, Gould, 2008). The increase in numbers of antibiotic resistant Gram-negative bacteria 
has been further exacerbated with the lack of new efficacious agents in the pipeline (Piddock, 
2012). 
 Gram-negative bacteria are associated with the major types of infections, i.e. 
pneumonia and urinary tract infection (Gaynes et al., 2005, Hidron et al., 2008). The number 
of antibiotic resistant Gram-negative bacteria such as E. coli has increased in European 
countries (Gagliotti et al., 2011) and elsewhere e.g. Taiwan (Chuang et al., 2010). Among the 
commonest Gram-negative bacteria causing infections are E. coli, K. pneumoniae, 
Enterobacter spp., Serratia marcescens, P. aeruginosa and Acinetobacter spp. (Gaynes et al., 
2005, Chuang et al., 2010). Although Enterobacter cloacae and S. marcescens associated 
infections occur less frequently as compared to E. coli and K. pneumoniae, but E. cloacae is 
able to cause a wide range of infections (including bacteraemia, endocarditis, septic arthritis, 
etc.) while S. marcescens is associated with sepsis, meningitis and lung inflammation in 
neonates that can be fatal (ECDC, 2013b, Pages and Davin, 2015, Polilli et al., 2011). The 
spread and persistence of ESBL-producing bacteria has driven more usage of carbapenems in 
treatment, but the emergence of carbapenemase-producing bacteria has threatened these ‘last-
line’ defence agents in clinical therapy against bacterial infections.  
Carbapenemases are categorised into Class A, B and D following the Ambler class 
system (Jean et al., 2015). Class A and D carbapenemases possess a serine residue in their 
active site while Class B requires a divalent ion for it to hydrolyse β-lactam antibiotics (Jean 
et al., 2015).  The members of the Class A carbapenemase include K. pneumoniae 
carbapenemase (KPC), Guiana extended spectrum enzyme (GES), not metalloenzyme 
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carbapenemase (NMC), imipenem-hydrolysing β-lactamase (IMI) and S. marcescens enzyme 
(SME). Class B metallo-β-lactamase is consists of imipenemase (IMP), Verona integron-
encoded metallo-β-lactamase (VIM), German imipenemase (GIM), Sao Paulo metallo-β-
lactamase (SPM), Seoul imipenemase (SIM) and New Delhi metallo-β-lactamase (NDM). 
The Class D carbapenemases are mainly oxacillinases (OXA-23-like, OXA-24-like, OXA-48-
like and OXA-58-like) (Jean et al., 2015). The classes of carbapenemases vary in their 
spectrum of activity on β-lactam antibiotics. Class A carbapenemases can hydrolyse all sub-
classes of β-lactam antibiotics but are susceptible to β-lactamase inhibitors. The Class B 
metallo-β-lactamases are only susceptible to aztreonam while Class D carbapenemases can 
hydrolyse all β-lactam antibiotics but they have weak hydrolytic activity on cephalosporins 
and carbapenems (Nordmann, 2014). Carbapenemases which are closely associated with 
mobile elements (such as plasmids) are able to spread widely across various countries and 
cause serious hospital outbreaks (Jean et al., 2015, Nordmann, 2014). Two carbapenemase 
enzymes of current clinical concern are the KPC and NDM enzymes (Yigit et al., 2001, Yong 
et al., 2009).  
 The KPC enzyme was first discovered in 1996 in a K. pneumoniae isolated from a 
hospital in North Carolina (Yigit et al., 2001). The ca. 32 kDa enzyme is encoded by an 879 
bp coding region, blaKPC-2 (originally called blaKPC-1) (Yigit et al., 2008) and confers 
resistance to penicillin, cephalosporin, carbapenem and monobactam antibiotics. The 
hydrolytic activity of KPC-2 is not influenced by ethylenediaminetetraacetic acid (EDTA) or 
zinc (II) chloride (ZnCl2), but is inhibited by clavulanic acid. Amino acid sequence homology 
and the presence of known or suggested catalytic residues places the KPC-2 enzyme as a 
member of the Class A family of β-lactamases. Among all the antibiotics tested, this enzyme 
had the highest activity against meropenem (Yigit et al., 2001).  
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 Currently, there are 22 variants of KPC enzymes (www.lahey.org). In contrast to the 
first discovered KPC enzyme, most KPC enzymes identified recently are associated with 
conjugative plasmids (Moland et al., 2003, Naas et al., 2005, Woodford et al., 2004, Yigit et 
al., 2001). This carbapenemase has developed to become the most common carbapenemase in 
the US (Gupta et al., 2011). Although the geographical location of K. pneumoniae-producing 
KPC enzymes was initially in the US, these bacteria are now found around the world 
(Bradford et al., 2004, Naas et al., 2005, Leavitt et al., 2007). The enzyme is also found in 
other species of Gram-negative bacteria, such as E. coli (Morris et al., 2011), Salmonella spp. 
(Miriagou et al., 2003, Rodríguez et al., 2014), S. marcescens (Cai et al., 2008), Pseudomonas 
putida (Bennett et al., 2009), Citrobacter freundii (Rosa Gomez-Gil et al., 2010) and E. 
cloacae (Zavascki et al., 2009). The blaKPC gene is located within a ca. 10 kb Tn4401 
transposon (Gootz et al., 2009). At least seven isoforms (a – f; 2 variants of isoform ‘d’) have 
been reported (Bryant et al., 2013). These isoforms contain varying length of deletions 
upstream of blaKPC which affect the expression of the carbapenemase gene (Bryant et al., 
2013, Seecoomar et al., 2013). This blaKPC carrying transposon is known to be mobile and 
have been found in various plasmid backbones contributing to the dissemination of this 
carbapenemase gene among Gram-negative bacteria (Partridge, 2014).  
 A more recently identified carbapenemase is the NDM enzyme which was first 
identified in K. pneumoniae isolated from the urine of an Indian patient in 2008 (Yong et al., 
2009). The enzyme, designated as NDM-1 is encoded by a gene of 807 bp, producing a 
protein of 269 amino acids with a molecular mass of ca. 27.5 kDa. The 180 kb plasmid 
carrying the blaNDM-1 gene in this patient, named pNDM-1 was shown to be conjugative. 
Interestingly, a carbapenem resistant E. coli was also isolated from the faecal sample of the 
patient, carrying a smaller, 140 kb plasmid which also harbours the blaNDM-1 gene. This led 
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the authors to suggest the possibility of in vivo conjugation and arrangement of the plasmid 
between the species resulting in two different plasmid sizes. The transfer of the pNDM-1 
plasmid to E. coli J53 via in vitro conjugation conferred the recipient cell with resistance to 
penicillins, monobactam, carbapenems, first-, second-, third- and fourth-generation 
cephalosporins (Yong et al., 2009). Since the discovery of the NDM-1 enzyme, 15 other 
variants have been identified (www.lahey.org). Over a short period of time since its discovery, 
this enzyme and its variants have been isolated in various species of bacteria in countries such 
as Kenya (Poirel et al., 2011), Australia (Poirel et al., 2010), China (Chen et al., 2011), Japan 
(Yamamoto et al., 2011), Norway (Samuelsen et al., 2011), Belgium (Bogaerts et al., 2011), 
UK (Jain et al., 2014) and the USA (CDC, 2010). 
The emergence of antibiotic resistant bacteria has been further compounded by the 
isolation and possible zoonotic transmission of these bacteria from companion animals (CDC, 
2001, Shaheen et al., 2011). Advances in aviation industry contributing to increase 
international travel and the distribution of food have also played against the human race by 
facilitating rapid dissemination of multidrug-resistant bacteria (Kenyon et al., 1996, Fey et al., 
2000, Hawkey, 2015). Poor hygiene practices observed in healthcare services may further 
encourage the spread of such bacteria (Pittet et al., 1999).  
1.3.4 Antibiotic Resistance Which Requires AcrAB-TolC 
Although target alterations have been known to generate antibiotic resistant strains of bacteria 
(Lambert, 2005); at times, this mechanism itself does not confer clinically relevant resistance 
level. Through multiple steps of selection in increasing concentration of enrofloxacin, S. 
Typhimurium mutants with increase resistance to ciprofloxacin were obtained (Giraud et al., 
2000). Fluoroquinolone resistance has been shown to arise from mutation in the DNA gyrase 
gene which affects the binding of the antibiotic to the gyrase-DNA complex (Willmott and 
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Maxwell, 1993). However, Giraud et al. (2000) showed a mutant (BN18/21) had increased 
ciprofloxacin resistance compared to the parent Salmonella (BN18) strain without having any 
mutations in the DNA gyrase or topoisomerase gene. Moreover, two other mutants (BN18/41 
and BN18/71) which had an identical substitution (Gly81Cys) in DNA gyrase (gyrA) showed 
four-fold difference in ciprofloxacin susceptibility. Immunoblotting showed that the increase 
in ciprofloxacin resistance correlated to the increase expression of efflux pump protein 
(AcrA), suggesting the role of active efflux in the reduce susceptibility towards ciprofloxacin 
(Giraud et al., 2000). 
 In another study, multidrug resistant S. Typhimurium strain which exhibited high level 
resistance towards various fluoroquinolones was also found to have no mutations in any of the 
DNA gyrase and topoisomerase subunit genes (Baucheron et al., 2004). In this study, it was 
shown that other strains carrying substitutions in gyrA were slightly more resistant to the 
antibiotics tested. Inactivation of the acrB and tolC genes in the multidrug resistant strains 
decreased the level of resistance towards the fluoroquinolones. Addition of efflux pump 
inhibitor, phenyl-arginine-β-naphthylamide (PAβN) also increased the susceptibility of these 
Salmonella strains (Baucheron et al., 2004). In addition to fluoroquinolone resistance, 
tetracycline resistance conferred by Tet(A) protein encoded on a pBR322 plasmid also 
showed large reduction in tetracycline MIC in the E. coli host with non-functional AcrAB-
TolC efflux pump (180 µg/ml to 30 µg/ml) (de Cristóbal et al., 2006).  
 It has been well established that AcrAB-TolC efflux pump is associated with 
resistance to some β-lactam antibiotics, including penicillins and cephalosporins (Nikaido et 
al., 1998, Opperman et al., 2014, Piddock, 2006a, Poole, 2004). Data from a study have 
suggested a possible synergistic effect of AcrAB-TolC and β-lactamase enzymes in 
conferring resistance to β-lactam antibiotics in K. pneumoniae (Pages et al., 2009). In this 
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study, it was observed that various clinical isolates carrying the chromosomal SHV-1 β-
lactamase enzyme showed increasing susceptibility to piperacillin in the presence of 
tazobactam (β-lactamase inhibitor) and PAβN (Pages et al., 2009). In the presence of 
tazobactam, the MIC values of piperacillin of the various isolates decreased 4- to 8-fold. 
However, in the presence of tazobactam and PAβN, the susceptibility of these isolates 
increased further by 4-fold. The authors suggested that tazobactam was possibly a substrate of 
the AcrAB-TolC efflux system. Hence, the inhibition of the efflux system by PAβN increased 
the intracellular concentration of tazobactam, allowing a stronger effect of the β-lactamase 
inhibitor on the SHV-1 enzyme (Pages et al., 2009). However, it has been previously shown 
that inactivation of AcrAB-TolC in E. coli resulted in 16-fold increase in susceptibility of the 
bacterium to piperacillin (Opperman et al., 2014). Therefore, it is also possible that the larger 
increase in susceptibility of the K. pneumoniae isolates to piperacillin in the presence of 
tazobactam and PAβN was a result of the combined loss of the functions of the SHV-1 β-
lactamase and the efflux system.  
These studies with others showed the synergistic role played by active efflux in the 
background for conferring clinically significant resistance in the presence of other resistance 
mechanisms (Chen et al., 2007).  
1.3.5 Efflux Inhibitors 
With the dwindling number of efficacious antibiotics against severe infections, search has 
been initiated for other treatment options. One of these is compounds which are able to 
potentiate the activity of currently available antibiotics (Fernebro, 2011). As efflux pump 
confers resistance to a broad spectrum of structurally distinct antibiotic classes and are in 
certain cases a pre-requisite for antibiotic resistance related mutations, studies are underway 
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to develop inhibitors for this particular resistance mechanism (Ricci et al., 2006, Van 
Bambeke et al., 2006). 
 An ideal efflux inhibitor (EI) will have to possess one or more characteristics which 
includes being inactive against eukaryotic cells, inexpensive to manufacture, stable against 
proteolysis, high specificity and efficacy towards targets, and low toxicity to human 
(Bhardwaj and Mohanty, 2012). Various strategies of efflux inhibition can or have been 
explored, such as newer antibiotic molecules which are less susceptible to efflux (e.g. 
tigecycline); blockage of substrate binding site (e.g. PAβN); allosteric site modulators of 
efflux pump which affects the conformation of the substrate binding sites; un-coupler of 
efflux pump’s energy source; blockers for outer membrane protein found in Gram-negative 
bacteria which is an important channel for antibiotics to exit the bacterial cell membrane; 
inhibitors which affects the assembly of efflux pumps; and inhibitors which reduce or abolish 
expression of the efflux pumps (Poole and Lomovskaya, 2006).  
 Through a screening of synthetic compound and fermentation extract using P. 
aeruginosa overexpressing various efflux pumps, a peptide-like compound (peptidomimetic) 
known as PAβN (previously, MC-207,110) which acts as an EI against Mex family of efflux 
pumps was discovered (Renau et al., 1999). This inhibitor was further examined for its 
activity as an EI (Lomovskaya et al., 2001). Lomovskaya et al. (2001) showed that PAβN 
fulfilled many of the criteria set to be an ideal inhibitor. PAβN showed no significant 
antibacterial activity but significantly decreased the MIC values for levofloxacin of P. 
aeruginosa overexpressing various efflux pumps. Moreover, the EI successfully decreased 
spontaneous mutant selections in wildtype P. aeruginosa similar to the level observed when 
efflux pumps were deleted from the bacterium (10-7 to <10-11 cfu/ml) (Lomovskaya et al., 
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1999, Lomovskaya et al., 2001). Further studies of structurally similar peptidomimetic 
compounds also yielded similar inhibition activity (Renau et al., 2002).  
1.4 Spread and Acquisition of Antibiotic Resistance 
The development of antibiotic resistant bacteria can occur through two ways, i.e. spontaneous 
mutation or lateral gene transfer (LGT) (MacLean et al., 2010). For bacteria which are 
intrinsically resistant to many antibiotics, such as P. aeruginosa, these mechanisms can 
increase the resistant levels to the antibiotics, in addition to acquisition of new resistance 
phenotypes (Nicas and Hancock, 1983, Sacha et al., 2008). On the other hand, spontaneous 
chromosomal mutations have been associated with resistance to various β-lactam antibiotics 
due to increase of AmpC β-lactamase activity (Raimondi et al., 2001), inhibition of antibiotic 
target affinity via target alteration (Katayama et al., 2004, Sreevatsan et al., 1996) and 
decreased antibiotic accumulation due to regulatory mutations that alter porin production and 
increase efflux activity (Yoneyama and Nakae, 1993, Chuanchuen et al., 2001). 
1.4.1 Lateral Gene Transfer (LGT) in Dissemination of Antibiotic Resistance 
While spontaneous mutation confers resistance to a particular bacterium and its progeny by 
cell division, LGT allows acquisition and dissemination of antibiotic resistance genes from 
and to other bacteria via transfer of genetic material (Mitsuhashi et al., 1967). The three 
mechanisms, whereby LGT occurs are: transformation which involves the uptake and 
subsequent incorporation of naked DNA from the environment into the genome of a 
competent host cell; transduction, in which the DNA from a bacterium is packaged into a 
bacteriophage and transferred into a recipient cell during infection by the bacteriophage; and 
conjugation which requires cell-to-cell contact for the transfer of genetic material from the 
donor to the recipient cell (Davison, 1999). An alternative pathway involving genetic material 
enclosed in membrane vesicles has also been described (Yaron et al., 2000). Such membrane 
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vesicles have been shown to be produced by E. coli, N. gonorrhoeae, P. aeruginosa and 
Acinetobacter baumannii (Pérez-Cruz et al., 2015, Yaron et al., 2000). These vesicles contain 
chromosomal DNA, plasmid and various proteins (Pérez-Cruz et al., 2015, Yaron et al., 2000). 
These membrane vesicles have been shown to be able to successfully transfer virulence and 
antibiotic resistance genes that are then expressed in the recipient cells (Yaron et al., 2000). 
However, the importance of such membrane vesicles and the mechanisms involving the 
packaging of the DNA in the vesicles remain unclear. 
 Although transformation is a very common methodology used in molecular biology 
research to confer a detectable trait in artificially competent host cells, this process also occur 
in the natural environment among naturally competent bacteria (Lorenz and Wackernagel, 
1994). In the natural environment, DNA is released to the surrounding environment by 
excretion from viable cells and cellular lysis (Lorenz et al., 1991, Sinha and Iyer, 1971). Even 
though DNA is prone to degradation by nucleases, DNA adsorbed on to groundwater aquifer 
material is 1000 times more resistant to DNase I. This suggest that extracellular DNA found 
in the natural environment bound to mineral material containing inorganic precipitates and 
organic matter can be readily available for natural transformation (Romanowski et al., 1993).  
Acquired β-lactamase resistance via natural transformation has been demonstrated in Gram-
negative bacteria such as Helicobacter pylori and N. gonorrhoeae (Kwon et al., 2003, Ohnishi 
et al., 2010). 
 Although evidence of transduction as a major method for antibiotic resistance 
dissemination between Gram-negative bacteria is lacking, a few studies have shown the 
occurrence of various β-lactamase genes in phage particles, suggesting the possibility of 
bacteriophage as a reservoir for these resistance determinants in the natural environment 
(Muniesa et al., 2004, Colomer-Lluch et al., 2011). As naked DNA is susceptible to 
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degradation in the natural environment, the organisation of DNA into a bacteriophage capsid 
may be protective and allow transduction to be an efficient process for the spread of antibiotic 
resistance genes (Colomer-Lluch et al., 2011). Some in vitro studies have also supported this 
notion where transduction carried out with bacteria such as P. aeruginosa and S. 
Typhimurium conferred antibiotic resistance to recipient cells (Schmieger and Schicklmaier, 
1999, Blahová et al., 1999). 
 In conjugation, genetic material is transferred from the donor to the recipient cell, 
either as a conjugative plasmid, which is able to effect its own transmission between cells; or 
a mobilisable plasmid, which is non-self-transmissible but can be transferred to the recipient 
cell with the help of a conjugative plasmid; or via a conjugative transposon (Clewell et al., 
1995, Davison, 1999). Plasmids are self-replicating covalently closed circular double-stranded 
extrachromosomal DNA molecules (Actis et al., 1999). Although not usually essential for the 
survival of host bacteria, plasmids can confer beneficial traits to its host, such as resistance to 
antimicrobial compounds, hence of benefit in terms of survival in a particular ecological niche 
(Foster, 1983). Similar to plasmids, conjugative transposons also play an important role in the 
carriage and dissemination of antibiotic resistance genes either by their own mobilisation or 
by effecting the transmission of non-conjugative plasmids (Clewell et al., 1995). 
1.5 Plasmid-mediated Antibiotic Resistance 
A study on Enterobacteriaceae found in the cultures collected by E.D.G Murray from 1917 to 
1954 was carried out to compare the conjugative plasmids present during the ‘pre-antibiotic’ 
era and the period after introduction of antibiotics, which is believed to be the driving force 
for dissemination and proliferation of bacteria carrying plasmids with resistance determinants 
(Anderson, 1965, Hughes and Datta, 1983). Hughes and Datta (1983) showed at least 19% of 
the strains collected from various geographical locations, including Europe, Malta, India, 
30 
 
Northern Russia, the Middle East and North America, before the antibiotic era harboured 
conjugative plasmids. Of note, none of these conjugative plasmids carried any antibiotic 
resistance determinants (Hughes and Datta, 1983). By incompatibility (Inc) testing, most of 
these conjugative plasmids were in the same Inc groups as modern resistance plasmids (Datta 
and Hughes, 1983).   
As conjugative plasmids were commonly found in Enterobacteriaceae during the ‘pre-
antibiotic’ era and these plasmids belong to the same groups as the resistance plasmids 
observed after the usage of antibiotics, it is hypothesised that the modern resistance plasmids 
are of the same lineages as the former and were derived via the acquisition of resistance 
determinants by existing vectors and not simply by the selection of rare resistance plasmids 
due to antibiotic usage. This finding also suggests plasmids have a high rate for acquisition 
and dissemination of genes amongst bacteria (Datta and Hughes, 1983). The discovery of 
antibiotic resistance genes being at least 30,000 years old further supports the possibility of 
plasmids as a vehicle to acquire and spread antibiotic resistance determinant (D'Costa et al., 
2011). 
1.5.1 The blaKPC-encoding pKpQIL Plasmid 
The KPC enzyme was first detected in North Carolina in 1996 (Yigit et al., 2001). In the 
following decade, this carbapenemase has successfully spread across most of the states in the 
USA and across the globe (Arnold et al., 2011). In Israel, this enzyme was reported in 2005 
and 2006, where 93% of the 46 carbapenem-resistant K. pneumoniae clinical isolates from 
various sites of infection carried this enzyme (Leavitt et al., 2007). Most isolates were from 
the same pulsotype determined by pulsed-field gel electrophoresis, designated as clone Q and 
carried the blaKPC-3 gene. During the same period, a similar outbreak of carbapenem-resistant 
K. pneumoniae carrying blaKPC-3 in patients from different clinical specialties was 
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documented in a nearby hospital (Samra et al., 2007). Clone Q was later found to be a hyper-
epidemic clone carrying a common plasmid causing a nationwide outbreak in Israel. This 
clone was genetically related to the outbreak strains of K. pneumoniae isolated from the US 
(Navon-Venezia et al., 2009). This clone was later determined as multilocus sequence type 
(ST) 258 (Kitchel et al., 2009). 
 The common plasmid which was associated with carbapenem resistance of the K. 
pneumoniae ST258 isolates in Israel was named pKpQIL (Leavitt et al., 2010b). The plasmid 
was shown to be conjugative and harboured a blaTEM-1 and blaKPC-3 β-lactamase genes (Leavitt 
et al., 2010b). Sequencing of the plasmid determined it to be a 113,637 bp IncFII-like plasmid 
(Leavitt et al., 2010a). The majority of pKpQIL (86,610 bp) shares 99% identity with the 
pKPN4 plasmid from multidrug-resistant K. pneumoniae MGH 78578 (ATCC 700721). The 
blaKPC-3 gene is organised within the Tn4401 transposon as previously described (Naas et al., 
2008). The plasmid was stable without apparent changes during the two years of the outbreak 
(Leavitt et al., 2010b). Recently, pKpQIL or its derivatives were detected in a majority of 
Polish blaKPC-producing Klebsiella spp. clinical isolates (Baraniak et al., 2011). A pKpQIL-
like plasmid has also been found to be involved in hospital outbreak in Italy, Korea and Czech 
(García-Fernández et al., 2012, Richter et al., 2012, Hrabák et al., 2013, Lee et al., 2014). A 
recent study suggested that the pKpQIL plasmid may have originated from the US as similar 
plasmids were identified from various Enterobacteriaceae isolated as early as 2003 (Chen et 
al., 2014a, Tang et al., 2014). These suggest the possibility of the success of pKpQIL 
plasmids across geographical borders since its isolation in the US and its stability as a 
platform for the dissemination of blaKPC genes. 
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1.6 Factors Important in Plasmid Dissemination in Enterobacteriaceae 
Although plasmid DNA can be transferred between bacterial cells via natural transformation 
and transduction (Garzon et al., 1995, Chamier et al., 1993), conjugation is the major 
mechanism of plasmid transfer (Barlow, 2009). Conjugation occurs in three steps: DNA 
substrate processing, substrate recruitment and translocation of substrate to recipient cell 
(Alvarez-Martinez and Christie, 2009). In conjugation, a nucleoprotein complex is formed 
between a relaxase and other auxiliary proteins with the origin of transfer (oriT) sequence on 
the plasmid DNA. This complex is termed the relaxosome and results in the nicking of the 
supercoiled plasmid to produce a relaxed form. The relaxosome then translocates across the 
conjugative pore into the recipient cell, where re-circularisation and establishment of the 
plasmid occurs (Frost and Koraimann, 2010). 
 Plasmids such as those from the IncF group contain a transfer region encoding more 
than 30 transfer (tra) genes, which play an important role in DNA metabolism, type IV 
secretion system (T4SS) and regulation of the plasmid transfer potential (Frost and 
Koraimann, 2010). There are eight core genes involved in regulation of conjugation (Table 
1.1).  
1.6.1 Plasmid Stability and Segregation 
In the presence of a selective pressure such as antibiotics, plasmid-harbouring cells which 
possess the beneficial trait such as resistance to the antibiotic would survive in the population. 
However, in the absence of the selective pressure, the plasmid may incur a metabolic burden 
on its host cell (Jakobsen et al., 2006, Loftie-Eaton and Rawlings, 2010). In order to avoid 
itself from being lost when the host cells are actively dividing, plasmids have acquired 
properties such as toxin-anti-toxin systems and active segregation machineries to allow 
plasmid persistence in the host (Engelberg-Kulka and Glaser, 1999, Greenfield et al., 2000). 
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Table 1.1 Function of genes involved in conjugation 
Gene  Function 
traM  Processing of DNA for transfer 
Regulation of its own promoter, Pm 
traJ  Activator of tra gene expression 
Activates Py 
traY  Processing of DNA prior to transfer 
Regulation of its own promoter, Py and activates Pm 
finP  Antisense RNA inhibitor of TraJ 
   
finO  Stabilises FinP to avoid degradation by RNase E 
hfq  Promotes TraJ degradation, hence reducing transfer potential 
arcA  May be involved in activation of Py  
ArcAB represses succinate dehydrogenase (sdhABCD) 
sdhABCD  May be involved in reduction of transfer potential by regulation of TraJ 
Adapted from Frost and Koraimann (2010). The tra locus of a conjugative plasmids may 
contain about 30 genes which are involved in the conjugation process. Eight genes which 
play the core regulative functions of conjugation are listed in the table. 
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Plasmid encoded toxin-anti-toxin systems play a role in postsegregational killing. In 
the presence of the plasmid, both the stable toxin and labile anti-toxin are produced. When the 
plasmid is lost, the host bacterium is unable to survive as there is no production of the labile 
anti-toxin to inhibit the effects of the more stable toxin still present in the cell. This ensures 
the permanent linkage between survival of the host cell with the presence of the plasmid 
(Yamaguchi and Inouye, 2011). Disruption of the interaction between the toxin and anti-toxin 
therefore eliminates the plasmid by killing the cell (Lioy et al., 2010). 
Although high-copy number plasmids may stably propagate by random segregation 
during cell division, low-copy number plasmids require an active partitioning system to 
ensure each daughter cell carries at least one copy of the plasmid. Most of the active 
partitioning systems are comprised of three components, i.e. ParA (a nucleotide-binding 
motor element), ParB (a DNA-binding adaptor protein), and a centromere-like region. In 
general, the ParB protein binds to the centromere-like region to form a nucleoprotein complex, 
which then interacts with the ParA motor element to allow the active partitioning of the 
plasmid at the opposite pole of the cell to ensure the persistence of the plasmid in each 
daughter cell after cell division (Ghosh et al., 2006, Salje, 2010). 
1.6.2 Inhibition of Plasmid Transfer 
Due to their importance in dissemination of antibiotic resistance, plasmids have been targeted 
by strategies designed to prevent the spread of plasmid DNA (Williams and Hergenrother, 
2008). 
 An in vitro study has shown that targeting F plasmid relaxase, the enzyme important 
for the formation of the relaxosome which allows the translocation of plasmid into the 
recipient cell, inhibits conjugation and selectively kills bacteria harbouring the conjugative 
plasmids through an unknown mechanism (Lujan et al., 2007). The authors showed that the 
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inhibition of relaxase was achieved using bisphosphonates, etidronate and clodronate, which 
are clinically approved for bone loss treatment. The results suggest an opportunity for the 
combination therapy between the bisphosphonates with antibiotics for the treatment of 
bacterial infections (Lujan et al., 2007). However, this hypothesis has yet to be investigated in 
vitro. 
 Plasmid incompatibility has also been exploited as a possible mechanism for the 
elimination of specific plasmids as those with the same incompatibility group cannot stably 
co-segregate into the daughter cells (Novick, 1987). The replication of IncB plasmids is 
regulated by the RepA protein which in turn is regulated by RNA I (Thomas et al., 2005). 
Screening of various aminoglycosides found apramycin to mimic the function of RNA I, by 
inhibiting the translation of RepA protein, which in turn inhibits plasmid replication and 
subsequently resulting in plasmid elimination and increased susceptibility of the host cell to 
antibiotics (Thomas et al., 2005, DeNap et al., 2004).  
1.7 Plasmid-mediated Antibiotic Resistance and Fitness 
A study competing plasmid RSF2124-carrying E. coli against plasmid-free E. coli without 
antibiotic showed an initial decrease in fitness of the plasmid-carrying strain (Helling et al., 
1981). However, after 18 generations of growth, it was found that the plasmid-carrying strain 
possess a better fitness relative to the plasmid-free strain. When the evolved plasmid after 18 
generation was introduced into the initial plasmid-free E. coli, no fitness advantage was 
observed. Hence, the authors concluded that adaptive changes in the host chromosome 
conferred the fitness advantage after a certain number of generations of growth (Helling et al., 
1981).  
A similar study also compared the fitness of plasmid-carrying and plasmid-free E. coli 
(Bouma and Lenski, 1988). The authors showed that E. coli carrying the pACYC184 plasmid 
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which encodes resistance determinants for chloramphenicol and tetracycline possessed a 
higher fitness cost compared to the plasmid-free strain. Interestingly, after the E. coli carrying 
the plasmid was grown for 500 generation (75 days) in the presence of chloramphenicol, the 
evolved host (H500) carrying the ancestral plasmid (H500P0) showed significant increase in 
fitness compared to plasmid-free host (H500) in the absence of antibiotic. This study also 
suggested the adaptive changes were found only on the host chromosome (Bouma and Lenski, 
1988).  
Further investigation was pursued to identify the determinants on the plasmid 
pACYC148 which resulted in the fitness cost of the naive host (H0) and the resulting fitness 
benefit of the pACYC148 coevolved host (H500) (Lenski et al., 1994). By constructing various 
deletions on the pACYC148 plasmid, the authors were able to show that the chloramphenicol 
resistance gene was responsible for the fitness cost incurred on the naive host. As the evolved 
host carrying the plasmid devoid of the chloramphenicol resistance still possesses a fitness 
advantage against plasmid-free evolved host, this suggested the chloramphenicol resistance 
gene was not involved in the fitness advantage observed. When the tetracycline resistance 
cassette was deleted, it was found that this function had a major role in the fitness advantage 
observed in the coevolved host as the coevolved host carrying this plasmid had a fitness cost. 
However, the importance of the tetracycline resistance gene in the evolution which 
ameliorates the fitness cost is unclear (Lenski et al., 1994). 
In contrast to the above experiments which were using non-conjugative laboratory 
plasmids, similar study was conducted on natural conjugative plasmids (ca.100 kb plasmid R1 
and ca. 60 kb plasmid RP4) in E. coli to assess the fitness impact of natural conjugative 
plasmids on their host (Dahlberg and Chao, 2003). Serial propagation of the plasmids with 
their host over a period of 166 days (ca. 1100 generation), showed the initial fitness cost 
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exhibited by the plasmid-carrying host was reduced significantly at the end of the study. 
Unlike the previous studies (Bouma and Lenski, 1988, Lenski et al., 1994), the compensatory 
adaptation was suggested to be in both the chromosome and plasmids. Although the 
chromosomal compensatory mutation was not determined, but the changes in the plasmids 
which led to a lower fitness cost were found to be deletions of loci associated with plasmid 
transfer function and antibiotic resistance (Dahlberg and Chao, 2003). Under the conditions 
tested, this study also found that the host which evolved in the absence of the plasmid was 
able to reduce the cost of the plasmids introduced into it. This suggests that the fitness cost 
alleviating adaptation which occurred in the host was also in part due to its own response to 
its growth conditions (Dahlberg and Chao, 2003). 
1.8 Background to This Project 
1.8.1 Plasmid pCT 
An IncK plasmid carrying a single blaCTX-M-14 ESBL gene was isolated from scouring 
(diarrhoea) cattle in the UK (Liebana et al., 2006). The pCT plasmid and pCT-like plasmids 
have since been detected in human clinical isolates from the UK, Spain, Australia and China 
(Cottell et al., 2011, Dhanji et al., 2012). Previous study of the pCT plasmid by inactivation of 
the blaCTX-M-14 ESBL gene found that it carries no fitness benefit or cost on its host in the 
presence or absence of antibiotic selection pressure (Cottell et al., 2012). Inactivation of 
various genes on the pCT plasmid also found no significant effect on the maintenance of the 
plasmid in the bacterial cell or in a bacterial population when compared to the wildtype 
plasmid (Cottell et al., 2014). This finding challenges the dogma which relates the persistence 
of antibiotic resistance gene carrying plasmids to antibiotic selective pressure (Anderson, 
1965). 
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1.8.2 Plasmid pKpQIL-UK & pKpQIL-D2 
Carbapenemase-producing Enterobacteriaceae was first isolated in the UK in 2003. However, 
it was not until 2008 that a drastic increase in the number of annually reported 
carbapenemase-producing isolates was observed. Until the second quarter of 2011, the 
dominant carbapenemase, i.e. blaKPC accounted for 384 (58%) of 657 carbapenemase-
producing Enterobacteriaceae isolates reported since 2003. Although the KPC enzymes have 
spread within some UK hospitals, this carbapenemase has been a problem particularly in the 
North Western (NW) region of England (HPA, 2011).  
 A study by Public Health England on 17 blaKPC-harbouring clinical isolates referred 
by various referral centres in the NW England region showed that 14 of the isolates carried 
the plasmid pKpQIL and its variant (Figure 1.6), with the remaining three isolates 
undetermined (Table 1.2). Most of the isolates were K. pneumoniae with the rest being other 
species of the Enterobacteriaceae family. Sequence analyses showed that most of the plasmids 
were similar to the one reported in Israel (henceforth, termed pKpQIL-UK). Five from the 14 
isolates harboured a derivative plasmid of pKpQIL-UK (Table 1.2). One derivative, named 
pKpQIL-D1 carries a new ca. 19 kb DNA segment which replaces the original ca. 11 kb 
segment beginning from the truncated blaOXA-9 to the vagC gene in the pKpQIL-UK (Figure 
1.7). Another derivative, named pKpQIL-D2 had a ca. 20 kb DNA segment between vagC 
and stbA of the pKpQIL-UK substituted with a new ca. 16 kb DNA segment (Figure 1.8). 
While most pKpQIL-UK plasmids were found in K. pneumoniae ST258, its derivative, i.e. 
pKpQIL-D2 was found in other Enterobacteriaceae species and sequence types of K. 
pneumoniae. It is possible the substitution with the new ca. 16 kb DNA segment has provided 
the variant plasmid with the ability to better disseminate across the species barrier.    
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Figure 1.6 Alignment of plasmid pKpQIL-UK and variants 
The diagram was generated using Blast Ring Image Generator. It shows the plasmid 
alignments of pKpQIL-UK with pKpQIL-D2, pKpQIL-D1 and pSLMT. From the inner 
most ring, (1) Size of the plasmid, (2) GC content of the sequence, (3) pKpQIL-UK 
(red), (4) pKpQIL-D2 (purple), (5) pKpQIL-D1 (yellow), (6) pSLMT (orange) and (7) 
plasmid genes of pKpQIL-UK (black) (Source: Woodford, N. Public Health England). 
 
 
Table 1.2 Distribution of pKpQIL-UK and variants from medical centres in North Western England Region 
Isolates Species ST-type Centre blaKPC Inc_type Plasmid Name
T4 K. pneumoniae 258 Centre_6 2 FIIK2 pKpQIL-UK 
T6 K. pneumoniae 258 Centre_2 3 FIIK2 pKpQIL-UK 
T8 K. pneumoniae 258 Centre_7 2 FIIK2 pKpQIL-UK 
T11 K. pneumoniae 258 Centre_8 2 FIIK5 ND 
T13 K. pneumoniae 11 Centre_1 3 FIIK2 pKpQIL-UK 
T19 K. pneumoniae 11 Centre_1 2 FIIK2 pKpQIL-D1 
T27 K. pneumoniae 258 Centre_5 2 FIIK2 pKpQIL-UK 
L16 K. pneumoniae 258 Centre_3 2 FIIK2 ND 
L19 K. pneumoniae 258 Centre_1 2 FIIK2 pKpQIL-UK 
L33 K. pneumoniae 468 Centre_3 2 FIIK2 pKpQIL-UK 
L27 K. pneumoniae 321 Centre_1 2 FIIK2 pKpQIL-D2 
L37 K. pneumoniae 491 Centre_1 2 FIIK2 ND 
L38 K. pneumoniae 490 Centre_1 2 FIIK2 pKpQIL-D2 
LENT Enterobacter spp. ND Centre_1 2 FIIK2 pKpQIL-D2 
LESC E. coli ND Centre_1 2 FIIK2 pKpQIL-D2 
I2 Escherichia coli ND Centre_4 2 FIIK2 pKpQIL-UK 
I1 K. pneumoniae ND Centre_4 2 FIIK2 pKpQIL-UK 
ND: Not determined 
 
The pKpQIL-UK and -D2 plasmids used in this PhD study were from the clinical isolate L33 and L27, respectively. 
Source: Woodford, N. Public Health England 
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Figure 1.7 Comparison of the substitution fragment of pKpQIL-UK and -D1 
pKpQIL-UK 
pKpQIL-D1 
The diagram shows the 11 kb region on pKpQIL-UK which has been substituted with a new 19 kb fragment to form the pKpQIL-D1 
plasmid. The open reading frames (ORF) include genes encoding resistance (Red), transposable elements (Blue), plasmid replicon 
(Purple), genes with no significant homologies to infer functions (White) and other plasmid genes (Yellow). Hypothetical protein 
(White) had no significant hit when analysed with BlastP (to search for protein homology), PROSITE (to detect conserved protein 
motif) and PSORT (protein localisation predictor). 
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Figure 1.8 Comparison of the substitution fragment of pKpQIL-UK and -D2 
pKpQIL-UK 
pKpQIL-D2 
The diagram shows the 20 kb region on pKpQIL-UK which has been substituted with a new 16 kb fragment to form the pKpQIL-D2 
plasmid. The open reading frames (ORF) include genes encoding resistance (Red), transposable elements (Blue), plasmid replicon 
(Purple), genes with no significant homologies to infer functions (White) and other plasmid genes (Yellow). The fragment on pKpQIL-
D2 (highlighted with brown bracket) shares 98% DNA sequence identity with pKPN5 plasmid from K. pneumoniae MGH78578. 
Hypothetical protein (White) had no significant hit when analysed with BlastP (to search for protein homology), PROSITE (to detect 
conserved protein motif) and PSORT (protein localisation predictor).
pKPN5 
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1.9 Hypotheses to be Investigated in This PhD Project 
Although the use of antibiotics has a role in the dissemination of antibiotic resistance 
plasmids, this may not account for the spread of all antibiotic resistance currently observed, 
especially since conjugative plasmids without any resistance determinants were already 
common among bacterial strains prior to the antibiotic era (Datta and Hughes, 1983, Hughes 
and Datta, 1983). The blaKPC gene has been observed to be transmitted by the pKpQIL 
plasmid in various countries around the world. The emergence of pKpQIL-D2 in the UK 
along with the original pKpQIL-UK plasmid warrants further investigation on both of these 
plasmids. The hypotheses to be investigated in this project are as follow: 
i) The ca. 16 kb substitution region in pKpQIL-D2 confers a fitness benefit to the 
plasmid and/or plasmid-carrying host when compared to pKpQIL-UK. 
ii) A functional AcrAB-TolC efflux pump is required to confer carbapenemase-
producing bacteria with high carbapenem resistance. 
1.10 Aims & Objectives 
The objective of the research was to investigate plasmid mediated carbapenemase resistance 
and identify the differences in effects caused by the two plasmids (pKpQIL-UK and pKpQIL-
D2) on the host. The specific aims were: 
1. To evaluate the role of a functional AcrAB-TolC efflux pump in plasmid-
mediated carbapenem resistance. 
2. To assess the fitness cost or benefit of pKpQIL-UK and -D2 on their hosts. 
3. To identify the potential gene(s) involved in conferring the fitness cost or 
benefit in the host. 
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CHAPTER TWO: METHODS 
2.1 Bacterial Strains, Plasmids & Culture Conditions 
Bacterial strains were routinely cultured in Luria Bertani (LB) agar (Sigma-Aldrich, Missouri, 
USA, Catalogue No.: L2897) and LB broth (Sigma-Aldrich, Missouri, USA, Catalogue No.: 
L3022) at 37°C. All bacterial cultures were stored on Protect Microorganisms Preservation 
System Beads (Thermo Fisher Scientific, Massachusetts, USA, Catalogue No.: TS80) at -
80°C (Salmonella strains were kept at -20°C). When required, a Protect Bead was used to 
streak the bacteria of interest on to LB agar to obtain single colonies. The culture was then 
incubated overnight (12 – 16 hours) at 37°C. When liquid cultures were required, a single 
colony was used to inoculate 10 ml LB broth and incubated at 37°C with shaking (200 rpm) 
for 12 – 16 hours. Temperature for incubation was reduced to 30°C for temperature sensitive 
strains and plasmids. When necessary, growth medium was supplemented with the relevant 
antibiotics (Table 2.1). All experiments involving bacterial cultures were carried out 
aseptically. The plasmids and bacterial strains used in this study are listed in Table 2.2 and 
Table 2.3, respectively. 
2.1.1 Bacterial Identification 
In order to ensure the bacterial strains used in the study were correct, the strains were 
frequently grown on differential and selective media such as Xylose-Lysine-Deoxycholate 
(XLD) agar (Oxoid, Massachusetts, USA, Catalogue No.: CM0469) and MacConkey agar 
(Oxoid, Thermo Fisher Scientific, Massachusetts, USA, Catalogue No.: CM0007). The 
bacterial strains were differentiated by their morphological appearance on the differential agar 
according to the manufacturer’s descriptions (Table 2.4). Gram staining (Sigma-Aldrich, 
Missouri, USA, Catalogue No.: 77730) was also used as a rapid test to confirm the type of 
bacteria as all the strains used in this study were Gram-negative bacteria. When a mutant  
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Table 2.1 List of antibiotics used in this study 
 
Antibiotic  Supplier  Catalogue No. Solvent 
Ampicillin  Calbiochem, Darmstadt, 
Germany 
 171254 Sterile water 
Biapenem  Sigma-Aldrich, 
Missouri, USA 
 SL0306 Sterile water 
Cefotaxime  Sigma-Aldrich, 
Missouri, USA 
 C7912 Sterile water 
Ceftazidime  Sigma-Aldrich, 
Missouri, USA 
 C3809 Sterile water 
Cephalothin  Sigma-Aldrich, 
Missouri, USA 
 C4520 Sterile water 
Chloramphenicol  Sigma-Aldrich, 
Missouri, USA 
 C0378 70% (v/v) ethanol in 
water 
Doripenem  Sigma-Aldrich, 
Missouri, USA 
 32138 Sterile water 
Ertapenem  MSD, New Jersey, USA  FR3843 Sterile water 
Erythromycin  Sigma-Aldrich, 
Missouri, USA 
 E5389 70% (v/v) ethanol in 
water 
Imipenem  Sigma-Aldrich, 
Missouri, USA 
 I0160 Sterile water 
Kanamycin  Sigma-Aldrich, 
Missouri, USA 
 60615 Sterile water 
Meropenem  Sigma-Aldrich, 
Missouri, USA 
 M2574 Sterile water 
Piperacillin  Cambridge Bioscience, 
Cambridge, UK 
 P3462 100% DMSO 
Rifampicin  Sigma-Aldrich, 
Missouri, USA 
 R3501 100% DMSO 
Tetracycline  Sigma-Aldrich, 
Missouri, USA 
 T3383 70% (v/v) ethanol in 
water 
DMSO: Dimethyl-sulfoxide (Sigma-Aldrich, Missouri, USA, Catalogue No.: D8418) 
 
 
 
Table 2.2 Plasmids 
 
Plasmid Antibiotic 
Resistance 
Gene 
Description Source 
pKpQIL-UK blaKPC-2 Plasmid pKpQIL [Leavitt et al. (2010)] which was isolated in the UK Woodford, N. 
pKpQIL-UK blaKPC::aph  Plasmid pKpQIL-UK with the inactivated blaKPC-2 carbapenemase  This study 
pKpQIL-D2 blaKPC-2 A variant of plasmid pKpQIL-UK Woodford, N. 
pKpQIL-D2 blaKPC::aph  Plasmid pKpQIL-D2 with the inactivated blaKPC-2 carbapenemase  This study 
pNDM-HK blaNDM-1 IncL/M plasmid isolated in Hong Kong carrying a blaNDM-1 
carbapenemase gene 
Ho, et al. (2011) 
pUC18 blaTEM-1 Cloning vector Norrander, et al. (1983) 
pCT blaCTX-M-14 IncK plasmid encoding a blaCTX-M-14 isolated from scouring calves Teale, et al. (2005) 
 
 
 
 
 
 
 
 
 
 
 
 
 46 
 
 
Table 2.3 Bacterial strains 
 
Strains Code Description Source 
K. pneumoniae    
K. pneumoniae 
ST468/pKpQIL-UK 
ST468/pKpQIL-
UK 
Clinical isolate of K. pneumoniae ST468 carrying plasmid pKpQIL-
UK, Dor0.25 
Woodford, N. 
K. pneumoniae 
ST321/pKpQIL-D2 
ST321/pKpQIL-
D2 
Clinical isolate of K. pneumoniae ST321 carrying plasmid pKpQIL-
D2, Dor0.25 
Woodford, N. 
K. pneumoniae ST258 ST258 Carbapenemase susceptible K. pneumoniae, Kan50 Kreiswirth, B. 
ST258/pKpQIL-UK - ST258 transconjugants carrying pKpQIL-UK, Kan50 & Dor0.25 This study 
ST258/pKpQIL-D2 - ST258 transconjugants carrying pKpQIL-D2, Kan50 & Dor0.25 This study 
K. pneumoniae Ecl8 Ecl8 -  Forage & Lin (1982) 
Ecl8 acrAB::aph - Ecl8 which the efflux pump acrAB has been inactivated Veleba, et al. (2012) 
Ecl8Rif - Rifampicin-resistant mutant of K. pneumoniae Ecl8, His537Leu, 
Rif100 
This study 
Ecl8 Rif acrAB - Rifampicin-resistant mutant of K. pneumoniae Ecl8 acrAB::aph, 
His537Leu, Rif100 
This study 
Ecl8Rif/pKpQIL-UK - Ecl8Rif transconjugants carrying pKpQIL-UK, Rif100 & Dor0.25 This study 
Ecl8 Rif acrAB/pKpQIL-
UK 
- Ecl8 Rif acrAB transconjugants carrying pKpQIL-UK, Kan50 & 
Dor0.25 
This study 
Where necessary growth media were supplemented with Rif100 (100 µg/ml rifampicin), Kan50 (50 µg/ml kanamycin), Dor0.25 (0.25 µg/ml 
doripenem) 
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Table 2.3 Bacterial strains (Continued) 
 
Strains Code Description Source 
K. pneumoniae    
Ecl8Rif/pKpQIL-UK 
blaKPC::aph 
- Ecl8Rif transconjugants carrying pKpQIL-UK blaKPC::aph, Rif100 & 
Kan50 
This study 
Ecl8Rif/pKpQIL-D2 - Ecl8Rif transconjugants carrying pKpQIL-D2, Rif100 & Dor0.25 This study 
Ecl8Rif/pKpQIL-D2 
blaKPC::aph 
- Ecl8Rif transconjugants carrying pKpQIL-D2 blaKPC::aph, Rif100 & 
Kan50 
This study 
E. coli    
E. coli SW105 - mcrA [mrr-hsdRMS-mcrBC] 80dlacZM15 lacX74 recA1 endA1 
araD139 [ara, leu]7697 galU pgl8 rpsL nupG ʎ(cI857ind1) {(cro-
bioA) )<>araC-PBAD flpe8 
Warming, S. et al. 
(2005) 
E. coli NCTC 10418 10418 Control strain for antibiotic susceptibility testing National Collection of 
Type Cultures (NCTC) 
10418Rif - Rifampicin-resistant 10418, Ser531Phe, Rif100 This study 
10418Rif/pKpQIL-UK - E. coli 10418Rif transconjugant carrying pKpQIL-UK, Rif100 & Dor0.25 This study 
10418Rif/pKpQIL-D2 - E. coli 10418Rif transconjugant carrying pKpQIL-D2, Rif100 & Dor0.25 This study 
Where necessary growth media were supplemented with Rif100 (100 µg/ml rifampicin), Kan50 (50 µg/ml kanamycin), Dor0.25 (0.25 µg/ml 
doripenem) 
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Table 2.3 Bacterial strains (Continued) 
 
Strains Code Description Source 
E. coli    
E. coli BW25113 BW25113 Parental strain of Keio Collection Baba, T. et al. (2006) 
BW25113 acrB::aph - BW25113 with inactivated acrB efflux pump gene, Kan50 Baba, T. et al. (2006) 
BW25113 tolC::aph - BW25113 with inactivated tolC efflux pump gene, Kan50 Baba, T. et al. (2006) 
BW25113Rif - Rifampicin-resistant BW25113, Pro574Leu, Rif100 & Kan50 This study 
BW25113Rif acrB - Rifampicin-resistant BW25113 acrB::aph, Pro574Leu, Rif100 & 
Kan50 
This study 
BW25113Rif tolC - Rifampicin-resistant BW25113 tolC::aph, His526Tyr, Rif100 & 
Kan50 
This study 
BW25113Rif/pKpQIL-UK - BW25113 Rif transconjugant carrying pKpQIL-UK, Rif100 & 
Dor0.25 
This study 
BW25113Rif acrB/pKpQIL-UK - E. coli BW25113Rif acrB transconjugant carrying pKpQIL-UK, 
Kan50 & Dor0.25 
This study 
BW25113Rif tolC/pKpQIL-UK - E. coli BW25113C tolC transconjugant carrying pKpQIL-UK, 
Kan50 & Dor0.25 
This study 
Where necessary growth media were supplemented with Rif100 (100 µg/ml rifampicin), Kan50 (50 µg/ml kanamycin), Dor0.25 (0.25 µg/ml 
doripenem) 
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Table 2.3 Bacterial strains (Continued) 
 
Strains Code Description Source 
E. coli    
ElectroMAXTM DH10BTM  DH10B F- mcrA Δ(mrr-hsdRMS-mcrBC) φ80lacZ ΔM15 ΔlacX74 recA1 
endA1 araD139 Δ(ara, leu)7697 galU galK λ - rpsL nupG tonA 
Invitrogen 
(California, USA) 
DH10B/pKpQIL-UK - E. coli DH10B transformant harbouring the pKpQIL-UK  This study 
DH10B/pKpQIL-D2 - E. coli DH10B transformant harbouring the pKpQIL-D2  This study 
DH10B/pNDM-HK - E. coli DH10B transformant harbouring the pNDM-HK  This study 
S. Typhimurium    
S. Typhimurium SL1344 SL1344 Wildtype Salmonella enterica serovar Typhimurium strain 
SL1344 isolated from cow 
Wray & Sojka 
(1978) 
SL1344Rif - Rifampicin-resistant SL1344, Ser522Phe, Rif100 This study 
SL1344Rif/pKpQIL-UK - SL1344Rif transconjugant carrying pKpQIL-UK, Rif100 & Dor0.25 This study 
SL1344Rif /pKpQIL-D2 - SL1344Rif transconjugant carrying pKpQIL-D2, Rif100 & Dor0.25 This study 
SL1344 ompC::aph SL1344 ompC SL1344 with inactivated ompC gene, Kan50  Lawler, A. 
SL1344 ompF::aph SL1344 ompF SL1344 with inactivated ompF gene, Kan50 Lawler, A. 
SL1344 ∆ompC ompF::aph SL1344 ompCF SL1344 with inactivated ompC & ompF genes, Kan50 Lawler, A. 
Where necessary growth media were supplemented with Rif100 (100 µg/ml rifampicin), Kan50 (50 µg/ml kanamycin), Dor0.25 (0.25 µg/ml 
doripenem) 
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Table 2.3 Bacterial strains (Continued) 
 
Strains Code Description Source 
S. Typhimurium     
SL1344 ompC/pKpQIL-UK - SL1344 ompC transconjugant carrying pKpQIL-UK, Kan50 & Dor0.25 This study 
SL1344 ompF/pKpQIL-UK - SL1344 ompF transconjugant carrying pKpQIL-UK, Kan50 & Dor0.25 This study 
SL1344 ompCF/pKpQIL-
UK 
- SL1344 ompCF transconjugant carrying pKpQIL-UK, Kan50 & Dor0.25 This study 
SL1344/pUC18 - SL1344 carrying pUC18 plasmid, Amp100  Blair, J. 
SL1344 acrA::aph/pUC18 - SL1344 with inactivated acrA gene carrying pUC18 plasmid, Amp100 
& Kan50 
Blair, J. 
SL1344 acrB::aph/pUC18 - SL1344 with inactivated acrB gene carrying pUC18 plasmid, Amp100 
& Kan50  
Blair, J. 
SL1344 tolC::aph/pUC18 - SL1344 with inactivated tolC gene carrying pUC18 plasmid, Amp100 & 
Kan50 
Blair, J. 
S. Typhimurium ATCC 
14028s 
14028s Wildtype Salmonella enterica serovar Typhimurium strain 
ATCC14028s isolated from chicken 
American Type 
Culture Collection 
14028sRif - Rifampicin-resistant 14028s, Ser522Tyr , Rif100 This study 
Where necessary growth media were supplemented with Rif100 (100 µg/ml rifampicin), Kan50 (50 µg/ml kanamycin), Dor0.25 (0.25 µg/ml 
doripenem), Amp100 (100 µg/ml ampicillin) 
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Table 2.3 Bacterial strains (Continued) 
 
Strains Code Description Source 
S. Typhimurium     
14028s acrAB::cat 14028s acrAB 14028s with inactivated acrAB efflux pump gene, Cm15 Nishino, et al. 
(2006) 
14028s tolC::cat 14028s tolC 14028s with inactivated tolC efflux pump gene, Cm15 Nishino, et al. 
(2006) 
14028sRif acrAB::cat - Transductant of 14028sRif with acrAB::cat, Rif100 & Cm15 This study 
14028sRif tolC::cat - Transductant of 14028sRif with tolC::cat, Rif100 & Cm15 This study 
14028sRif/pKpQIL-UK - 14028sRif transconjugant carrying pKpQIL-UK, Rif100 & Dor0.25 This study 
14028sRif acrAB/pKpQIL-
UK 
- 14028sRif acrAB transconjugant carrying pKpQIL-UK, Cm15 & Dor0.25 This study 
14028sRif tolC/pKpQIL-UK - 14028sRif tolC transconjugant carrying pKpQIL-UK, Cm15 & Dor0.25 This study 
14028sRif /pKpQIL-D2 - 14028sRif transconjugant carrying pKpQIL-D2, Rif100 & Dor0.25 This study 
14028sRif acrAB/pKpQIL- 
D2 
- 14028sRif acrAB transconjugant carrying pKpQIL-D2, Cm15 & Dor0.25 This study 
14028sRif tolC/pKpQIL- D2 - 14028sRif tolC transconjugant carrying pKpQIL-D2, Cm15 & Dor0.25 This study 
Where necessary growth media were supplemented with Rif100 (100 µg/ml rifampicin), Dori0.25 (0.25 µg/ml doripenem), Amp100 (100 µg/ml 
ampicillin) 
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Table 2.3 Bacterial strains (Continued) 
 
Strains Code Description Source 
S. Typhimurium     
14028sRif /pNDM-HK - 14028sRif transconjugant carrying pNDM-HK, Rif100 & Dor0.25 This study 
14028sRif acrAB/pNDM-HK - 14028sRif acrAB transconjugant carrying pNDM-HK, Cm15 & Dor0.25 This study 
14028sRif tolC/pNDM-HK - 14028sRif tolC transconjugant carrying pNDM-HK, Cm15 & Dor0.25 This study 
14028sRif/pCT - 14028sRif transconjugant carrying pCT, Rif100 & Ctx8 This study 
14028sRif acrAB/pCT - 14028sRif acrAB transconjugant carrying pCT, Cm15 & Ctx8 This study 
14028sRif tolC/pCT - 14028sRif tolC transconjugant carrying pCT, Cm15 & Ctx8 This study 
14028sRif/pCT blaCTX::aph - 14028sRif transconjugant carrying pCT blaCTX::aph, Rif100 & Kan50 This study 
14028sRif acrAB/pCT blaCTX::aph - 14028sRif acrAB transconjugant carrying pCT blaCTX::aph, Cm15 & 
Kan50 
This study 
14028sRif tolC/pCT blaCTX::aph - 14028sRif tolC transconjugant carrying pCT blaCTX::aph, Cm15 & Kan50 This study 
Where necessary growth media were supplemented with Rif100 (100 µg/ml rifampicin), Kan50 (50 µg/ml kanamycin), Dor0.25 (0.25 µg/ml 
doripenem), Cm15 (15 µg/ml chloramphenicol), Ctx8 (8 µg/ml cefotaxime) 
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Table 2.3 Bacterial strains (Continued) 
 
Strains Code Description Source 
E. cloacae     
E. cloacae NCTC10005 Ecloacae E. cloacae isolated from cerebrospinal fluid NCTC 
EcloacaeRif - Rifampicin-resistant E. cloacae, Ser328Ala, Rif100 This study 
EcloacaeRif/pKpQIL-UK - EcloacaeRif transconjugant carrying pKpQIL-UK, Rif100 & Dor0.25 This study 
EcloacaeRif/pKpQIL-D2 - EcloacaeRif transconjugant carrying pKpQIL-D2, Rif100 & Dor0.25 This study 
S. marcescens    
S. marcescens NCTC10211 Serratia S. marcescens isolated from pond water NCTC 
SerratiaRif - Rifampicin-resistant S. marcescens, Asp516Gly, Rif100 This study 
SerratiaRif/pKpQIL-UK - SerratiaRif transconjugant carrying pKpQIL-UK, Rif100 & Dor0.25 This study 
SerratiaRif/pKpQIL-D2 - SerratiaRif transconjugant carrying pKpQIL-D2, Rif100 & Dor0.25 This study 
Where necessary growth media were supplemented with Rif100 (100 µg/ml rifampicin), Dor0.25 (0.25 µg/ml doripenem) 
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Table 2.4 Morphological appearance on differential and selective agar 
 
(a) Xylose-Lysine-Deoxycholate (XLD) 
Bacteria  Growth  Colony 
E. coli  Partial to complete 
inhibition of some 
strains 
 Yellow and opaque colonies 
S. Typhimurium  Good growth  Red colonies with black centers 
K. pneumoniae  Good growth  Yellow, mucoid and opaque 
E. cloacae  Good growth  Yellow and opaque  
S. marcescens  Good growth  Yellow and opaque  
Gram-positive  Partial to complete 
inhibition 
 - 
E. coli ATCC25922  Inhibited  - 
Source: Adapted from product sheets of XLD agar of Oxoid (CM0469), Sigma-Aldrich 
(95586) and Becton Dickinson GmbH (PA-254055.06) 
 
 
(b) MacConkey Agar 
Bacteria  Growth  Colony 
E. coli  Good growth  Red colonies with hazy (pink halo) 
surrounding due to bile precipitate 
S. Typhimurium  Good growth  Colourless (White/pale yellow) 
K. pneumoniae  Good growth  Red and mucoid with hazy (pink 
halo) surrounding due to bile 
precipitate 
E. cloacae  Good growth  Red colonies with hazy (pink halo) 
surrounding due to bile precipitate 
S. marcescens  Good growth  Pale pink 
Gram-positive  Weak to good growth  Staphylococcus: pale pink and 
opaque 
Source: Adapted from product sheets of XLD agar of Oxoid (CM0007) and Sigma-Aldrich 
(70143)  
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strain has been constructed, the strain was checked using API® 20E Gram-negative 
Identification Strip (Biomérieux, France) according to manufacturer’s recommendation. This 
strip is used to distinguish the different species of Enterobacteriaceae using results from a 
panel of biochemical assays. 
2.2 Plasmid Extraction 
In order to extract plasmids, bacterial strains carrying the plasmids were inoculated into 10 ml 
of LB broth supplemented with the necessary antibiotics. Cultures were then incubated 
overnight at 37°C, with shaking at 200 rpm. Plasmids were extracted using the GeneJETTM 
Plasmid Miniprep Kit (Fermentas, Ontario, Canada, Catalogue No.: K0503) according to 
manufacturer’s instructions. 
2.3 Polymerase Chain Reaction 
The polymerase chain reaction (PCR) was used to routinely amplify various DNA targets 
with MyTaqTM Red Mix (Bioline, London, UK, Catalogue No.: BIO-25044) according to the 
manufacturer’s instructions.  
 The reactions used the following thermal cycling conditions: 
 Initial denaturation  95°C for 5 min 
 Cycling conditions (30 cycles) 
i) Denaturation  95°C for 15 sec 
ii) Annealing (Ta) 15 sec (Temperature used is primer dependent) 
iii) Extension  72°C  (10 sec per 1 kb) 
Storage   4°C (Indefinite) 
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Where the amplicon was larger than 2 kb, a different polymerase, MyFiTM Mix 
(Bioline, London, UK, Catalogue No.: BIO-25050) was used with the same thermal cycling 
conditions with a modification in the extension time. The extension time using MyFiTM Mix 
was estimated as 60 sec per 1 kb amplicon. All primers (Table 2.5) used in this study were 
designed using Vector NTI AdvanceTM 11.5 (Life Technologies, USA). 
2.4 DNA Gel Electrophoresis 
Whenever DNA (plasmid or PCR amplicons) needed to be visualised, the DNA was separated 
using electrophoresis in 1% (w/v) agarose gels (Sigma-Aldrich, Catalogue No.: A9539). 
Midori Green nucleic acid stain (Labgene Scientific, Fribourg, Switzerland, Catalogue No.: 
MG02) was added into molten agarose (ca. 60°C) to give a final concentration of 1X (Stock 
concentration: 50,000X) before pouring the molten agarose into the electrophoresis gel tray. 
The DNA sample mixed with loading buffer (1 μl of 5X buffer per 4 μl of sample) was 
separated at 150 volts until the indicator dye has migrated 75% of the length of the gel. The 
separated DNA was visualised and images captured using G:Box Gel Documentation System 
(Syngene, Cambridge, UK). 
2.5 DNA Sequencing 
Where a nucleotide sequence was required, PCR amplicons were purified using the 
QIAquick® PCR purification Kit (Qiagen, Maryland, USA, Catalogue No.: 28104) or 
QIAquick® Gel Extraction Kit (Qiagen, Maryland, USA, Catalogue No.: 28704) according to 
manufacturer’s instructions. The purified amplicons were quantified using the Qubit® dsDNA 
HS Assay Kit (Life Technologies, USA, Catalogue No.: Q32854). Then, the sequencing 
reaction was prepared as instructed by and sent to the Genomics Laboratory, School of 
Biosciences, College of Life and Environmental Sciences, University of Birmingham. The 
 
 
Table 2.5 Primers used in this study 
 
Primer Name Amplicon 
(bp) 
Ta (°C) Sequence (5’ to 3’) Description Source 
RpoB-F1 4482 56 ACACTGTTTGACTACTGCTGTGC To amplify S. Typhimurium  
SL1344/ATCC14028s rpoB 
This study 
RpoB-R1 4482 56 CTCAGGTTTGAACGTACGGTAGT This study 
RpoB-R2 - - GGCATTGCGGAAAGTGT For sequencing of S. 
Typhimurium rpoB 
This study 
RpoB-F3 - - GCGAAGCCAGAGCAATT This study 
RpoB-R3 - - TCGCCAATACCTTTCGCAG For sequencing of S. 
Typhimurium rpoB 
This study 
RpoB-F4 - - ACGCCAAGCCGATTTCC This study 
RpoB-F5 - - TTCCACGGCATGAACGC For sequencing of S. 
Typhimurium rpoB 
This study 
RpoB-R4 - - ATGTGTGTCTCTGGGCGAG This study 
RpoB-R5 - - AAACGCCGTATCCAGCC For sequencing of S. 
Typhimurium rpoB 
This study 
RpoB-R2 - - TGAGGCATCAGGGTATCCA This study 
RpoB-Ecoli-F1 4288 56 GGCATTGCGGAAAGTGT To amplify E. coli rpoB This study 
RpoB-Ecoli-R1 4288 56 GCGAAGCCAGAGCAATT This study 
RpoB-Ecoli-F2 - - CGCATCTTTTGACATCGA For sequencing of E. coli rpoB This study 
RpoB-Ecoli-R2 - - GTAAGGCATATCTTCGATCG This study 
RpoB-Ecoli-F3 - - ACGCACAAACGTCGTATC For sequencing of E. coli rpoB This study 
RpoB-Ecoli-R3 - - GTTGTAACCATTCCACGG This study 
Ta: Annealing temperature 
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Table 2.5 Primers used in this study (Continued) 
 
Primer Name Amplicon 
(bp) 
Ta (°C) Sequence (5’ to 3’) Description Source 
RpoB-Ecoli-F4 - - TCAGAACATGCGCGTAG For sequencing of E. coli rpoB This study 
RpoB-Ecoli-F5 - - CGGTAACAAGGGTGTAATTT This study 
RpoB-Ecoli-R4 - - TTGTGCGTAATCTCAGACAG For sequencing of E. coli rpoB This study 
RpoB-Ecoli-R5 - - CGATGTACTCAACCGGG  This study 
KPCg-colpcrF 785 56 ATGTCACTGTATCGCCGTCT Internal primers for blaKPC gene This study 
KPCg-colpcrR 785 56 TAGACGGCCAACACAATAGG This study 
Chlor-Fwd   500 60 TTATACGCAAGGCGACAAGG To verify inactivation of Salmonella 
acrAB, no amplicon for wildtype 
Nishino et al. 
(2006) AcrA-Up 500 60 GATTGCGCCGCGCGTCACGCCAGCA 
AcrB-Down 415 60 TGCCCGATTTACGCCATTTTTGC To verify inactivation of Salmonella 
acrAB, no amplicon for wildtype 
Nishino et al. 
(2006) Chlor-Rev 415 60 GATCTTCCGTCACAGGTAGG 
TolC-Check-F 2489 56 CTTCTATCATGCCGGCGACC To verify inactivation of Salmonella 
tolC, mutant will yield 1812 bp 
Buckley et al. 
(2006) TolC-Check-R 2489 56 CGCTTGCTGGCACTGACCTT 
pQIL-F 383 56 CAGCATGACAGAATAGCGAGGCTT To differentiate pKpQIL-UK from -
D2 
This study 
pQIL-R 383 56 TACAAGGAGATGTGCCATGACCGT This study 
pMan-F 600 56 CTTACTGGCAAACTGTTGA To differentiate pKpQIL-D2 from -
UK 
This study 
pMan-R 600 56 ATCCCGTGTGTTCAAAA This study 
Ta: Annealing temperature 
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Table 2.5 Primers used in this study (Continued) 
 
Primer Name Amplicon 
(bp) 
Ta (°C) Sequence (5’ to 3’) Description Source 
NDM1-colpcrF 578 56 TTGATGCTGAGCGGGTG To verify the presence of blaNDM 
gene 
This study 
NDM1-colpcrR 578 56 CTGTCCTTGATCAGGCAGC This study 
pHK-F 1407 56 TTTTCATCGCGTATGCTCCC To verify the presence of pNDM-HK 
plasmid  
This study 
pHK-R 1407 56 AATACCGCTAAACCGCAACG This study 
acrB fwd 3482 51 CGGATGACAAAGTGGAAACC To verify inactivation of E. coli 
acrB, mutant would yield 1659 bp 
Morris, F 
acrB rvs 3482 51 CGTATGAGATCCTGAGTTGG Morris, F 
tolC fwd 2131 51 CCGCGATAAAGTGTTTCTCG To verify inactivation of E. coli tolC, 
mutant would yield 1976 bp 
Morris, F 
tolC rvs 2131 51 TTCAGCGCATTGTTGTACGC Morris, F 
OmpC-F 1927 53 TCGATACCAACCACGCTCAC To verify inactivation of ompC, 2207 
bp (+aph), 753 bp (∆ompC) 
Lawler, A 
OmpC-R 1927 53 TCTTACGAACGGTGCAGCAG Lawler, A 
OmpF-F 780 53 CCGTCAATGCCGAGATAGTT To verify inactivation of ompF, no 
amplicon for wildtype 
Lawler, A 
OmpF-R 780 53 CAGTCATAGCCGAATAGCCT Lawler, A 
gyrB-F 273 45 GTACCTGGTGGAAGGGGACT To check for DNA contamination in 
RNA samples 
Blair, J 
gyrB-R 273 45 AACAGCAGCGTACGGATG Blair, J 
KpQIL-KPC-F 1580 56 AGCTACCGCTTGAAGGACAA To sequence the entire blaKPC gene This study 
KpQIL-KPC-R 1580 56 GGATTGCGTCAGTTCAGCAT This study 
Ta: Annealing temperature 
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Table 2.5 Primers used in this study (Continued) 
 
Primer 
Name 
Amplicon 
(bp) 
Ta (°C) Sequence (5’ to 3’) Description Source 
KPCg-KO-F 1494 51 CAACCTCGTCGCGGAACCATTCGCTAAACTCGAA
CAGGACTTTG(GTGTAGGCTGGAGCTGCTTC) 
For inactivation of blaKPC-2 
gene on pKpQIL-UK & -
D2 plasmid. Nucleotide 
sequence in parenthesis is 
homologous to the aph 
gene  
This study 
KPCg-KO-R   GCCAGTGCAGAGCCCAGTGTCAGTTTTTGTAAGC
TTTCCG(GGGAATTAGCCATGGTCCAT) 
 
Ta: Annealing temperature 
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sequencing services provided used BigDye terminator chemistry. The obtained nucleotide 
sequence was analysed using Vector NTI AdvanceTM 11.5 (Life Technologies, USA). 
2.6 Insertional Inactivation of Plasmidic Genes  
The method used to inactivate plasmidic genes by insertion of an antibiotic resistance marker 
in the target gene and was done as previously described (Sharan et al., 2009, Cottell et al., 
2014, Cottell et al., 2012) with some modifications as listed below. 
2.6.1 Primer design 
The primers used to amplify the aminoglycoside phosphotransferase (aph) or 
chloramphenicol acetyltransferase (cat) antibiotic resistance marker conferring kanamycin 
and chloramphenicol resistance, respectively, consisted of 40 bp of sequence homologous to 
the target plasmid gene either side of 20 bp of sequence homologous to the antibiotic 
resistance marker i.e. aph or cat gene. 
2.6.2 Electrocompetent Cell Preparation and Electroporation 
Where plasmids needed to be transferred into E. coli SW105 which contained a 
chromosomally encoded λ-Red recombinase gene for inactivating plasmidic genes (Warming 
et al., 2005), electrocompetent cells were prepared by inoculating an overnight culture of the 
bacteria into 50 ml fresh LB broth at a 1:50 dilution and incubated at 30°C (to avoid 
expression of the recombinase genes) with shaking at 200 rpm. When the culture achieved 
mid-logarithmic phase i.e. an optical density at a wavelength of 600 nm (OD600) of 
approximately 0.6, the culture was chilled in ice slurry for 15 min. Then, the culture was 
centrifuged at 4°C, 2,500 x g, 15 min. The cell pellet was resuspended in 50 ml of sterile 15% 
(v/v) ice-cold glycerol (Sigma-Aldrich, Missouri, USA, Catalogue No.: G5516), followed by 
centrifugation at 4°C, 2,500 x g, 15 min. This washing step was repeated twice and the cell 
pellet was resuspended in 100 µl ice-cold 15% glycerol. A volume of 50 µl of 
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electrocompetent cells was used for each electroporation. About 20 – 100 ng plasmid DNA 
was mixed with the electrocompetent cells and the cell suspension was left on ice for 15 min. 
The electroporation parameters used were 13 kV/cm, 25 µF, 200 Ω and 5 ms. Immediately 
after electroporation, 1 ml of pre-warmed (30°C) LB broth was added to the cells and mixed 
gently by pipetting. The transformants were recovered at 30°C with shaking at 200 rpm for 3 
hours. Then, 100 µl of the transformants were spread on the surface of LB agar supplemented 
with appropriate antibiotics (Table 2.2) and incubated overnight at 30°C. The transformants 
were verified by PCR to carry the plasmid of interest. 
2.6.3 Gene Inactivation by Homologous Recombination 
Plasmids harbouring target genes were transferred into E. coli SW105 (Warming et al., 2005) 
by electroporation (Section 2.6.2). The amplicons generated using the chimeric primers were 
purified by the QIAquick® PCR Purification Kit or QIAquick® Gel Extraction Kit. Two 50 ml 
LB broths were inoculated with overnight cultures of E. coli SW105 carrying the plasmid of 
interest at a dilution of 1 in 50 and were allowed to grow at 30°C until an OD600 of 0.6. One 
of the cultures was then incubated at 42°C with shaking for 15 min to activate the λ-Red 
Recombinase. The other culture was left at 30°C as the non-activated control. After the 
incubation, both cultures were immediately cooled in ice-slurry for 15 min. The cells were 
made electrocompetent and electroporation was also done as in Section 2.6.2. The amplicons 
were electroporated into E. coli SW105 carrying the plasmid of interest. Depending on the 
resistance cassette use for gene inactivation, the transformants were selected on LB agar 
supplemented with 50 µg/ml kanamycin or 25 µg/ml chloramphenicol. Successful 
inactivation of the target gene was further verified by PCR and sequencing using appropriate 
primers (Table 2.5). The recombinant plasmid was then extracted and transferred into 
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Invitrogen MegaX DH10BTM T1R ElectrocompTM cells (Invitrogen, California, USA, 
Catalogue No.: C6400-03) by electroporation following manufacturer’s instructions. 
2.7 β-lactamase Assay 
β-lactamase activity was studied by measuring the hydrolysis of nitrocefin evident as a colour 
change. An overnight culture was diluted 1 in 50 in 100 ml of fresh LB broth and allowed to 
grow until an OD600 of 0.6 at 37°C with shaking (200 rpm). The culture was centrifuged at 
2,500 x g for 10 min at 4°C. The cell pellet was resuspended in 3 ml of ice-cold sodium 
phosphate buffer pH 7.0. The cell suspension was sonicated in ice slurry (Soniprep 150, MSE, 
UK) at an amplitude of 5 micron for 30 seconds four times with 30-second intervals to avoid 
overheating of the cell lysates. The cell lysate was centrifuged at 12,000 x g for 10 min at 4°C. 
The supernatant which contains the β-lactamase was transferred into a new microfuge tube. 
The amount of total protein was determined using the Bradford Reagent (Sigma-Aldrich, 
Missouri, USA, Catalogue No.: B6916) by mixing 10 μl of the samples with 990 μl of the 
reagent and measuring the absorbance at a wavelength of 595 nm. The values were compared 
against a series of bovine serum albumin (Sigma-Aldrich, Missouri, USA, Catalogue No.: 
P0914) of known concentrations (0.05 – 0.5 mg/ml). A total of 15 µg of total protein in 50 μl 
sodium phosphate buffer was transferred into wells of 96-well plate (Appleton Woods, 
Birmingham, UK, Catalogue No.: CC653) in triplicates. Freshly prepared nitrocefin (Oxoid, 
Massachusetts, USA, Catalogue No.: SR0112) was added into the reservoir of the injector of 
a FLUOstar Optima plate reader (BMG Labtech, Ortenberg, Germany). The injector was set 
to inject 10 μl of nitrocefin after 10 seconds incubation and the absorbance was monitored at a 
wavelength of 482 nm every minute for 5 minutes. The changes in absorbance were then 
plotted against time. The slopes of the initial reaction (where the graph was linear) were 
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compared against the S. Typhimurium 14028s crude lysate control. The experiment was 
repeated three times and significant difference was analysed using Student’s t-test (p<0.05). 
2.8 Hoechst 33342 Accumulation Assay 
The activity of efflux pumps was inferred by measuring accumulation of Hoechst 33342 
efflux substrate in the absence and presence of efflux inhibitors as previously described 
(Webber and Coldham, 2010). An overnight culture of the strain of interest was diluted with 
fresh LB broth to give a 4% inoculum in 10 ml. The culture was allowed to grow at 37°C with 
shaking (200 rpm) until it achieved an OD600 of 0.6. The cultures were centrifuged at 2,500 x 
g for 10 min at room temperature. The supernatant was discarded and the cell pellet was 
resuspended in 3 ml sterile phosphate saline buffer (PBS) (Life Technologies, California, 
USA, Catalogue No.: 14190-094). The OD600 of the suspension was determined again and 
each cell suspension was diluted to an OD600 of 0.1 with PBS. Then, 180 μl of the diluted cell 
suspension was transferred into three wells in a black 96-well plate (Appleton Woods, 
Birmingham, UK, Catalogue No.: CC708). Three replicates (176 μl) of the same cell 
suspension were added into three more wells and 4 μl of 50X efflux inhibitor was added (e.g. 
if a final concentration of 25 µg/ml PAβN was needed, then 4 μl of 1250 µg/ml PAβN was 
added into the wells). For positive control, 200 μl of boiled overnight culture was transferred 
into three wells. For negative control, 200 μl PBS was transferred into three wells and 180 μl 
PBS was added into another three wells. The fluorescence of each well was monitored at 
37°C using FLUOstar Optima plate reader (BMG Labtech, Ortenberg, Germany). The 
reservoir of the injector was added with 25 μM Hoechst 33342 (Sigma-Aldrich, Missouri, 
USA, Catalogue No.: B2261). The injector was set to inject 20 μl of Hoechst 33342 into wells 
containing 180 μl of cell suspension. The fluorescence was measured at an excitation and 
emission wavelengths of 355 and 465 nm, respectively for 30 cycles (1 min per cycle). The 
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fluorescence of the samples at the 30th cycle were compared using Student’s t-test with 
p<0.05 considered as significant. 
2.9 Outer Membrane Protein Extraction 
Bacterial outer membrane proteins were purified as previously described (Piddock et al., 
1990). Briefly, an overnight culture of the bacteria of interest was diluted 1 in 50 in 90 ml of 
fresh LB broth and allowed to grow until an OD600 of 0.6. The cultures were centrifuged at 
2,500 x g and 4°C for 15 min. The supernatant was discarded and the cell pellet was 
resuspended in 30 ml of 50 mM sodium phosphate buffer pH 7.0 to wash the cells. The cell 
suspension was centrifuged again at 2,500 x g and 4°C for 15 min. The washed cell pellet was 
resuspended in 1 ml of 50 mM sodium phosphate buffer pH 7.0 and transferred into a sterile 
microfuge tube and froze overnight at -80°C. After freezing, the cell suspension was thawed 
on ice then homogenised by sonication in ice slurry (Soniprep 150, MSE, UK) at 5 micron 
amplitude for 30 seconds for four times with 30-second intervals to avoid overheating of the 
cell lysates. The cell lysates were centrifuged at 6,000 x g for 1 min at 4°C to discard larger 
cell debris. The supernatant was transferred into a microfuge tube and centrifuged again at 
12,000 x g for 30 min at 4°C. Then, the supernatant was discarded. The pellet was 
resuspended vigorously in 200 μl 2% sarcosyl (Sigma-Aldrich, Missouri, USA, Catalogue No.: 
L5125) and incubated at room temperature for 30 min. The samples were centrifuged again at 
12,000 x g for 30 min at 10°C. All the supernatant was carefully removed to ensure most of 
the detergent containing solution had been removed. The protein pellet was resuspended in 
100 μl of 50 mM sodium phosphate buffer pH 7.0 and centrifuged at 12,000 x g for 10 min at 
4°C to remove residual detergent from the outer membrane protein preparations. The 
supernatant was discarded and the extracted outer membrane proteins were resuspended in 50 
μl of 50 mM sodium phosphate buffer pH 7.0. The amount of total protein in each samples 
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were quantified using Bradford Reagent (Sigma-Aldrich, Missouri, USA, Catalogue No.: 
B6916) against a series of bovine serum albumin standards (Sigma-Aldrich, Missouri, USA, 
Catalogue No.: P0914) of known concentrations (0.05 – 0.5 mg/ml).  
2.10 Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
The extracted outer membrane proteins were separated by SDS-PAGE using a PROTEAN® 
II xi Electrophoresis Cell (Bio-Rad, California, USA). A 16 x 20 x 0.1 cm discontinuous gel 
(4% stacking gel and 10 % resolving gel) was prepared according to the manufacturer’s 
instruction for the separation of protein samples. Sample loading buffer (Sigma-Aldrich, 
Missouri, USA, Catalogue No.: 161-0747) was added to the protein samples and the protein 
samples were heated at 95°C for 10 min. A total of 2 µg of total protein was loaded per lane 
for separation. The electrophoresis was done using 1X Tris/Glycine/SDS buffer (Sigma-
Aldrich, Missouri, USA, Catalogue No.: 161-0732). Once the protein samples had been 
loaded into the wells, electrophoresis was started using 100 volts (constant) until the samples 
migrated into the resolving gel where the voltage was increased to 200 volts. The protein 
samples were allowed to separate until the dye front reached the end of the gel. The gel was 
then carefully removed from the electrophoresis tank and stained with PhastGel® Blue R 
(Sigma-Aldrich, Missouri, USA, Catalogue No.: B4921) for 1 hour with gentle shaking. Then, 
the protein gel was de-stained using de-staining buffer [10% (v/v) methanol and 5% (v/v) 
acetic acid in water] overnight with gentle shaking. The de-stained protein gel was visualised 
and image taken using G:Box Gel Documentation System (Syngene, Cambridge, UK).   
2.11 Selection of Rifampicin Resistant Bacteria 
To determine the conjugation frequency of plasmids or to transfer the plasmids into different 
bacterial strains, recipient strains required a selection marker to differentiate the 
transconjugants from the donor strain. Selection of rifampicin resistant mutants was used to 
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gain strains suitable for selection. A single colony of the desired recipient strain was 
inoculated into 10 ml of Iso-sensitest broth (Oxoid, Massachusetts, USA, Catalogue No.: 
CM0473) and incubated overnight at 37°C, 200 rpm. The overnight bacterial culture was sub-
cultured into 100 ml of Iso-sensitest broth at a dilution of 1:100 and incubated overnight at 
37°C (shaken at 200 rpm). A volume of 100 µl of the culture at various concentrations and 
dilutions (100X, 10X, 1X, 0.1X and 0.01X) was then spread on Iso-sensitest agar (Oxoid, 
Massachusetts, USA, Catalogue No.: CM0471) supplemented with 100 µg/ml rifampicin. The 
culture was also serially diluted and spread on antibiotic-free Iso-sensitest agar to determine 
the viable count. The mutation frequency of the rifampicin resistant strain was determined as 
the number of rifampicin-resistant mutants [colony forming unit (cfu)/ml] divided by the total 
number of colonies (cfu/ml) of the strain determined by viable counting. 
2.12 P22 Transduction 
Bacteriophage P22 was used to transfer genes inactivated by insertion of antibiotic resistance 
genes (e.g. acrAB::cat and tolC::cat) into different S. Typhimurium strains. An overnight 
culture of the strain carrying the genes to be transferred by P22 was diluted 1 in 100 in 5 ml 
LB broth supplemented with filter-sterilised 10 mM magnesium (II) sulphate (MgSO4) 
(Sigma-Aldrich, Missouri, USA, Catalogue No.: M7506) and 5 mM calcium (II) chloride 
(CaCl2) (Sigma-Aldrich, Missouri, USA, Catalogue No.: C1016). The culture was incubated 
for 30 min at 37°C with shaking, 200 rpm. Then, 5 μl of P22 stock was added to this culture 
and left to incubate overnight at 37°C with shaking. After the overnight incubation, 1 ml of 
chloroform (Sigma-Aldrich, Missouri, USA, Catalogue No.: C2432) was added to the culture 
and mixed with vigorous shaking. The lysed cells were centrifuged at 2,500 x g for 15 min at 
4°C. The supernatant was transferred into a sterile glass bottle and 200 μl of chloroform was 
added. This phage stock was stored at 4°C until further use.  
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In order to transfer genes containing markers into the strain of interest, 5 ml overnight 
culture of the recipient strain was centrifuged at 2,500 x g for 15 min at room temperature. 
The cell pellet was resuspended in 1 ml LB broth supplemented with 10 mM MgSO4 and 5 
mM CaCl2. Then, various volumes (5, 10, 50 and 100 μl) of the prepared phage stock were 
added to 100 μl aliquots of the resuspended cell pellet. The cell suspension was incubated at 
37°C for 15 min. To stop the transduction, 1 ml of LB broth and 100 μl of filter-sterilised 1 M 
sodium citrate (Sigma-Aldrich, Missouri, USA, Catalogue No.: C7254) were added to the cell 
suspensions (transductants). The mixtures were incubated at 37°C for 45 min. The 
transductants were spread on LB agar supplemented with the relevant antibiotics (Table 2.3) 
and incubated at 37°C for 24 – 48 hours.  
2.13 Conjugation 
The plasmids used in this study are large. Hence, filter conjugation was frequently used to 
transfer the plasmids between bacterial strains and species. A volume of 1 ml of overnight 
liquid culture of donor and recipient strains grown with the appropriate antibiotics were 
centrifuged at 12,000 x g for 1 min. The cell pellets were washed with 1 ml of fresh LB broth 
and centrifuged again to remove traces of antibiotic from the overnight culture. The donor and 
recipient cell pellets were each resuspended in 50 µl of LB broth and mixed together. The cell 
suspension was transferred on to a sterile 0.45 µm 25 mm nylon membrane filter (Millipore, 
Massachusetts, USA, Catalogue No.: HNWP02500) placed on LB agar and incubated 
overnight at 37°C to ensure the plasmids have been successfully transferred. Then, the 
membrane filter was transferred into a sterile microfuge tube and 1 ml of LB broth was added. 
The cells were detached from the membrane by vigorous agitation. The filter membrane was 
removed after the cell suspension was centrifuged at 12,000 x g for 1 min. The supernatant 
was removed and the cell pellet was resuspended in 1 ml of LB broth. The cell suspension 
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was serially diluted and spread on LB agar supplemented with the necessary antibiotics (Table 
2.3) to obtain single colonies. 
2.14 Growth Kinetics 
Bacterial growth rate at the logarithmic phase was used to determine the fitness of the strain 
when a particular mutation or plasmid had been introduced into the strain (Cottell et al., 2014). 
To do this, a single colony was inoculated into LB broth supplemented with the appropriate 
antibiotic and incubated overnight at 37°C, 200 rpm. The overnight culture was diluted with 
fresh LB broth to give a final inoculum of 4% (v/v). A volume of 200 µl of this diluted culture 
was transferred into wells of 96-well microtitre plate (Sterilin, Catalogue No.: 612U96). Three 
biological replicates and four technical replicates were used per experiment. The growth of 
the cultures was monitored at OD600 at 10 min intervals per cycle for 100 cycles using the 
FLUOstar Optima plate reader (BMG Labtech, Ortenberg, Germany). The growth rates 
(generation time) for the bacteria were calculated from the logarithmic phase of growth using 
the following formula: 
Generation time ൌ ሺݐଵ െ ݐ଴ሻ
൜3.3  ൈ ቂ݈݋݃ଵ଴ ቀ݊ଵ݊଴ቁቃൠ 
 
Where, t1 – t0 is the difference in minutes between the estimated time when the logarithmic 
growth phase ends and starts. The variables, n1 and n0 are the estimated number of cells at the 
end and the beginning of the logarithmic growth phase obtained by multiplication of the 
OD600 reading with a constant of 106. The experiment was repeated three times. The 
generation times were compared using a Student’s t-test, p values less than 0.05 were 
considered statistically significant. 
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2.15 Determination of Conjugation Frequency 
The conjugation frequency of plasmids from their original clinical isolates was determined as 
previously described (Cottell et al., 2014). Overnight cultures of the donor and recipient 
bacterial strains were prepared from single colonies. Overnight cultures of the donor and 
recipient strains were then used to inoculate fresh 20 ml LB broth cultures at a dilution of 1 in 
50. This fresh culture was allowed to incubate at 37°C with shaking (200 rpm) until they 
reached an OD600 of 0.6. Then, 1 ml of the culture was transferred into sterile microfuge tubes. 
The donor and recipient strains were centrifuged at 12,000 x g, 1 min and the supernatants 
were discarded. The donor was resuspended in 100 μl LB broth while the recipient strain was 
resuspended in 50 μl LB broth. Then, 50 μl of the donor strain was mixed with 50 μl of the 
recipient strain so that the donor:recipient ratio was 1:2. This was done to ensure that all 
donor cells were in contact with at least one recipient cell. The suspension was then 
transferred on to sterile 0.45 μm nylon filters placed on LB agar. The conjugation mixture was 
then left to incubate at 37°C for 3 hours. After the incubation period, the filter was aseptically 
transferred into a sterile microfuge tube and 1 ml of LB broth was added. The transconjugants 
were liberated from the filters by vigorous agitation. The transconjugants were serially diluted 
and plated on LB agar supplemented with relevant antibiotics. The transconjugants were left 
to incubate overnight at 37°C. The conjugation frequency of the plasmids was calculated 
according to the formula below. Conjugation frequencies were determined on three separate 
occasions and differences were deemed significant when p<0.05 by Student’s t-test. 
Conjugation Frequency  ൌ  Number of transconjugants (cfu/ml)1
2 ൈ Number of donors (cfu/ml)
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2.16 Minimum Inhibitory Concentration (MIC) Determination 
The MIC of various antibiotics against the strains used in this study was routinely determined. 
The values were determined using the guidelines recommended by the British Society for 
Antimicrobial Chemotherapy (BSAC) (Andrews, 2001). E. coli NCTC10418 was used as a 
control strain for susceptibility testing. Where the MIC values of the control strain were not 
within 2-fold dilution of those reported in the BSAC guidelines, all the MIC values for that 
particular experiment were disregarded. Similarly, a difference in MIC value of more than 2-
fold dilution was considered significant according to BSAC guidelines. 
2.17 Biofilm Assay 
2.17.1 Biofilm Formation on Plastic in Microtitre Tray 
The impact of plasmid carriage on biofilm formation by bacterial strains was assessed in 96-
well microtitre trays as previously described (Baugh et al., 2012). Briefly, overnight cultures 
of the bacterial strains were diluted in fresh LB broth without sodium chloride [10 g/L 
tryptone (Oxoid, Catalogue No.: LP0042) and 5 g/L yeast extract (Oxoid, Catalogue No.: 
LP0021)] to give a final inoculum of 4% (v/v). It has been shown that Salmonella strains are 
able to form biofilm more efficiently in LB broth without salt (Jain and Chen, 2007). Hence, 
this condition was chosen and used throughout the biofilm assays. A total of 200 μl of the 
diluted liquid culture was transferred into the wells of the microtitre tray. The microtitre tray 
was incubated at 30°C with gentle shaking for 48 hours. After incubation, the cultures were 
decanted from the tray and the biofilm formed in the wells was stained with 0.1% (w/v) 
crystal violet solution (Sigma Aldrich, Missouri, USA, Catalogue No.: C6158) for 15 min. 
Then, the dye was removed and the microtitre tray was washed with sterile water to remove 
the excess dye. The crystal violet stain was solubilised in 200 μl of 70% (v/v) ethanol (Analar 
Normapur, Pennsylvania, USA, Catalogue No.: 20821.330) with gentle shaking for 15 min. 
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The intensity of the solubilised crystal violet which relates to the amount of biofilm formed 
was measured at OD600. In each experiment, three biological and four technical replicates 
were included for each strains tested. The biofilm formation of each strain was determined in 
three independent experiments. The data were analysed using Student’s t-test and p<0.05 was 
considered as significant. 
2.17.2 Biofilm Formation on Glass Under Flow 
The ability of the plasmid carrying bacteria to form biofilms was also assessed under constant 
flow of liquid media in glass microfluidic flow cells as previously described (Baugh et al., 
2014) with some modifications. In order to prime the BioFluxTM 200 48-well low shear plate 
(0-20 dynes/cm2) (Fluxion Biosciences, California, USA), 200 μl of LB broth (without salt) 
was added into the output well (used for waste collection) (Figure 2.1a). The BioFluxTM 
interface was tightly fastened on to the 48-well plate. Flow tubes were attached to the 
BioFluxTM interface and the settings (LB broth at 19°C, flow rate = 5 dynes/min) were 
selected on the BioFluxTM system software. The flow of LB (without salt) was started by 
applying air pressure at the output well to allow the flow channel to be primed with broth for 
5 min. Overnight cultures of the strains were diluted into an OD600 of 0.1. The excess broth 
was removed from the input and output wells (Dark blue) (Figure 2.1a). This left a small 
amount of broth in the inner region (Orange) of the input and output wells. About 50 μl of LB 
broth (without salt) was added to the input well. An equal volume of diluted bacteria was 
added into the output well. Then, the BioFluxTM interface was attached and the air pressure 
was applied on the output well again at a flow rate of 3 dynes/min for 3 seconds. The flow 
was then stopped immediately. The presence of bacteria in the flow cell (Light blue) (Figure 
2.1a) was verified with a LabtechScope LTSi-1000 inverted microscope (Labnet, New Jersey, 
USA) at 400X magnification. The 48-well plate was then incubated on a heating block 
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Each microfluidic system consists 
of a paired inlet and outlet well, 
and a channel which links the 
two. 
Input Wells Output Wells 
Observation 
Area 
(a) 
(a) The general layout of the BioFlux system (Top view). (b) The functions of the 
individual components of the BioFlux system (Side view). The air pressure will force the 
LB broth (no salt) in the input well (1) to slowly flow through the microfluidic channel 
into the output well (2) at a constant flow rate. This will provide constant nutrients to the 
bacteria and mimic the conditions within blood vessels. The Bioflux interface (3) creates 
an airtight environment between the wells and the environment. The cover glass bottom 
(5) allows bacterial cells (6) to attach and form the biofilm. An inverted microscope can 
be used to observe the biofilm in the observation area (4).  
 
Source: Adapted from BioFluxTM instruction manual. 
Figure 2.1 BioFlux system 
(b) 
Microscope
Observation area 
Attached bacterial cells
Output wellInput well 
Air pressure Pressure interface
Cover glass bottom 
75 
 
(AccuBlockTM, Labnet) set at 30°C for 2 hours. This is to allow the bacteria to attach to the 
surface of the microfluidic channel (Figure 2.1b). After incubation, the excess broth was 
removed from the output well and 1 ml of fresh LB broth (without salt) was added into the 
input well. The flow rate was set to a constant 0.3 dynes/min by applying air pressure on the 
input well and the plate was incubated on the heating block for 48 hours. The biofilms were 
observed at 6, 12, 24 and 48-hour time points at 400X magnification. The area of coverage by 
the biofilm in the microfluidic channel was determined using image analysis software, ImageJ 
(http://imagej.nih.gov/ij/). The student’s t-test was used to determined whether a significant 
difference (p<0.05) was observed in the area of coverage. 
2.18 Plasmid Persistence 
The proportion of the bacterial population which retains a plasmid was determined over a 
period of 20 days as previously described (Cottell et al., 2014). A single colony was 
inoculated in 10 ml LB broth supplemented with 0.25 µg/ml doripenem. The culture was 
incubated overnight at 37°C with agitation, 200 rpm. On the next day, the culture was sub-
cultured into 10 ml of fresh LB broth without antibiotics at a dilution of 1 in 100. This step 
was repeated daily for 20 days. At appropriate intervals (e.g. day 5, 10, 15 and 20), the culture 
was serially diluted and plated on LB agar and incubated overnight at 37°C. On the following 
day, the colonies were replica plated using sterile velveteen squares on to LB agar 
supplemented with 0.25 µg/ml doripenem. The retention of the plasmid in a particular 
bacterial strain was calculated as a percentage of doripenem resistant colonies over the total 
number of colonies observed on the antibiotic-free LB agar. The experiment was repeated on 
three separate occasions. To determine the number of generations the bacterial strains had 
achieved after 24 hours of incubation, viable counting was done to determine the number of 
cfu/ml of bacteria after the sub-culturing step of 1 in 100 and after the 24-hour incubation 
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period. The number of generations the bacteria had achieved after 24 hours were calculated 
using the following formula: 
Number of generations  ൌ logଶ P െ logଶ Q  
 
P is the number of cfu/ml of the culture after 24 hours of incubation whereas Q is the number 
of cfu/ml after the initial dilution of the overnight culture. 
2.19 Pairwise Competition Assay 
Single colonies of pKpQIL-UK and pKpQIL-D2 blaKPC::aph carrying K. pneumoniae Ecl8Rif 
strains were inoculated into 10 ml LB broth supplemented with 0.25 µg/ml doripenem and the 
cultures were incubated overnight at 37°C (shaken at 200 rpm). The overnight cultures were 
diluted with fresh LB broth into an OD600 of 0.1. Then, 50 μl of each bacterial culture was 
inoculated into 10 ml of fresh LB broth without antibiotic selection. The cultures were 
incubated overnight at 37°C with agitation (200 rpm). On the following day, the culture was 
sub-cultured into 10 ml of fresh LB broth to give a 1 in 100 dilution. This step was repeated 
20 days to allow both bacterial strains to compete against each other over the duration of the 
experiment. To determine the ratio of both of the plasmid carrying strains within the 
population, the culture was serially diluted and plated on LB agar and incubated overnight at 
37°C at appropriate intervals (e.g. day 5, 10, 15 and 20). On the following day, the colonies 
were replica plated using sterile velveteen squares on to two LB agar each supplemented with 
0.25 µg/ml doripenem and 50 µg/ml kanamycin. The competition experiment was repeated on 
three separate occasions. The competition index of the bacterial strains was calculated using 
the following formula (Luo et al., 2005):  
Competition Index  ൌ    X  െ  YX  ൅  Y 
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X is the average proportion of pKpQIL-D2 carrying K. pneumoniae Ecl8Rif in the total 
bacterial population whereas Y is the equivalent for the pKpQIL-UK carrying strain at the end 
of the experiment. A positive value indicates that the pKpQIL-D2 carrying strain is fitter than 
the pKpQIL-UK carrying strain. A negative value indicates the opposite. 
2.20 Galleria mellonella Infection Model 
Overnight cultures of K. pneumoniae ST258 and its pKpQIL-UK and -D2 carrying strains 
were prepared by inoculating a single colony of the bacterial strain into 10 ml LB broth 
supplemented with 0.25 µg/ml doripenem. Viable counting was done to determine the cfu/ml 
of the overnight cultures of the K. pneumoniae ST258 and its pKpQIL-UK and -D2 carrying 
strains. The Galleria mellonella Wax Moth larvae were purchased from Livefood UK Limited 
(www.livefoods.co.uk). The larvae were placed in groups of 10 into sterile petri dishes. The 
larvae used were about 2 cm in length. Using the data from the viable counting, the overnight 
cultures of the bacterial strains were diluted in sterile PBS to obtain an inoculum of 107 cfu/ml. 
A total of 105 cfu in 10 μl was injected into each larva at the last right proleg. The larvae were 
incubated in the dark at 37°C. The percentage of survival of the larvae was recorded every 24 
hours over a period of five days. The larva was considered dead when it was black in colour 
and no movement was observed when the larva was gently agitated. The experiment was 
repeated on two separate occasions. Log-rank (Mantel-Cox) test was used to determine 
whether a significant difference (p<0.05) was observed between the groups of larvae infected 
with the different strains.  
2.21 RNA Sequencing 
2.21.1 RNA Extraction 
In order to understand the effects of plasmids on host bacterium gene expression, RNA 
sequencing was used. Five overnight cultures (biological replicates) of the strains of interest 
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(K. pneumoniae ST258, K. pneumoniae ST258/pKpQIL-UK and K. pneumoniae 
ST258/pKpQIL-D2) were grown in MOPS minimal medium (Teknova, California, USA, 
Catalogue No.: M2101) at 37°C with shaking, 200 rpm. The strains were then sub-cultured 
into fresh MOPS medium the next day at a dilution of 1 in 50 and allowed to grow until the 
OD600 reached 0.6. Then, three OD units of the culture were centrifuged at 12,000 x g, 1 min. 
RNA was extracted from the cell pellets using the RiboPureTM RNA Purification Kit (Ambion, 
California, USA, Catalogue No.: AM1925) according to the manufacturer’s instructions. 
Instead of using a vortex mixer as instructed by the manual, bacterial cells were homogenised 
three times using a RiboLyser (Hybaid, Basingstoke, UK) at 6.5 meters/sec for 45 sec (with 1 
min interval to avoid overheating) to disrupt the capsular cells. The extracted RNA was 
diluted 1 in 10 and quantified using a Qubit® RNA HS Assay Kit (Life Technologies, 
Catalogue No.: Q32852). Undiluted RNA was also quantified for the presence of 
contaminating DNA using a Qubit® dsDNA HS Assay Kit (Life Technologies, Catalogue No.: 
Q32854). The percentage of DNA over the total amount of nucleic acid (DNA+RNA) was 
calculated. Where the percentage of DNA exceeded 5%, RNA samples were treated with 
TURBOTM DNase (Ambion, Catalogue No.: AM1907). DNase treatment was repeated until 
the percentage of DNA was less than 5%. Contamination with genomic DNA will reduce the 
efficiency of ribosomal RNA (rRNA) removal and affect RNA library preparation. The 
presence of DNA was also confirmed using PCR (40 cycles) to amplify the gyrase gene 
(gyrB). The quality of the DNAse-treated RNA samples was analysed using a 2100 
Bioanalyzer (Agilent, California, USA) with the RNA 6000 Nano Kit (Agilent, California, 
USA, Catalogue No.: 5067-1511).  
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2.21.2 Ribosomal RNA (rRNA) Reduction 
To avoid rRNA saturation of the RNA sequencing experiment, rRNA depletion is needed. 
The efficiency of the rRNA removal can be affected by the presence of contaminating salts 
and solvents from the reagents of the RNA extraction and DNAse treatment kits. Hence, 
samples with no detectable DNA contamination were purified to remove salts or solvents 
using the RNA Clean & ConcentratorTM-5 Kit (Zymo Research, California, USA, Catalogue 
No.: R1015). The RNA was eluted with RNAse-free water in the final step of the clean-up 
process. The ribosomal RNA in the purified total RNA samples was depleted using the Ribo-
ZeroTM rRNA Removal Kit (Gram-negative bacteria) (Epicentre, Wisconsin, USA, Catalogue 
No.: MRZGN126) according to the manufacturer’s instructions. Although the kit’s manual 
stated a maximum of 5 µg total RNA can be used per reaction, a lesser amount ca. 2 – 4 µg 
was used to avoid overloading of the reaction which would result in reduced rRNA removal 
efficiency. The rRNA-depleted RNA samples were concentrated into 7 μl total volume using 
the RNA Clean & ConcentratorTM-5 Kit in RNAse-free water. Then, the samples (1 μl each) 
were analysed using 2100 Bioanalyzer (Agilent, California, USA) with the RNA 6000 Pico 
Kit (Agilent, California, USA, Catalogue No.: 5067-1513) which can detect a lower 
concentration of RNA compared to the RNA 6000 Nano Kit. 
2.21.3 RNA Library Preparation 
Four RNA samples from each of the three strains (K. pneumoniae ST258, K. pneumoniae 
ST258/pKpQIL-UK and K. pneumoniae ST258/pKpQIL-D2) which possessed the correct 
quantity (10 – 400 ng) and quality (no detectable rRNA, DNA contamination and RNA 
degradation) were chosen for library preparation. The library preparation used the TruSeq® 
Stranded mRNA Sample Preparation Kit (Illumina, California, USA, Catalogue No.: RS-122-
2102). The kit is designed for library preparation with eukaryotic mRNA. Therefore, the 
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initial stages of mRNA purification stated in the manufacturer’s manual were replaced with 
rRNA-depletion (Section 2.21.2). For each sample, a volume of 5 μl of concentrated rRNA-
depleted RNA (10 – 400 ng) was used for library preparation. The process began with 
fragmentation of the RNA transcripts to smaller fragments by heating and priming with 
random hexamers at 94°C. The fragmented RNA was then converted to cDNA 
(complementary DNA) using reverse transcriptase and then into double stranded cDNA. Each 
of the 12 samples (cDNA) was then ligated with different adapters which possessed unique 
nucleotide sequences. The adapters were needed to differentiate all the 12 samples during 
sequencing. The double stranded cDNA linked with adapters were selectively enriched by 
PCR and purified as instructed in the manufacturer’s manual. The quality of the prepared 
libraries for each sample were determined using the 2200 TapeStation (Agilent, California, 
USA) with the D1000 ScreenTape Kit (Agilent, California, USA, Catalogue No.: 5067-5582). 
A successful library preparation yielded a single major peak representing a majority of 260 bp 
amplicons on the electropherogram. The libraries were also diluted 1000 times in nuclease-
free water and quantified using the KAPA Library Quantification Kit for Next-Generation 
Sequencing (KAPA Biosystems, Massachusetts, USA, Catalogue No.: KK4824). This kit 
quantifies the library by measuring their amplification signals using qRT-PCR against a 
standard curve. All the libraries were then normalised to 10 nM and pooled together. 
2.21.4 Sequencing 
Before the sequencing step, the pooled library was diluted to 1 nM in nuclease-free water. A 
volume of 20 μl of the 1 nM library was mixed with 20 μl sodium hydroxide (0.2 N) (Sigma-
Aldrich, Missouri, USA, Catalogue No.: 72082) to denature the library into single stranded 
cDNA. The mixture was incubated at room temperature for 5 min. Then, 40 μl of 200 mM 
Tris pH 7.0 was added to stop the denaturation process. The library was further diluted 10X in 
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HT1 (Hybridisation) buffer (Illumina, California, USA) to obtain a library at a final 
concentration of 25 pM for sequencing. The sequencing was done using a MiSeq® Sequencer 
(Illumina, California, USA) and MiSeq® Reagent Kit v3 (Illumina, California, USA, 
Catalogue No.: MS-102-3003). The sequencing parameters were set at 200 bp paired-end for 
400 cycles. 
2.21.5 Data Analyses 
The RNA sequencing data was analysed using a variety of programmes hosted in Galaxy 
(https://usegalaxy.org). The general workflow is summarised in Figure 2.2. Briefly, the format 
of the sequencing files was converted into Sanger FASTQ format which was compatible with 
the analysis software on the website using ‘FASTQ Groomer’. The converted forward and 
reverse reads of each sequence were then mapped on to a reference sequence (K. pneumoniae 
MGH78578 Accession No.: CP000647, pKpQIL-UK or pKpQIL-D2) using ‘Tophat2’. As the 
sequences were of fragmented transcripts, the ‘Cufflinks’ programme was used to associate 
reads (sequences) to genes. The output from the ‘Cufflinks’ programme was then used to map 
the sequences on to known annotated genes on the reference sequence using ‘Cuffcompare’. 
Finally, ‘Cuffdiff’ was used to detect the genes which were differentially expressed between 
the three different strains. The ‘Cuffdiff’ programme provides a list of genes which were the 
expression was significantly different between the three strains (K. pneumoniae ST258, 
ST258/pKpQIL-UK and ST258/pKpQIL-D2). The protein sequences of the genes were 
checked for known homology using the BlastP database. Then, the genes were categorised 
into their respective Clusters of Orthologous Groups (COG) (http://www.microbesonline.org/).  
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Figure 2.2 RNA sequencing data analyses workflow 
Sequencing output files (FASTQ) 
Convert format with ‘FASTQ 
Groomer’ 
Map sequencing reads to 
reference genome with ‘Tophat2’ 
Associate read fragments into 
full length genes with ‘Cufflinks’ 
Map reads to annotated reference 
genome with ‘Cuffcompare’ 
Identify differentially expressed 
genes with ‘Cuffdiff’ 
Check gene products with known 
proteins by BlastP 
Categorised genes into Clusters 
of Orthologous Groups (COG) 
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CHAPTER THREE: THE CELL ENVELOPE AND CARBAPENEM RESISTANCE 
3.1 Background 
Detection of carbapenemase-producing Enterobacteriaceae (CPE) is usually carried out by 
susceptibility testing. However, this phenotypic test is not always accurate. Some CPE 
isolates are inhibited by a carbapenem MIC value in the susceptible range even in the 
presence of carbapenemases, resulting in false susceptible reports (Jain et al., 2014, Voulgari 
et al., 2013, Moland et al., 2003, Psichogiou et al., 2008, Scoulica et al., 2004, Bratu et al., 
2005, Landman et al., 2010, Landman et al., 2011, Hrabák et al., 2013, Nahid et al., 2013, 
Tijet et al., 2013). Although the Clinical and Laboratory Standards Institute (CLSI) 
carbapenem recommended breakpoint concentration values were revised in 2010, so that 
isolates which were previously classified as carbapenem susceptible are now classified as 
carbapenem non-susceptible, there is the still possibility of false negative reports arising from 
the detection methods used (Doern et al., 2011, Zavascki et al., 2014). BSAC 
(http://bsac.org.uk/) and EUCAST (http://www.eucast.org/) which recommend higher MIC 
breakpoint concentrations also do not address this problem. The heterogeneity in carbapenem 
MIC values ranging from susceptible to resistant observed in these isolates may be associated 
with a combination of resistance mechanisms present in each isolate. Porins have been shown 
to affect the susceptibility of carbapenemase-producing K. pneumoniae to carbapenems via 
the OmpK35 (OmpF homologue) and OmpK36 (OmpC homologue), where the latter has 
been reported to play a more significant role (Tsai et al., 2011, Landman et al., 2009). Not 
much is known about the contribution of the AcrAB-TolC efflux system to carbapenem 
resistance in the presence of carbapenemases. However, this system is required for resistance 
to fluoroquinolones conferred by mutations in the DNA gyrase genes, and also to various β-
lactam antibiotics (Piddock, 2006b).  
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3.2 Hypothesis and Aims 
It was hypothesised that a functional AcrAB-TolC efflux system is required for the 
elaboration of resistance to clinically important carbapenem antibiotics in carbapenemase-
producing Enterobacteriaceae. Therefore, the aims of this study were: 
1. To transfer carbapenemase-encoding plasmids into AcrAB and TolC efflux pump 
component deletion mutants of K. pneumoniae, E. coli and Salmonella. 
2. To determine the susceptibility of the plasmid carrying strains in the presence and 
absence of AcrAB or TolC to clinically relevant carbapenem antibiotics. 
3.3 Carbapenem Resistance by blaKPC is Seen Even in the Absence of the Tripartite 
AcrAB-TolC Multidrug Resistance Efflux Pump  
3.3.1 Strain Constructions  
To investigate the function of the AcrAB-TolC efflux system in carbapenem resistance, a set 
of isogenic efflux mutants (AcrAB and TolC) were used. The carbapenemase gene encoding 
plasmids pKpQIL-UK and pKpQIL-D2 are large (ca. 114 kb) and transfer to new bacterial 
host strains via transformation is difficult (Hanahan, 1983, Ohse et al., 1995). Therefore, 
conjugation was used as the mode of transfer. To do this, the host bacterium K. pneumoniae 
Ecl8 and its isogenic AcrAB mutant needed a resistance marker so that the transconjugants 
carrying the plasmids could be selected from the donor bacterium. Unfortunately, despite 
repeated requests for a K. pneumoniae TolC mutant from T. Schneiders, the strain was not 
provided due to not being confirmed as the correct strain in her laboratory. Rifampicin-
resistance was the chosen marker for the recipient strains as this is easily selected in vitro 
(Miller et al., 2002). The rifampicin-resistant K. pneumoniae Ecl8 and AcrAB mutants were 
selected at a frequency of 8.6 x 10-9 and 8.5 x 10-10, respectively. This suggested a single point 
mutation during the selection of the mutants (Miller et al., 2002). No difference in generation 
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times was observed between the parental and the isogenic efflux mutant strain (Figure 3.1 & 
Table 3.1). The rpoB gene which encodes for the subunit of bacterial RNA polymerase is a 
known target for rifampicin and mutation in this gene can lead to resistance to this antibiotic 
(Miller et al., 2002).  
A set of efflux deletion mutants was also constructed in E. coli BW25113. Rifampicin-
resistant mutants were selected from the E. coli strain and its isogenic efflux mutants 
concurrently. The E. coli BW25113 and its isogenic efflux mutants (acrB::aph and tolC::aph) 
from the Keio Collection were used for this experiment (Baba et al., 2006). Rifampicin-
resistant mutants of E. coli BW25113 (to give E. coli BW25113Rif), E. coli BW25113 
acrB::aph (to give BW25113Rif acrB) and E. coli BW25113 tolC::aph (to give BW25113Rif 
tolC) were selected at a frequency of 2.3 x 10-8, 1.3 x 10-8 and 1.1 x 10-8, respectively. 
Sequencing of the purified rpoB gene PCR amplicon (Figure 3.2) showed a single point 
mutation in all the three strains. E. coli BW25113Rif and its AcrB mutant possess a single 
C1691T (Pro574Leu) substitution, whereas the E. coli BW25113Rif tolC mutant contained a 
single C1576T (His526Tyr) substitution. The rifampicin-resistant mutants of the E. coli strain 
set were then verified by PCR to ensure that the correct efflux pump component genes were 
inactivated (Figure 3.3). Due to the difference in the mutation found in the rpoB gene, the 
generation time of the three strains were investigated. Without the rifampicin-resistant marker, 
there was no difference in generation time of the Keio Collection strains with/without AcrB or 
TolC (Figure 3.4a, Table 3.2). Compared to the E. coli BW25113Rif, the rifampicin-resistant 
mutants with the inactivated efflux pump component genes had the same significant, but 
slower generation time (p<0.05) (Figure 3.4b). Despite this, the slower growth rate of the 
rifampicin-resistant mutants is unlikely to have a significant impact on carbapenem activity as  
86 
 
 
Growth kinetics was done to compare the growth of the rifampicin-susceptible and -
resistant K. pneumoniae Ecl8 and its isogenic acrAB mutant. Absorbance values were 
recorded as mean ± standard deviation of three independent experiments. Generation 
times were recorded in Table 3.1.
Figure 3.1 Growth kinetics of rifampicin-susceptible/resistant mutants of K. 
pneumoniae Ecl8 and its efflux mutants 
(a) 
(b) 
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Table 3.1 Generation times of rifampicin-susceptible/resistant K. pneumoniae Ecl8 
and its isogenic acrAB mutant 
 
K. pneumoniae Strain Generation Time (min) Student’s t-test 
Ecl8 27.4 ± 3.8 - 
Ecl8 acrAB::aph 29.1 ± 2.3 0.54 
Ecl8Rif 28.7 ± 1.0 - 
Ecl8Rif  acrAB::aph 27.2 ± 1.3 0.25 
Generation time was determined to assess the fitness impact of the rifampicin resistant marker 
in the K. pneumoniae Ecl8 and its isogenic acrAB mutant. Generation time is shown as a 
mean ± standard deviation of three independent experiments. Student’s t-test was used to 
analyse the generation times (p<0.05). 
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Figure 3.2 PCR amplification of rpoB of rifampicin-resistant E. coli BW25113 
for DNA sequencing 
 
5000 bp bp4288
M
Wildtype 
BW25113 
BW25113Rif 
acrB::aph 
BW25113Rif 
tolC::aph 
 
 
 
 
The rpoB genes of the various E. coli BW25113 strains were amplified. The amplicons 
were purified for sequencing to determine the mutation in the rpoB gene. M: 
Hyperladder I (Bioline); Primers: RpoB-Ecoli-F1/R1; Expected amplicon: 4288 bp. 
 
BW25113Rif 
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Figure 3.3 PCR verification of inactivated acrB and tolC genes in rifampicin-
resistant mutants of Keio Collection strains 
The various rifampicin-resistant mutants of E. coli BW25113 were verified by PCR for 
the presence of the inactivated tolC gene. M: Hyperladder I (Bioline); Lane 10: 
BW25113 tolC::aph genomic DNA (Positive control); Lane 11: BW25113 genomic 
DNA (Negative control); Lane 12: Water (Contamination control). Primers: tolC 
fwd/rev; Expected amplicon: 1976 bp (mutant), 2131 bp (wildtype). 
 
(b) PCR to check for inactivated tolC gene 
(a) PCR to check for inactivated acrB gene 
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The various rifampicin-resistant mutants of E. coli BW25113 were verified by PCR for 
the presence of the inactivated acrB gene. M: Hyperladder I (Bioline); Lane 10: 
BW25113 acrB::aph genomic DNA (Positive control); Lane 11: BW25113 genomic 
DNA (Negative control); Lane 12: Water (Contamination control). Primers: acrB 
fwd/rev; Expected amplicon: 1659 bp (mutant), 3482 bp (wildtype). 
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Growth kinetics was done to compare the growth of the rifampicin-susceptible and -
resistant E. coli BW25113 and its isogenic efflux mutants. Absorbance values were 
recorded as mean ± standard deviation of three independent experiments. Generation 
times were recorded in Table 3.2. 
 
Figure 3.4 Growth kinetics of rifampicin-susceptible/resistant mutants of E. 
coli BW25113 and its efflux mutants 
(a) 
(b) 
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Table 3.2 Generation times of rifampicin-susceptible/resistant E. coli BW25113 and 
its isogenic efflux pump mutants 
 
E. coli Strain Generation Time (min) Student’s t-test 
BW25113 35.7 ± 4.4 - 
BW25113 acrB::cat 31.9 ± 2.3 0.07 
BW25113 tolC::cat 35.3 ± 2.4 0.86 
BW25113Rif 34.6 ± 2.0 - 
BW25113Rif acrB::cat 39.2 ± 3.3 0.04* 
BW25113Rif tolC::cat 40.6 ± 2.9 0.002* 
Asterisk (*) denotes statistically significant difference (p<0.05) between the generation time 
of the mutants relative to the parental strain (BW25113/BW25113Rif). Generation time is 
shown as a mean ± standard deviation of three independent experiments. 
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the killing effect of carbapenem antibiotics is growth independent (Cozens et al., 1989, Eng et 
al., 1991). 
Rifampicin-resistant S. Typhimurium ATCC14028s mutants (henceforth call 14028sRif) 
were selected at a frequency of 7.3 x 10-10, suggesting a single mutation had occurred during 
selection (Miller et al., 2002). The rpoB gene was amplified by PCR, and the 4482 bp 
amplicon, which contained the rpoB gene, was purified for DNA sequencing (Figure 3.5a). 
The sequence data revealed a single C1565A nucleotide substitution (single Ser522Tyr amino 
acid substitution) in the rpoB gene.  
In order to ensure that efflux pump component mutants (acrAB::cat and tolC::cat) 
were in the same genetic background, the inactivated efflux pump genes from insertion 
mutants of EG16564 (tolC::cat) and EG16566 (acrAB::cat) (Nishino et al., 2006) were 
transferred into 14028sRif by P22 phage transduction. The S. Typhimurium 14028sRif 
acrAB::cat (henceforth call 14028sRif acrAB) and 14028sRif tolC::cat (henceforth call 
14028sRif tolC) transductants were then verified by PCR to carry the correct inactivated efflux 
pump component genes (Figure 3.5b). PCR was also used to verify the presence of the 
chloramphenicol resistance gene (cat) which had been inserted to inactivate the acrAB genes. 
Only the mutant with the inactivated genes would yield the amplicons of 500 bp (Primers: 
Chlor-Fwd/AcrA-Up) and 415 bp (Primers: AcrB-Down/Chlor-Rev). The inactivated tolC 
gene yielded a 1812 bp amplicon. The strains carrying the wildtype tolC gene gave a larger 
amplicon of 2489 bp. All strains were correct by PCR. The generation time of 14028sRif 
tolC::cat was significantly slower than 14028sRif (p<0.05) (Figure 3.6, Table 3.3). The efflux 
mutant series were also checked by API® 20E Gram-negative identification strips to confirm 
they were K. pneumoniae, E. coli and S. Typhimurium.  
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The rpoB gene of the rifampicin-resistant S. Typhimurium 14028s mutants was 
amplified. The amplicons were purified for sequencing to determine the mutation in 
the rpoB gene. M: Hyperladder I (Bioline); Lane 6: Water (Contamination control); 
Primers: RpoB-F1/R1; Expected amplicon: 4482 bp. 
 
Figure 3.5 PCR amplification of rpoB of rifampicin-resistant S. Typhimurium 
ATCC14028s for sequencing and mutant verification 
The various rifampicin-resistant mutants of S. Typhimurium 14028s were verified by 
PCR for the presence of the respective inactivated efflux component genes. M: 
Hyperladder I (Bioline); Lane 1: 14028sRif; Lane 2: 14028sRif acrAB::cat; Lane 3: 
14028sRif tolC::cat; Lane 4: Water (Contamination control).  
 
To check for the inactivated AcrA, Primers: Chlor-Fwd & AcrA-Up; Expected 
amplicon: 500 bp (mutant), no amplicon (wildtype).  
 
To check for the inactivated AcrB, Primers: AcrB-Down & Chlor-Rev; Expected 
amplicon: 415 bp (mutant), no amplicon (wildtype). 
 
To check for the inactivated TolC, Primers: TolC-Check-F/R; Expected amplicon: 
1812 bp (mutant), 2489 bp (wildtype). 
 
Red box: Amplification due to false priming.
(a) Amplification of rpoB gene from rifampicin-resistant Salmonella 
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Growth kinetics was done to compare the growth of the rifampicin-susceptible and -
resistant S. Typhimurium 14028s and its isogenic efflux mutants. Absorbance values 
were recorded as mean ± standard deviation of three independent experiments. 
Generation times were recorded in Table 3.3. 
 
Figure 3.6 Growth kinetics of rifampicin-susceptible/resistant mutants of S. 
Typhimurium 14028s and its efflux mutants 
(a) 
(b) 
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Table 3.3 Generation times of rifampicin-susceptible/resistant S. Typhimurium 
14028s and its isogenic efflux pump mutants 
 
S. Typhimurium Strain Generation Time (min) Student’s t-test 
14028s 30.9 ± 3.1 - 
14028s acrB::cat 35.1 ± 4.6 0.05 
14028s tolC::cat 42.8 ± 4.6 <0.001* 
14028sRif 39.8 ± 4.0 - 
14028sRif  acrB::cat 40.7 ± 3.6 0.61 
14028sRif tolC::cat 53.7 ± 9.2 0.002* 
Asterisk (*) denotes statistically significant difference (p<0.05) between the generation time 
of the mutants relative to the parental strain (14028s/14028sRif). Generation time is shown as a 
mean ± standard deviation of three independent experiments. 
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In order to assess the contribution of a functional AcrAB-TolC efflux pump in 
carbapenem resistance, the blaKPC-encoding plasmid pKpQIL-UK was transferred from E. 
coli DH10B into the various parental and isogenic efflux mutant strains by filter conjugation. 
The K. pneumoniae Ecl8Rif and Ecl8Rif acrAB mutant with/without pKpQIL-UK were verified 
by PCR for the inactivation of the acrAB genes (Figure 3.7a). The transconjugants were also 
checked by PCR for the presence of the blaKPC (Figure 3.7b) and pKpQIL-UK plasmid 
(Figure 3.7c). All transconjugants were verified by PCR for the presence of the expected 
amplicons which represent the blaKPC gene (Primers: KPCg-colpcrF/R), a plasmid backbone 
fragment which differentiates pKpQIL-UK from -D2 (Primers: pQIL-F/R), and the respective 
inactivated efflux pump component genes (Primers: AcrABdelchkF/R). All transconjugants 
contained the expected amplicons i.e. blaKPC gene (785 bp), pKpQIL-UK backbone fragment 
(383 bp) and inactivated acrAB genes (3000 bp). The series of E. coli BW25113Rif 
transconjugants carrying pKpQIL-UK were also verified by PCR for the presence of the 
blaKPC gene (Figure 3.8a) and pKpQIL-UK plasmid (Figure 3.8b). 
PCR verifications were also done for the various S. Typhimurium 14028sRif strains 
carrying the pKpQIL-UK plasmids: 14028sRif/pKpQIL-UK (Figure 3.9a & b), 14028sRif 
acrAB/pKpQIL-UK and 14028sRif tolC/pKpQIL-UK (Figure 3.10a & b). In order to 
investigate whether the plasmid variant region had an impact on the carbapenem resistance of 
the host bacterium, pKpQIL-D2 was also transferred into the Salmonella strains using the 
same method. All transconjugants were confirmed by PCR to carry the blaKPC gene and the 
respective plasmids (Figure 3.10a, 3.11 & 3.12). In order to differentiate the highly similar 
plasmids pKpQIL-UK and pKpQIL-D2, a primer pair (pMan-F/R) which only amplifies a 600 
bp fragment of the pKpQIL-D2 backbone was also included in the PCR tests. 
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The various rifampicin-resistant mutants of K. pneumoniae Ecl8 were verified by 
PCR for the presence of the inactivated acrB gene and the pKpQIL-UK plasmid. M: 
Hyperladder I (Bioline); Lane 1: Ecl8Rif; Lane 2: Ecl8Rif acrAB; Lane 3: 
Ecl8Rif/pKpQIL-UK; Lane 4: Ecl8Rif acrAB/pKpQIL-UK; Lane 5: Water 
(Contamination control). 
 
(a) Check for inactivation of acrAB 
Primers: AcrABdelchkF/R 
Expected amplicon: 5543 bp (wildtype), 3000 bp (mutant) 
 
(b) Check for blaKPC 
Primers: KPCg-colpcrF/R 
Expected amplicon: 785 bp 
 
(c) Check for pKpQIL-UK 
Primers: pQIL-F/R 
Expected Amplicon: 383 bp 
 
Figure 3.7 PCR verification of K. pneumoniae Ecl8, acrAB, Ecl8Rif/pKpQIL-
UK and Ecl8Rif acrAB/pKpQIL-UK 
M 1 2 3 4 
6000 bp 
5 
5543 bp 
383 bp 400 bp 
(a) PCR check for the inactivation of acrAB 
M 1 2 3 4 5
(b) PCR check for the presence of blaKPC 
4000 bp 3000 bp 
M 1 2 3 4 5 
785 bp 800 bp 
(c) PCR check for the presence of pKpQIL-UK 
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Figure 3.8 PCR verification for the presence of pKpQIL-UK in the E. coli 
BW25113Rif and isogenic efflux mutants 
The various rifampicin-resistant mutants of E. coli BW25113 were verified by PCR for 
the presence of the pKpQIL-UK plasmid’s backbone gene. M: Hyperladder I (Bioline); 
Lane 10: pKpQIL-UK plasmid (Positive control); Lane 11: BW25113Rif genomic DNA 
(Negative control); Lane 12: Water (Contamination control); Primers: pQIL-F/R; 
Expected Amplicon: 383 bp. 
 
 
 
(a) PCR to check for presence of blaKPC 
4000 bp 
3000 bp 
3482 bp
1659 bp
M 1 2 3 4 5 6 7 8 9 10 11 12 
BW25113Rif 
BW25113Rif 
acrB::aph 
BW25113Rif 
tolC::aph 
2000 bp 
1500 bp 
The various rifampicin-resistant mutants of E. coli BW25113 were verified by PCR for 
the presence of the pKpQIL-UK plasmid’s blaKPC gene. M: Hyperladder I (Bioline); 
Lane 10: pKpQIL-UK plasmid (Positive control); Lane 11: BW25113Rif genomic DNA 
(Negative control); Lane 12: Water (Contamination control); Primers: KPCg-
colpcrF/R; Expected amplicon: 785 bp. 
 
400 bp 383 bp
M 1 2 3 4 5 6 7 8 9 10 11 12 
BW25113Rif 
BW25113Rif 
acrB::aph 
BW25113Rif 
tolC::aph 
(b) PCR to check for presence of pKpQIL-UK 
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The various rifampicin-resistant mutants of S. Typhimurium 14028s were verified by 
PCR for the presence of the pKpQIL-UK plasmid’s (a) blaKPC and (b) backbone 
genes. M: Hyperladder I (Bioline); Lane 5: Plasmid pKpQIL-UK (Positive control); 
Lane 6: 14028sRif genomic DNA (Negative control); Lane 7: Water (Contamination 
control).  
 
(a) Check for blaKPC 
Primers: KPCg-colpcrF/R 
Expected amplicon: 785 bp 
 
(b) Check for pKpQIL-UK 
Primers: pQIL-F/R 
Expected Amplicon: 383 bp 
 
 
Figure 3.9 PCR verification of 14028sRif/pKpQIL-UK transconjugants 
M 1 2 3 4 
800 bp 
5 6 7 
785 bp 
383 bp 400 bp 
14028sRif/pKpQIL-UK 
(a) PCR check for the presence of blaKPC 
M 1 2 3 4 5 6 7 
14028sRif/pKpQIL-UK 
(b) PCR check for the presence of pKpQIL-UK 
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Figure 3.10 PCR verification of 14028sRif acrAB/pKpQIL-UK, 14028sRif 
tolC/pKpQIL-UK and 14028sRif acrAB/pKpQIL-D2 
The various rifampicin-resistant efflux component mutants of S. Typhimurium 14028s 
were verified by PCR for the presence of the pKpQIL-UK plasmid’s backbone gene. 
M: Hyperladder I (Bioline); Lane 9: Plasmid pKpQIL-UK (Positive control); Lane 10: 
Plasmid pKpQIL-D2 (Negative control); Lane 11: Water (Contamination control); 
Primers: pQIL-F/R; Expected amplicon: 383 bp.  
 
 
The various rifampicin-resistant efflux component mutants of S. Typhimurium 14028s 
were verified by PCR for the presence of the pKpQIL-UK and -D2 plasmid’s blaKPC 
genes. M: Hyperladder I (Bioline); Lane 13: Plasmid pKpQIL-UK (Positive control); 
Lane 14: 14028sRif genomic DNA (Negative control); Lane 15: Water (Contamination 
control); Primers: KPCg-colpcrF/R; Expected amplicon: 785 bp. 
 
M 1 2 3 4
800 bp 
5 6 7 8 9 10 11 12 13 14 15
785 bp 
14028sRif acrAB/ 
pKpQIL-UK 
14028sRif tolC/ 
pKpQIL-UK 
14028sRif acrAB/ 
pKpQIL-D2 
(b) PCR check for the presence of pKpQIL-UK 
M 1 2 3 4
400 bp 
5 6 7 8 9 10 11
383 bp 
14028sRif acrAB/ 
pKpQIL-UK 
14028sRif tolC/ 
pKpQIL-UK 
(a) PCR check for the presence of blaKPC
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Figure 3.11 PCR verification of 14028sRif/pKpQIL-D2 and 14028sRif 
tolC/pKpQIL-D2 
The various rifampicin-resistant efflux component mutants of S. Typhimurium 14028s 
were verified by PCR for the presence of the pKpQIL-D2 plasmid’s backbone gene. 
M: Hyperladder I (Bioline); Lane 13: Plasmid pKpQIL-D2 (Positive control); Lane 14: 
Plasmid pKpQIL-UK (Negative control); Lane 15: Water (Contamination control); 
Primers: pMan-F/R; Expected amplicon: 600 bp. 
 
 
 
The various rifampicin-resistant efflux component mutants of S. Typhimurium 
14028s were verified by PCR for the presence of the pKpQIL-D2 plasmid’s blaKPC 
gene. M: Hyperladder I (Bioline); Lane 13: Plasmid pKpQIL-D2 (Positive control); 
Lane 14: 14028sRif genomic DNA (Negative control); Lane 15: Water (Contamination 
control); Primers: KPCg-colpcrF/R; Expected amplicon: 785 bp. 
 
 
M 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
785 bp800 bp 
(a) PCR check for the presence of blaKPC
14028sRif/pKpQIL-D2 14028sRif tolC/pKpQIL-D2 
(b) PCR check for the presence of pKpQIL-D2 
14028sRif/pKpQIL-D2 14028sRif tolC/pKpQIL-D2 
600 bp 
600 bp 
M 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
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The various rifampicin-resistant efflux component mutants of S. Typhimurium 14028s 
were verified by PCR for the presence of the pKpQIL-D2 plasmid’s backbone gene. 
M: Hyperladder I (Bioline); Lane 5: Plasmid pKpQIL-D2 (Positive control); Lane 6: 
Plasmid pKpQIL-UK (Negative control); Lane 7: Water (Contamination control); 
Primers: pMan-F/R; Expected Amplicon: 600 bp. 
 
 
Figure 3.12 PCR verification of 14028sRif acrAB/pKpQIL-D2 transconjugants 
M 1 2 3 4
600 bp 
5 6 7
600 bp 
14028sRif acrAB/pKpQIL-D2 
PCR check for the presence of pKpQIL-D2 
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3.3.2 The MICs of Antibiotics in Strains Lacking a Component of the AcrAB-TolC 
Efflux Pump 
The susceptibility of K. pneumoniae Ecl8 and isogenic AcrAB mutant carrying the pKpQIL-
UK plasmid was tested (Table 3.4). No difference in β-lactam antibiotic MIC values was 
observed between the plasmid-free strains. However, when pKpQIL-UK was present, the 
AcrAB mutant strain showed an 8- and 4-fold decrease in susceptibility to ertapenem and 
meropenem, respectively. Similarly the E. coli BW25113 acrB::aph carrying the plasmid 
showed a 4-fold decrease in susceptibility to ertapenem. However, the E. coli TolC mutant 
was significantly more susceptible to meropenem, doripenem, biapenem and ceftazidime. 
Other antibiotics such as chloramphenicol, erythromycin, ciprofloxacin and tetracycline were 
included as controls to verify the phenotype of the efflux mutants. As expected, antibiotics 
which are known substrates to the AcrAB-TolC efflux system had lower MIC values for the 
mutant strains. 
The susceptibility of the Salmonella efflux mutants in the presence and absence of the 
pKpQIL-UK plasmid was also determined. With the exception of ertapenem in the absence of 
the plasmid, there was no difference in susceptibility observed between the parental strain 
(14028sRif) and the respective efflux pump component mutants (14028sRif acrAB and 
14028sRif tolC) for the β-lactam antibiotics tested (Table 3.4). However, compared to 
14028sRif, the TolC mutant showed a 4-fold decrease in ertapenem susceptibility (0.008 µg/ml 
to 0.03 µg/ml). Although chloramphenicol is a substrate of this efflux pump, the MIC value 
for chloramphenicol was higher in the mutants as a chloramphenicol resistance gene (cat) was 
inserted in the efflux pump genes to construct the mutants (Nishino et al., 2006). 
 In the presence of the blaKPC carbapenemase-encoding pKpQIL-UK, compared to the 
parental Salmonella strain (14028sRif), the TolC mutant was 4- to 8-fold less susceptible to 
 
 
Table 3.4 MIC values of various antibiotics for efflux pump component mutants carrying the pKpQIL-UK plasmid  
Strains Genotype Plasmid Introduced 
Antibiotics (µg/ml) 
ETP IMI MER DOR BIA CAZ CHL CIP EM TET 
E. coli NCTC10418 Wildtype - 0.015 0.25 0.03 0.03 0.06 0.25 2 0.008 32 1 
K. pneumoniae Ecl8    
Ecl8Rif RifR - 0.015 0.12 0.015 0.03 0.25 0.03 2 0.008 64 0.5 
Ecl8Rif  acrAB::aph - 0.015 0.12 0.03 0.03 0.25 0.06 1 0.004 4 0.5 
Ecl8Rif RifR pKpQIL-UK 4 4 1 2 4 16 4 0.008 64 0.5 
Ecl8Rif  acrAB::aph pKpQIL-UK 32 8 4 4 8 16 1 0.004 4 0.5 
E. coli BW25113    
BW25113Rif RifR - 0.015 0.25 0.03 0.06 0.06 0.06 8 0.008 32 2 
BW25113Rif  acrB::aph - 0.015 0.5 0.03 0.06 0.06 0.06 1 0.004 4 0.5 
BW25113Rif  tolC::aph - 0.008 0.12 0.015 0.015 0.015 0.03 1 0.002 2 0.5 
BW25113Rif RifR pKpQIL-UK 0.12 2 0.25 0.5 2 2 8 0.008 32 1 
BW25113Rif  acrB::aph pKpQIL-UK 0.5 2 0.25 1 4 2 1 0.004 4 0.5 
BW25113Rif  tolC::aph pKpQIL-UK 0.06 1 0.03 0.12 0.12 0.5 1 0.002 2 0.5 
Continued overleaf. 
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Table 3.4 (Continued) MIC values of various antibiotics for efflux pump component mutants carrying the pKpQIL-UK plasmid 
Strains Genotype Plasmid Introduced 
Antibiotics (µg/ml) 
ETP IMI MER DOR BIA CAZ CHL CIP EM TET 
S. Typhimurium ATCC14028s    
14028s Wildtype - 0.015 0.25 0.03 0.03 0.06 0.25 4 0.015 64 2 
14028sRif RifR - 0.008 0.5 0.03 0.03 0.03 0.25 8 0.015 128 2 
14028sRif  acrAB::cat - 0.008 0.12 0.015 0.015 0.03 0.12 >16 0.004 4 0.5 
14028sRif  tolC::cat - 0.03 0.25 0.03 0.03 0.06 0.5 >16 0.004 2 0.5 
14028sRif RifR pKpQIL-UK 2 4 1 1 4 8 8 0.015 64 2 
14028sRif  acrAB::cat pKpQIL-UK 2 4 2 1 4 8 >16 0.004 4 0.5 
14028sRif  tolC::cat pKpQIL-UK 16 8 8 4 4 32 >16 0.004 2 0.5 
ETP: Ertapenem; IMI: Imipenem; MER: Meropenem; DOR: Doripenem; BIA: Biapenem; CAZ: Ceftazidime; CHL: Chloramphenicol; CIP: 
Ciprofloxacin; EM: Erythromycin; TET: Tetracycline; Bolded fonts denote significant increase/decrease in MIC values; Changes of 4-fold or 
more in MIC values are considered significant. 
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three carbapenem antibiotics (ertapenem, meropenem and doripenem). No significant 
difference in MIC value was observed for biapenem between the strains. A similar increase in 
the MIC value of ceftazidime was also observed. Compared to the parental strain (14028sRif), 
there was no significant difference in MIC values between the 14028sRif AcrAB mutant 
carrying the plasmid.    
3.4 The Salmonella TolC Mutant is Less Susceptible to β-lactam Antibiotics and This 
is Not Specific to Carbapenemase 
The AcrAB-TolC efflux system is one of the most well characterised RND efflux pump 
which is highly conserved among Gram-negative bacteria (Piddock, 2006a, Nikaido and 
Zgurskaya, 2001). It has been reported that the amino acid identity of AcrA and AcrB proteins 
among Proteus mirabilis, E. coli, K. pneumoniae and Enterobacter aerogenes is 75%. The 
acrB gene shares about 85-88% identity among the latter three bacteria (Visalli et al., 2003). 
The S. Typhimurium AcrAB-TolC has also been shown to have high DNA sequence identity 
(>70%) and amino acid similarity (>80%) with its E. coli counterpart (Piddock, 2006a). The 
AcrAB-TolC protein sequence identities of the various strains used in this PhD study were 
compared to K. pneumoniae MGH78578 by BlastP (Table 3.5). It is well established that S. 
Typhimurium is a model organism for studying Gram-negative bacteria as there are tractable 
infection models (Garai et al., 2012). Therefore, the AcrAB-TolC efflux system in this 
bacterium has been used in this PhD study as a model to investigate its contribution towards 
carbapenem resistance in other Gram-negative bacteria.  
Although it was observed that the carriage of the pKpQIL-UK plasmid in the TolC 
mutant conferred higher resistance to β-lactam antibiotics compared to the 14028sRif/pKpQIL-
UK, it was hypothesised that this observation was specific to this plasmid. Hence, in order to 
investigate whether the increase in MIC values of the various β-lactam antibiotics tested was a  
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Table 3.5 Protein sequence homology of AcrAB-TolC efflux system 
 
Species Genbank Accession No. 
Percentage Protein Sequence 
Identity (Coverage) 
AcrA AcrB TolC 
K. pneumoniae MGH78578 CP000647 - - - 
K. pneumoniae Ecl8 HF536482 100 (100) 100 (100) 99 (100) 
E. coli K12 MG1655 U00096 85 (100) 92 (100) 84 (99) 
E. coli BW25113 CP009273 85 (100) 92 (100) 84 (99) 
S. Typhimurium 14028s CP001363 85 (99) 92 (100) 86 (100) 
S. Typhimurium SL1344 FQ312003 85 (99) 92 (100) 86 (100) 
AcrAB-TolC efflux pump protein sequence identity of the various strains was compared to K. 
pneumoniae MGH78578 
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result specific to pKpQIL-UK, its variant (pKpQIL-D2) and a blaNDM carbapenemase-
encoding plasmid (pNDM-HK) were tested. The plasmid pNDM-HK was transferred into S. 
Typhimurium 14028sRif, 14028sRif acrAB and 14028sRif tolC strains by filter conjugation. All 
transconjugants were verified by PCR for the presence of the carbapenemase gene (Figure 
3.13a) and a backbone fragment of the plasmid (Primers: pHK-F/R; 1407 bp) (Figure 3.13b). 
A similar increase in MIC values of ertapenem, meropenem, doripenem and ceftazidime was 
observed for the plasmid pKpQIL-D2 and the unrelated pNDM-HK in the TolC mutant 
(Table 3.6). Together, these data suggest that the increase in carbapenem MIC value was not 
due to the presence of the blaKPC gene or the plasmids used, but instead due to a different 
mechanism of resistance. 
 To determine whether the reduction in carbapenem susceptibility was also observed 
when a non-carbapenemase β-lactamase was present. The MICs of antibiotics for S. 
Typhimurium SL1344 and its isogenic efflux mutants (∆acrA, ∆acrB and ∆tolC) carrying a 
blaTEM-1 β-lactamase-encoding plasmid (pUC18) were also determined. Except for ertapenem, 
no significant difference was observed in the MIC values for the various β-lactam antibiotics 
tested. Compared to S. Typhimurium SL1344/pUC18, SL1344 ∆tolC/pUC18 was 4-fold less 
susceptible to ertapenem (Table 3.6). These data further suggest that the reduced 
susceptibility to β-lactam antibiotics observed in the S. Typhimurium TolC mutant is not 
specific to the plasmids or β-lactamase genes it carries. 
3.5 Increased Carbapenem Resistance is Not Associated with Passive Release of 
Carbapenemase from the Periplasmic Space of the Salmonella Efflux Mutant 
Previous study has suggested that the membrane of an E. coli TolC mutant is under stress as 
there was an increase in the expression of the Tol-Pal system which is essential for 
maintaining membrane integrity (Cascales et al., 2002, Dhamdhere and Zgurskaya, 2010).  
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The various rifampicin-resistant efflux component mutants of S. Typhimurium 14028s 
were verified by PCR for the presence of the pNDM-HK plasmid’s blaNDM gene. M: 
Hyperladder I (Bioline); Lane 13: Plasmid pNDM-HK (Positive control); Lane 14: 
14028sRif genomic DNA (Negative control); Lane 15: Water (Contamination control); 
Primers: NDM1-colpcrF/R; Expected amplicon: 578 bp. 
Figure 3.13 PCR verification of transconjugants of 14028sRif and its mutants 
carrying the plasmid pNDM-HK 
The various rifampicin-resistant efflux component mutants of S. Typhimurium 14028s 
were verified by PCR for the presence of the pNDM-HK plasmid’s backbone gene. M: 
Hyperladder I (Bioline); Lane 13: Plasmid pNDM-HK (Positive control); Lane 14: 
14028sRif genomic DNA (Negative control); Lane 15: Water (Contamination control); 
Primers: pHK-F/R; Expected amplicon: 1407 bp.  
 
 
(a) PCR check for the presence of blaNDM-1 
M 1 2 3 4
600 bp 
5 6 7 8 9 10 11 12 13 14 15 
578 bp 
14028sRif/ 
pNDM-HK 
14028sRif acrAB/ 
pNDM-HK 
14028sRif tolC/ 
pNDM-HK 
(b) PCR check for the presence of pNDM-HK 
1500 bp 1407 bp 
M 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 
14028sRif/ 
pNDM-HK 
14028sRif acrAB/ 
pNDM-HK 
14028sRif tolC/ 
pNDM-HK 
 
 
Table 3.6 MIC values of various antibiotics for efflux pump component mutants carrying various plasmids 
Strains Genotype Plasmid Introduced 
Antibiotics (µg/ml) 
ETP IMI MER DOR BIA CAZ CHL CIP EM TET 
S. Typhimurium ATCC14028s    
14028sRif RifR pKpQIL-D2 1 4 1 1 4 8 8 0.016 64 2 
14028sRif  acrAB::cat pKpQIL-D2 2 4 1 1 4 8 >16 0.004 4 0.5 
14028sRif  tolC::cat pKpQIL-D2 16 8 4 4 4 32 >16 0.004 2 0.5 
14028sRif RifR pNDM-HK 8 8 4 8 2 >512 8 0.016 256 2 
14028sRif  acrAB::cat pNDM-HK 8 8 4 4 2 >512 >16 0.004 512 0.5 
14028sRif  tolC::cat pNDM-HK 32 16 16 16 1 >512 >16 0.004 128 0.5 
S. Typhimurium SL1344    
SL1344 Wildtype - 0.03 0.5 0.06 0.125 0.06 2 8 0.016 64 2 
SL1344 ∆acrA pUC18 0.03 0.5 0.06 0.125 0.125 2 1 0.004 2 0.5 
SL1344 ∆acrB pUC18 0.03 0.5 0.06 0.125 0.25 2 1 0.004 2 0.5 
SL1344 ∆tolC pUC18 0.125 1 0.125 0.25 0.125 2 1 0.002 2 0.5 
ETP: Ertapenem; IMI: Imipenem; MER: Meropenem; DOR: Doripenem; BIA: Biapenem; CAZ: Ceftazidime; CHL: Chloramphenicol; CIP: 
Ciprofloxacin; EM: Erythromycin; TET: Tetracycline; Bolded fonts denote significant increase/decrease in MIC values; Changes of 4-fold or 
more in MIC values are considered significant. 
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E. coli TolC mutant is also known to have an alteration in its lipopolysaccharide which 
compromises its membrane integrity and permeability, resulting in passive release of enzymes 
including RNase and β-lactamase (Cascales et al., 2002, Li et al., 2012, Stone and Miller, 
1995). As the increased carbapenem MIC values were only observed when the carbapenemase 
gene was associated with the S. Typhimurium TolC mutant, it was hypothesised that S. 
Typhimurium TolC mutant leaked carbapenemase into the external environment, thereby 
hydrolysing the carbapenem and preventing it from reaching its target. This results in the 
higher carbapenem MIC values in the TolC mutant. To explore this hypothesis, the hydrolytic 
activity of the crude cell lysates of the three strains (14028sRif, 14028sRif acrAB and 14028sRif 
tolC) carrying the plasmid pKpQIL-UK was tested using nitrocefin. The crude lysates of these 
three strains showed comparable hydrolytic activity against nitrocefin (Figure 3.14). As the 
amount of total protein in the supernatant was insufficient (15 µg of total protein was required 
for hydrolysis of nitrocefin), the carbapenemase activity in the supernatant (i.e. LB broth 
which the strains were grown in) could not be determined directly. A release of 
carbapenemase enzyme from the cell would cause the hydrolytic activity in the crude cell 
lysate to decrease as there would be lesser enzymes within the bacterial cell. If the bacterial 
cells with higher membrane permeability (i.e. compromised membrane integrity) were lysed 
and used for the β-lactamase assay, the slope of the graph showing the initial hydrolysis of 
nitrocefin would be reduced corresponding to the lower hydrolytic activity. However, this was 
not observed, suggesting no passive release of carbapenemase into the environment was 
detected. 
112 
 
 
All values were mean ± standard deviation of three independent experiments. The 
carbapenemase activity in the crude lysate was tested with nitrocefin to determine the 
difference in the total amount of the carbapenemase in the three S. Typhimurium 
strains. The initial enzyme activity represented by the slope from the 10th to the 50th 
second was not significantly different (Analysed by GraphPad Prism). 
Figure 3.14 β-lactamase activity assay for pKpQIL-UK carrying Salmonella 
and isogenic efflux pump component mutants 
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3.6 Efflux Inhibitor Alters Susceptibility to Some β-lactam Antibiotics 
3.6.1 PAβN Reduces β-lactam Antibiotic Susceptibility in K. pneumoniae, E. coli and 
Salmonella 
As a complete set efflux mutant was available for S. Typhimurium, the effect of the efflux 
inhibitor (PAβN) was tested on this set of carbapenemase-producing strains. PAβN has been 
repeatedly shown to decrease the susceptibility of some antibiotics, including β-lactams and 
fluoroquinolones (Piddock, 2006a). The TolC mutant had the lowest MIC value for PAβN (50 
µg/ml). Hence, the MIC values for the antibiotics were determined in the presence of a sub-
inhibitory concentration, 25 µg/ml PAβN (Table 3.7). In the presence of PAβN, there was a 4- 
to 16-fold increase in the MIC of ertapenem for the wildtype and AcrAB mutant carrying the 
pKpQIL-UK, pNDM-HK or pUC18 plasmids. The increase in MIC was similar to the trend 
observed between the wildtype S. Typhimurium 14028sRif and its isogenic TolC mutant 
carrying the plasmids in the absence of PAβN. Apart from S. Typhimurium SL1344/pUC18, 
which showed a 4-fold increase in cephalothin susceptibility in the presence of PAβN, no 
other strain carrying any of the plasmids showed differences in cephalothin susceptibility in 
the presence and absence of PAβN.  
To investigate the role of RND efflux pumps in the susceptibility of the strains to 
carbapenem antibiotics, CCCP, a proton-motive force uncoupler was used to remove the 
energy source required for RND efflux pumps (Richmond et al., 2013). Except for S. 
Typhimurium 14028sRif/pNDM-HK, which showed 4-fold decrease in the ertapenem MIC 
value (8 µg/ml to 2 µg/ml), generally no difference in the MIC values of ertapenem and 
cephalothin were observed in the presence of 25 µM CCCP. Tetracycline was included as a 
control to detect reduced efflux function in the presence of 25 µg/ml PAβN and 25 µM CCCP. 
The S. Typhimurium and E. coli TolC mutants were tested in the presence of 3 µM CCCP as
 
 
Table 3.7 Effects of PAβN and CCCP on MIC of β-lactam antibiotics 
Strains Genotype Plasmid Introduced 
ETP CEP TET PAβN CCCP - +PAβN +CCCP - +PAβN +CCCP - +PAβN +CCCP
E. coli 
NCTC 
10418 
Wildtype - 0.015 0.015 0.015 8 16 8 1 0.5 0.25 200 50 
S. Typhimurium 14028s   
14028sRif RifR pKpQIL-UK 2 32 2 1024 2048 512 2 1 1 400 100 
14028sRif acrAB::cat pKpQIL-UK 2 16 2 512 512 512 0.5 0.25 0.25 100 100 
14028sRif tolC::cat pKpQIL-UK 16 8 32 512 128 1024 0.5 0.12 0.5 50 12.5 
14028sRif RifR pNDM-HK 8 64 2 2048 2048 2048 2 1 1 400 100 
14028sRif acrAB::cat pNDM-HK 8 32 4 1024 1024 1024 0.5 0.25 0.25 100 100 
14028sRif tolC::cat pNDM-HK 32 4 64 512 32 512 0.5 0.12 0.5 50 12.5 
S. Typhimurium SL1344   
SL1344 Wildtype pUC18 0.03 0.5 0.03 512 2048 512 2 1 1 400 100 
SL1344 ∆acrA pUC18 0.03 0.25 0.03 512 512 256 0.5 0.25 0.25 50 200 
SL1344  ∆acrB pUC18 0.03 0.25 0.06 512 1024 512 0.5 0.25 0.25 100 100 
SL1344 ∆tolC pUC18 0.12 0.25 0.06 512 128 512 0.5 0.25 0.25 50 12.5 
All values are in µg/ml. Unit for CCCP is in µM. ETP: Ertapenem; CEP: Cephalothin; TET: Tetracycline; PAβN: Phenylalanine-arginine-β-
naphthylamide; CCCP: Carbonyl cyanide m-chlorophenyl hydrazone; Bolded fonts denote significant increase/decrease in MIC (without 
efflux inhibitors); Bolded and underlined fonts denote significant increase in MIC (with efflux inhibitors); TolC mutants were tested in the 
presence of 3 µM CCCP. All other strains were tested in the presence of 25 µM CCCP. 
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the MIC value for CCCP was 12.5 µM. E. coli DH10B carrying the plasmids also showed a 
similar decrease in ertapenem susceptibility in the presence of PAβN (Table 3.8). In the 
presence of PAβN, even without the carbapenemase-encoding plasmids, E. coli DH10B was 
less susceptible to ertapenem and cephalothin. In the absence of the plasmids, the S. 
Typhimurium 14028sRif and its isogenic AcrAB mutant were also less susceptible to 
ertapenem and cephalothin in the presence of PAβN. 
Another known efflux inhibitor 1-(1-naphtylmethyl)-piperazine (NMP) and a novel 
AcrAB specific inhibitor (denoted as Compound A) were used to investigate whether the 
decrease in susceptibility towards ertapenem was specific to PAβN. In order to determine 
which concentration of the compounds would give a similar inhibitory effect to that of 25 
µg/ml PAβN, Hoechst H33342 accumulation assays comparing 25 µg/ml of PAβN with 
varying concentrations of NMP and Compound A were carried out using the parental S. 
Typhimurium 14028sRif carrying pKpQIL-UK. The AcrAB mutant was included as a control. 
It was found that 2.5 µg/ml Compound A (Figure 3.15a) and 100 µg/ml NMP (Figure 3.15b) 
gave comparable intracellular accumulation of H33342 to that in the presence of 25 µg/ml 
PAβN.  
No difference in susceptibility was observed in the presence of various efflux 
inhibitors for the K. pneumoniae Ecl8Rif carrying the pKpQIL-UK plasmid. Only in the 
presence of PAβN, did the isogenic K. pneumoniae Ecl8Rif AcrAB mutant carrying the 
pKpQIL-UK show a difference: a 16-fold increase in susceptibility to ertapenem. In contrast, 
and as found for Salmonella, the series of pKpQIL-UK carrying E. coli BW25113Rif (wildtype, 
AcrB and TolC mutants) had decreased susceptibility to ertapenem in the presence of PAβN 
and NMP. The E. coli TolC mutant was less susceptible to ertapenem in the presence of 
 
 
Table 3.8 Effects of PAβN and CCCP on MIC of β-lactam antibiotics 
Strains Genotype Plasmid Introduced 
ETP CEP TET PAβN CCCP - +PAβN +CCCP - +PAβN +CCCP - +PAβN +CCCP
S. Typhimurium 14028s   
14028s Wildtype - 0.008 0.03 0.015 4 16 4 2 1 1 >400 100 
14028sRif RifR - 0.008 0.03 0.008 4 16 4 2 1 1 400 100 
14028sRif acrAB::cat - 0.008 0.03 0.008 0.5 4 0.5 0.5 0.5 0.5 100 100 
14028sRif tolC::cat - 0.03 0.015 0.03 0.5 0.12 1 0.5 0.25 0.5 50 12.5 
S. Typhimurium SL1344   
SL1344 Wildtype - 0.015 0.015 0.015 4 16 4 2 1 1 >400 100 
SL1344Rif RifR - 0.008 0.03 0.008 4 16 4 2 1 1 >400 100 
E. coli DH10B    
DH10B Wildtype - 0.015 0.06 0.015 4 16 4 2 1 1 200 100 
DH10B Wildtype pKpQIL-UK 1 4 2 256 512 256 2 1 1 200 100 
DH10B Wildtype pKpQIL-D2 1 4 1 256 512 256 2 1 1 200 100 
DH10B Wildtype pNDM-HK 8 32 16 1024 2048 1024 2 1 1 200 100 
All values are in µg/ml. Unit for CCCP is in µM. ETP: Ertapenem; CEP: Cephalothin; TET: Tetracycline; PAβN: Phenylalanine-arginine-β-
naphthylamide; CCCP: Carbonyl cyanide m-chlorophenyl hydrazone; Bolded fonts denote significant increase/decrease in MIC (without 
efflux inhibitors); Bolded and underlined fonts denote significant increase in MIC (with efflux inhibitors); TolC mutants were tested in the 
presence of 3 µM CCCP. All other strains were tested in the presence of 25 µM CCCP. 
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Hoechst accumulation assay was done to determine the concentration needed for the 
Compound A and NMP to give comparable efflux inhibition to that of 25 µg/ml 
PAβN. All values were recorded as mean ± standard deviation of three independent 
experiments. 
Figure 3.15 Hoechst 33342 accumulation assay for PAβN and varying 
concentrations of Compound A and NMP 
(a) 
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Hoescht Accumulation Assay of PA N and
Compound  A
14
02
8s
Ri
f
14
02
8s
Ri
f ac
rA
B 
14
02
8s
Ri
f +2
5 
g/m
l P
A
N
14
02
8s
Ri
f  + 
2.5
 g
/m
l C
om
po
un
d A
14
02
8s
Ri
f  + 
5 
g/m
l C
om
po
un
d A
14
02
8s
Ri
f  +1
0 
g/m
l C
om
po
un
d A
0
100
200
300
400
500
14
02
8s
Ri
f
14
02
8s
Ri
f ac
rA
B 
14
02
8s
Ri
f +2
5 
g/m
l P
A
N
14
02
8s
Ri
f  + 
50
 g
/m
l N
MP
14
02
8s
Ri
f  + 
10
0 
g/m
l N
MP
14
02
8s
Ri
f  +1
50
 g
/m
l N
MP
Fl
uo
re
sc
en
ce
 (A
rb
itr
ar
y 
 U
ni
t)
118 
 
CCCP and Compound A. In the presence of NMP, the Salmonella and isogenic efflux mutants 
carrying pKpQIL-UK were 4- to 8-fold less susceptible to ertapenem (Table 3.9).  
As it was found that S. Typhimurium TolC mutant carrying a blaTEM-1 encoding 
plasmid had reduced susceptibility to ertapenem, the susceptibility of S. Typhimurium strains 
carrying a blaCTX-M-14 (ESBL)-encoding plasmid (pCT) was also determined in the presence 
of the various efflux inhibitors. In the presence of PAβN, both S. Typhimurium 14028sRif/pCT 
and 14028sRif acrAB/pCT had a 4-fold reduction in susceptibility to ertapenem. However, the 
14028sRif tolC/pCT strain was more susceptible to ertapenem in the presence of PAβN. 
Nonetheless it was 4- and 8-fold less susceptible to ertapenem in the presence of Compound 
A and NMP, respectively. Inactivation of the blaCTX-M-14 gene on pCT showed that the ESBL 
enzyme played a minimal role in the susceptibility of the strains towards ertapenem (Table 
3.9). 
3.6.2 PAβN Increases Carbapenem Resistance in Clinical Isolates of 
Enterobacteriaceae 
As data from this study suggested that PAβN conferred increased resistance to some β-lactam 
antibiotics, it was hypothesised that the PAβN-associated decrease in β-lactam antibiotic 
susceptibility would be observed among clinical isolates of Enterobacteriaceae. Hence, the 
effect of PAβN on the susceptibility of clinical isolates of carbapenemase producing 
Enterobacteriaceae was investigated. Eighty six non-replicate of clinical isolates from Public 
Health England were tested for their ertapenem susceptibility in the absence and presence of 
25 µg/ml PAβN. The isolates included various species including Klebsiella oxytoca (n = 4), K. 
pneumoniae (n = 25), Enterobacter asburiae (n = 1), E. aerogenes (n = 3), E. cloacae (n = 22), 
Enterobacter gergoviae (n = 2) and E. coli (n = 29). Each of these strains carry one of the  
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Table 3.9 Ertapenem MIC in the presence of various efflux inhibitors 
Strains Genotype Plasmid Introduced 
MIC of Ertapenem (µg/ml) 
- +PABN +CCCP + A +NMP
E. coli 
NCTC10418 
Wildtype - 0.015 0.015 0.015 0.015 0.015
K. pneumoniae Ecl8    
Ecl8Rif RifR pKpQIL-UK 4 8 4 4 4
Ecl8Rif acrAB::cat pKpQIL-UK 32 2 32 32 32
E. coli BW25113    
BW25113Rif RifR pKpQIL-UK 0.12 1 0.12 0.12 0.5
BW25113Rif acrB::aph pKpQIL-UK 0.5 4 1 1 4
BW25113Rif tolC::aph pKpQIL-UK 0.06 0.25 0.5 0.25 0.5
S. Typhimurium ATCC14028s   
14028sRif RifR - 0.008 0.03 0.008 0.008 0.015
14028sRif  acrAB::cat - 0.008 0.015 0.008 0.008 0.015
14028sRif  tolC::cat - 0.015 0.008 0.03 0.03 0.06
14028sRif RifR pKpQIL-UK 2 32 2 2 16
14028sRif  acrAB::cat pKpQIL-UK 1 4 2 2 8
14028sRif  tolC::cat pKpQIL-UK 16 0.008 32 32 64
S. Typhimurium SL1344    
SL1344Rif RifR pKpQIL-UK 1 8 2 2 8
SL1344 ompC::aph pKpQIL-UK 2 32 2 2 8
SL1344 ompF::aph pKpQIL-UK 16 32 16 16 16
SL1344 
∆ompC 
ompF::aph 
pKpQIL-UK 32 64 32 32 32
Continued overleaf. 
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Table 3.9 (Continued) Ertapenem MIC in the presence of various efflux inhibitors 
Strains Genotype Plasmid Introduced 
MIC of Ertapenem (µg/ml) 
- +PABN +CCCP + A +NMP
S. Typhimurium ATCC14028s   
14028sRif RifR pCT 0.015 0.06 0.015 0.015 0.03
14028sRif  acrAB::cat pCT 0.015 0.06 0.015 0.015 0.03
14028sRif  tolC::cat pCT 0.03 0.008 0.06 0.12 0.25
14028sRif RifR pCT blaCTX-M-
14::aph 
0.008 0.03 0.008 0.004 0.016
14028sRif  acrAB::cat pCT blaCTX-M-
14::aph 
0.008 0.015 0.008 0.004 0.008
14028sRif  tolC::cat pCT blaCTX-M-
14::aph 
0.015 0.008 0.03 0.03 0.06
All values are in µg/ml. PAβN: Phenylalanine-arginine-β-naphthylamide; CCCP: Carbonyl 
cyanide m-chlorophenyl hydrazone; Compound A: Novel AcrAB specific inhibitor; NMP: 1-
(1-naphthylmethyl)-piperazine; Bolded fonts denote significant increase/decrease in MIC 
(when inhibitors are added); TolC mutants were tested in the presence of 3 µM CCCP. All 
other strains were tested in the presence of 25 µM CCCP. 
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major carbapenemase genes found in the UK i.e. blaOXA-48 (n = 18), blaIMP (n = 12), blaVIM (n 
= 16), blaNDM (n = 20) and blaKPC (n = 20).  
 In the presence of 25 µg/ml PAβN, 42% (n = 36) of the Enterobacteriaceae isolates 
became 4-fold or more resistant to ertapenem (Table 3.10a). 26% (n = 22) and 30% (n = 26) 
of the isolates showed no change or a 2-fold increase in ertapenem MIC values, respectively. 
When compared to the ertapenem MIC values in the absence of the inhibitor, only two 
isolates were more susceptible to ertapenem in the presence of PAβN.  
 To investigate whether a higher concentration of PAβN would result in a larger 
number of clinical isolates showing greater resistance to ertapenem, 100 µg/ml PAβN was 
used. At this concentration and compared with 25 µg/ml PAβN, the number of isolates for 
which the ertapenem MIC increased 4-fold was reduced to seven (8.1%). A total of 26 (30.2%) 
and 33 (38.4%) isolates showed 2-fold increase or no changes in ertapenem MIC value, 
respectively. Twenty isolates (ca. 23%) showed more than 2-fold increase in ertapenem 
susceptibility. The 36 isolates for which 25 µg/ml PAβN conferred a 4-fold or more increase 
in the ertapenem MIC were affected differently when 100 µg/ml PAβN was used (Table 
3.10b). At the higher PAβN concentration, only seven of the isolates were 4-fold less 
susceptible to ertapenem compared to when no PAβN was added. Of the remaining isolates, 
23 were 2-fold less susceptible and 6 isolates had no change in ertapenem MIC value. In the 
presence of 25 µg/ml PAβN, the MIC50 and MIC90 values of the clinical isolates increased 4- 
and 2-fold, respectively. However, no changes in MIC50 and MIC90 values were observed in 
the presence of 100 µg/ml PAβN (Table 3.11).  
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Table 3.10 Changes in ertapenem resistance of clinical isolates in the presence of 
PAβN 
 
(a) Comparison of the changes in ertapenem resistance between two PAβN concentrations 
Changes in MIC 
25 µg/ml PAβN 100 µg/ml PAβN 
Number of 
isolates 
Percentage (%) Number of 
isolates 
Percentage (%) 
≥4-fold Reduction - - 6 7.0 
2-fold Reduction 2 2.3 14 16.3 
No Change 22 25.6 33 38.4 
2-fold Increase 26 30.2 26 30.2 
≥4-fold Increase 36ϯ 41.9 7 8.1 
Total 86 100.0 86 100.0 
ϯThe impact of 100 µg/ml PAβN on this 36 isolates were recorded in (b). 
 
(b) The impact of 100 µg/ml PAβN on the isolates which showed 4-fold increase or more 
in ertapenem MIC in the presence of 25 µg/ml PAβN 
Concentration 
The number of isolates (%) with altered ertapenem 
MIC in the presence of PAβN* Total 
number 
of isolates 
No Change 2-fold Increase 4-fold Increase 
100 µg/ml 6 (16.7) 23 (63.9) 7 (19.4) 36 
*Changes in ertapenem MIC is relative to the MIC of ertapenem in the absence of PAβN 
 
The MIC values of ertapenem were determined for a set of 86 non-replicate clinical isolates of 
various Enterobacteriaceae (Klebsiella spp., E. coli and Enterobacter spp.), each carrying one 
of the five major carbapenemase genes (blaKPC, blaNDM, blaVIM, blaIMP and blaOXA-48) detected 
in the UK. (a) The changes in the susceptibility of the isolates in the presence of 25 and 100 
µg/ml PAβN. (b) The effect of 100 µg/ml of PAβN on the susceptibility of the 36 isolates (ϯ) 
which showed ≥4-fold increase in ertapenem MIC value in the presence of 25 µg/ml PAβN. 
The MIC values were determined on two separate occasions. 
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Table 3.11 The changes in MIC50 and MIC90 of ertapenem of the clinical isolates in 
the absence and presence of PAβN  
 
Concentration of PAβN  MIC50 (µg/ml) MIC90 (µg/ml) 
0 µg/ml 16 128 
25 µg/ml 64 256 
100 µg/ml 32 128 
*MIC50 and MIC90 are defined as the MIC values of which the growth of 50% and 90% of the 
bacterial isolates are inhibited (Turnidge et al., 2006). In the presence of various concentration 
of PAβN, the MIC50 and MIC90 of ertapenem were determined for a set of 86 non-replicate 
clinical isolates of various Enterobacteriaceae (Klebsiella spp., E. coli and Enterobacter spp.), 
each carrying one of the five major carbapenemase genes (blaKPC, blaNDM, blaVIM, blaIMP and 
blaOXA-48) detected in the UK. The MIC values were determined on two separate occasions. 
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3.7 PAβN and Lack of TolC Alter the Porin Profile and Confers Decreased 
Susceptibility to β-lactam Antibiotics 
3.7.1 Outer Membrane Protein Mutants Showed Reduced Susceptibility to Ertapenem 
As there was no effect on the MICs in the absence of AcrB, it was hypothesised that the 
PAβN effect on the MICs was due to this compound altering expression of the outer 
membrane proteins. Furthermore, it was hypothesised that reduction in outer membrane 
protein expression, possibly porin proteins, caused the observed reduced susceptibility to 
ertapenem. Hence, plasmid pKpQIL-UK was transferred by filter conjugation into S. 
Typhimurium SL1344 in which the genes encoding major outer membrane proteins (OmpC 
and OmpF) have been inactivated (henceforth called SL1344 ompC, SL1344 ompF and 
SL1344 ompCF double mutant). The transconjugants were verified by PCR (Figure 3.16 & 
3.17) and the lack of the respective outer membrane proteins were verified by SDS-PAGE 
(Figure 3.18) (Please also see Section 3.7.2). 
 Without the carbapenemase-producing plasmid, compared to the wildtype S. 
Typhimurium SL1344 there was a 2-fold increase in the ertapenem MIC value between the 
OmpC and OmpF double mutant (SL1344 ompCF) (Table 3.12). However, there was a larger 
difference (4-fold increase) in the cephalothin MIC value between these two strains. In the 
presence of the plasmid pKpQIL-UK, the increase in ertapenem MIC value was more 
apparent for the OmpF mutant (8-fold increase) and OmpC-OmpF double mutants (16-fold 
increase). An increase in MIC value was also observed for cephalothin.  
There was also a 16-fold increased in the ertapenem MIC value for S. Typhimurium 
SL1344Rif/pKpQIL-UK in the presence of 25 µg/ml PAβN. When PAβN was present, this 
increase in carbapenem resistance was greater for the S. Typhimurium OmpC mutant (16-
fold), than the OmpF and OmpCF mutants (4-fold) (Table 3.12). The changes in the MIC of 
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The various porin mutants of S. Typhimurium SL1344 were verified by PCR for the 
presence of the pKpQIL-UK plasmid’s blaKPC gene. M: Hyperladder I (Bioline); Lane 
10: Plasmid pKpQIL-UK (Positive control); Lane 11: SL1344 genomic DNA (Negative 
control); Lane 12: Water (Contamination control); Primers: KPCg-colpcrF/R; Expected 
amplicon: 785 bp. 
Figure 3.16 PCR verification of SL1344 porin mutants carrying pKpQIL-UK 
The various porin mutants of S. Typhimurium SL1344 were verified by PCR for the 
presence of the pKpQIL-UK plasmid’s backbone gene. M: Hyperladder I (Bioline); 
Lane 10: Plasmid pKpQIL-UK (Positive control); Lane 11: Plasmid pKpQIL-D2 
(Negative control); Lane 12: Water (Contamination control); Primers: pQIL-F/R; 
Expected amplicon: 383 bp. 
 
 
M 1 2 3 4 
800 bp 
5 6 7 8 9 10 11 12 
(a) PCR check for the presence of blaKPC 
SL1344 ompC/ 
pKpQIL-UK 
SL1344 ompF/ 
pKpQIL-UK 
SL1344 ompCF/ 
pKpQIL-UK 
785 bp
(b) PCR check for the presence of pKpQIL-UK 
400 bp 
M 1 2 3 4 5 6 7 8 9 10 11 12 
SL1344 ompC/ 
pKpQIL-UK 
SL1344 ompF/ 
pKpQIL-UK 
SL1344 ompCF/ 
pKpQIL-UK 
383 bp 
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Figure 3.17 PCR verification of SL1344 porin mutants carrying pKpQIL-UK 
The S. Typhimurium porin mutants were verified by 
PCR for the presence of the inactivated ompC. 
 
Key to lanes: 
M: Hyperladder I (Bioline) 
Lane 4: SL1344 ompC genomic DNA (Positive 
control) 
Lane 5: SL1344 genomic DNA (Negative control) 
Lane 6: Water (Contamination control) 
 
Primers: OmpC-F/R 
Expected amplicon: 2207 bp (mutant), 1927 
(wildtype) 
The S. Typhimurium porin mutants were verified 
by PCR for the presence of the inactivated ompF. 
 
Key to lanes: 
M: Hyperladder I (Bioline) 
Lane 4: SL1344 ompF genomic DNA (Positive 
control) 
Lane 5: SL1344 genomic DNA (Negative control) 
Lane 6: Water (Contamination control) 
 
Primers: OmpF-F/R 
Expected amplicon: 780 bp (mutant), no amplicon 
for wildtype gene 
The S. Typhimurium double porin mutants were 
verified by PCR for the presence of the 
inactivated ompC and ompF. 
 
Key to lanes: 
M: Hyperladder I (Bioline) 
Lane 1 – 3: SL1344 ompCF/pKpQIL-UK 
Lane 4: SL1344 ompCF genomic DNA (Positive 
control) 
Lane 5: SL1344 genomic DNA (Negative 
control) 
Lane 6: Water (Contamination control) 
PCR check for inactivated ompC 
Primers: OmpC-F/R 
Expected amplicon: 753 bp (∆ompC mutant), 
1927 (wildtype) 
 
PCR check for inactivated ompF 
Primers: OmpF-F/R 
Expected amplicon: 780 bp (mutant), no 
amplicon for wildtype gene 
 
2500 bp 
2000 bp 
(a) PCR check for inactivated ompC 
M 1 2 3 4 5 6 M M 1 2 3 4 5 6 M 
1000 bp 
800 bp 
(c) PCR check for inactivated ompC and ompF in the double mutant 
(b) PCR check for inactivated ompF 
SL1344 ompC/ 
pKpQIL-UK 
SL1344 ompF/ 
pKpQIL-UK 
2500 bp 
2000 bp 
M 1 2 3 4 5 6 M 
800 bp 
1 2 3 4 5 6 M 
PCR check for 
inactivated ompC 
PCR check for 
inactivated ompF 
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Figure 3.18 Outer membrane protein profile of Salmonella Typhimurium 
SL1344 and its isogenic efflux pump mutants 
(a) SDS-PAGE comparing the outer membrane porin profile of the various S. 
Typhimurium strains. (b) 6 µg of the total protein of SL1344 OmpC mutant was 
loaded to allow the faint band migrating slightly slower than the OmpD protein to be 
excised for mass spectrometry. 
 
Ladder: PageRuler Plus Prestained Protein Ladder (Thermo Scientific) 
 
Band C, D, A and F were determined as OmpC, OmpD, OmpA and OmpF, 
respectively by mass spectrometry. The amount of total protein was determined by 
Bradford assay and 2 µg of total protein was loaded per lane. The blue box indicates 
equal loading of each sample.  
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Table 3.12 Effects of PAβN and CCCP on MIC of β-lactam antibiotics 
Strains Genotype Plasmid Introduced 
ETP CEP TET PAβN CCCP - +PAβN +CCCP - +PAβN +CCCP - +PAβN +CCCP
S. Typhimurium SL1344   
SL1344Rif RifR - 0.015 0.015 0.015 4 16 4 2 1 1 >400 100 
SL1344 ompC::aph - 0.015 0.03 0.015 8 32 8 2 1 1 >400 100 
SL1344 ompF::aph - 0.015 0.06 0.015 8 32 8 2 1 1 400 100 
SL1344 
∆ompC 
ompF::aph 
- 0.03 0.06 0.03 16 32 16 2 1 1 400 100 
SL1344Rif RifR pKpQIL-UK 1 8 2 512 2048 1024 2 1 1 400 100 
SL1344 ompC::aph pKpQIL-UK 2 32 2 2048 4096 2048 2 1 1 400 100 
SL1344 ompF::aph pKpQIL-UK 8 32 8 1024 2048 512 2 1 1 400 100 
SL1344 
∆ompC 
ompF::aph 
pKpQIL-UK 16 64 16 2048 4096 2048 2 1 1 400 100 
All values are in µg/ml. Unit for CCCP is in µM. ETP: Ertapenem; CEP: Cephalothin; TET: Tetracycline; PAβN: Phenylalanine-arginine-β-
naphthylamide; CCCP: Carbonyl cyanide m-chlorophenyl hydrazone; Bolded fonts denote significant increase in MIC (without efflux 
inhibitors); Bolded and underlined fonts denote significant increase in MIC (with efflux inhibitors); Changes of 4-fold or more in MIC values 
are considered significant. 
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cephalothin were less obvious for the porin mutants carrying the plasmid. Nonetheless, the 
susceptibility of S. Typhimurium SL1344-Rif/pKpQIL-UK to cephalothin decreased 4-fold in 
the presence of PAβN. However, there were no changes in β-lactam antibiotic susceptibility 
in the presence of CCCP. Tetracycline was used as a control and all strains showed reduced 
susceptibility to tetracycline in the presence of PAβN and CCCP. 
The susceptibility to ertapenem of the porin mutants in the presence of Compound A 
and NMP was also determined (Table 3.13). The largest decrease in ertapenem susceptibility 
was only observed in the plasmid carrying S. Typhimurium SL1344 OmpC mutant when 
PAβN was present. In the presence of NMP, the decrease in susceptibility was also observed 
in S. Typhimurium SL1344 and its isogenic OmpC mutant. These data suggest that OmpF 
plays a more important role in the changes in susceptibility to ertapenem. 
3.7.2 PAβN Reduces Outer Membrane Protein Expression in Salmonella Strains 
The loss of outer membrane proteins (OmpC and OmpF) was associated with the reduction in 
susceptibility of the S. Typhimurium strains towards β-lactam antibiotics. Hence, it was 
hypothesised that the repression of outer membrane proteins (OmpC and OmpF) resulted in 
the reduced β-lactam antibiotic susceptibility in the S. Typhimurium TolC mutants. Therefore, 
the expression of the outer membrane protein of the Salmonella strains in the absence of the 
AcrAB/TolC efflux pump components and when treated with PAβN was investigated. The 
outer membrane proteins were prepared from wildtype Salmonella SL1344 and its isogenic 
efflux pump mutants (AcrB and TolC). From the SDS-PAGE gel, no apparent difference were 
observed for the efflux pump mutants compared to the wildtype S. Typhimurium SL1344 
(Figure 3.18a; On page 127). Based on protein mobility, there is contradictory identification 
of outer membrane proteins of Salmonella in the literature (Piddock et al., 1993, Santiviago et 
al., 2003). As there was no specific outer membrane protein anti-serum available for this  
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Table 3.13 Ertapenem MIC in the presence of various efflux inhibitors 
Strains Genotype Plasmid Introduced 
MIC of Ertapenem (µg/ml) 
- +PABN +CCCP + A +NMP
S. Typhimurium SL1344    
SL1344Rif RifR pKpQIL-UK 1 8 2 2 8
SL1344 ompC::aph pKpQIL-UK 2 32 2 2 8
SL1344 ompF::aph pKpQIL-UK 8 32 8 16 16
SL1344 
∆ompC 
ompF::aph 
pKpQIL-UK 16 64 16 32 32
All values are in µg/ml. PAβN: Phenylalanine-arginine-β-naphthylamide; CCCP: Carbonyl 
cyanide m-chlorophenyl hydrazone; Compound A: Novel AcrAB specific inhibitor; NMP: 1-
(1-naphthylmethyl)-piperazine; Bolded fonts denote significant increase in MIC (when 
inhibitors are added). 
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study, the three major protein bands around 35 kDa were excised for N-terminal sequencing 
to determine the identity of the proteins. After repeated attempts, N-terminal sequencing was 
only able to identify the protein band labelled as ‘A’. Hence, mass spectrometry was used to 
identify the protein bands ‘C’, ‘D’ and a very faint protein band ‘F’ which was only observed 
in the OmpC mutant (Figure 3.18b). All the bands were identified as OmpC (Band C), OmpF 
(Band F), OmpD (Band D) and OmpA (Band A). From the SDS-PAGE gel, there was a 
concentration dependent down-regulation of outer membrane proteins when PAβN was added. 
In the presence of PAβN, there was a clear difference in the total intensity of protein bands 
visible on the gel even when 2 µg of total protein was used in each lane for electrophoresis. 
Although this may suggest unequal loading of protein samples, this phenomenon was 
repeatedly observed, despite equal loadings being used in all experiments indicated by the 
lower molecular mass protein (ca. 15 kDa) highlighted with the blue box.  
3.7.3 Outer Membrane Protein Profile of Clinical Isolates of Enterobacteriaceae 
Sixty-two Enterobacteriaceae clinical isolates had reduced susceptibility to ertapenem in the 
presence of PAβN. It was hypothesised that PAβN altered the outer membrane and/or porin 
expression in these isolates, resulting in reduced susceptibility to ertapenem. Hence, selected 
isolates of E. coli which were tested for their susceptibility in the presence and absence of 
PAβN (Section 3.6.2) were chosen to determine whether 25 µg/ml PAβN changed their outer 
membrane protein profile. The selected clinical isolates consisted of isolates which had 
increased ertapenem MIC values and one isolate which was not affected by the presence of 
PAβN. Based on previous studies of E. coli (Erdei et al., 1994, Ma et al., 2013, Oteo et al., 
2008), protein bands C, F and A were identified as OmpC, OmpF and OmpA, respectively 
(Figure 3.19). After SDS-PAGE, it was observed that for isolates which showed an increase 
in ertapenem resistance in the presence of PAβN, also showed reduced expression of OmpF. 
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Figure 3.19 Outer membrane protein of E. coli clinical isolates in the presence 
and absence of 25 µg/ml PAβN  
L: PageRuler Plus Prestained Protein Ladder (Thermo Scientific) 
 
Strain PAβN (25 µg/ml) Ertapenem MIC (µg/ml) 
E. coli NCTC10418 − 0.016 
 + 0.016 
Isolate 298 − 8 
 + 64 
Isolate 359 − 2 
 + 8 
Isolate 388 − 8 
 + 32 
Isolate 656 − 128 
 + 128 
Isolate 669 − 8 
 + 16 
−: Not added; +: Added 
Band C, F and A are assumed as OmpC, OmpF and OmpA by previously published 
data. Blue and yellow box were determined by mass spectrometry as OmpC and 
OmpA, respectively. Bolded fonts denote significant increase in MIC values. Where 
the strains showed a change in the MIC values of ertapenem in the presence of 25 
µg/ml PAβN, these strains also showed reduced expression of their porins when 
treated with the compound. Yellow arrows show the changes in the intensity of the 
porin bands. 
L - + - + - + - + - + 
55 kDa
35 kDa
25 kDa
15 kDa
- + L 
C 
F 
A 
298 359 388 656NCTC 669 
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Isolate 656, which showed no difference in ertapenem MIC value when PAβN was added, 
also had no detectable changes in OmpC and OmpF production. The outer membrane protein 
of higher molecular mass (Blue box) of isolate 298 was determined by mass spectrometry to 
be OmpC. The smaller outer membrane protein band (Yellow box) of isolate 656 was 
confirmed to be OmpA by mass spectrometry. Other isolates of Enterobacter spp. (n = 4) and 
Klebsiella spp. (n = 5) were also selected to assess the effects of PAβN on the outer 
membrane protein profiles. In both cases, the addition of PAβN changed the outer membrane 
protein profile of the isolates of these two species (Figure 3.20 and Figure 3.21). In 
conclusion, in many of the isolates where PAβN was found to have increased the ertapenem 
MIC values, the compound was also found to alter porin expression of these isolates. 
However, exceptions were observed in some cases (e.g. Figure 3.21 isolate 582 & 664). 
3.8 Discussion 
Previous studies have shown that in E. coli the AcrAB-TolC efflux system works 
synergistically with other mechanisms to confer a higher level of resistance to antibacterial 
compounds, such as triclosan and ciprofloxacin (McMurry et al., 1998, Oethinger et al., 2000). 
However, the data obtained from my study suggest that a functional AcrAB-TolC is not 
required for the full elaboration of carbapenem resistance i.e. not as expected in the 
hypothesis (Section 3.2). This is in disagreement with some reports that have often implicated 
increased efflux to contribute (at least in part) to carbapenem resistance among 
Enterobacteriaceae (Bornet et al., 2003, Lavigne et al., 2012, Woodford et al., 2007). Some 
authors have also suggested that the AcrAB efflux pump plays a role in carbapenem 
resistance (Bornet et al., 2003, Lavigne et al., 2012, Seecoomar et al., 2013). During the 
course of treatment with imipenem, susceptible isolates of E. aerogenes which evolved into 
imipenem intermediate and fully resistant strains had elevated AcrA and TolC expression 
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Figure 3.20 Outer membrane protein of Enterobacter spp. clinical isolates in the 
presence and absence of 25 µg/ml PAβN  
L: PageRuler Plus Prestained Protein Ladder (Thermo Scientific) 
 
Strain PAβN (25 µg/ml) Ertapenem MIC (µg/ml) 
E. cloacae  − 0.5 
NCTC10005 + 0.5 
Isolate 200 − 16 
(E. cloacae) + 32 
Isolate 278 − 4 
(E. asburiae) + 4 
Isolate 428 − 32 
(E. cloacae) + 64 
Isolate 559 − 8 
(E. cloacae) + 32 
−: Not added; +: Added; ND: Not determined; Bolded fonts denote significant 
increase in MIC values.  
 
Where the strains showed a change in the MIC value of ertapenem in the presence of 
25 µg/ml PAβN, changes in the porin profile were also observed. Yellow arrows 
show the changes in the intensity of the porin bands. 
55 kDa 
35 kDa 
25 kDa 
15 kDa 
L - + - + - + - + - + L 
200 278 428 559 NCTC
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Figure 3.21 Outer membrane proteins of Klebsiella spp. clinical isolates in the 
presence and absence of 25 µg/ml PAβN  
L: PageRuler Plus Prestained Protein Ladder (Thermo Scientific) 
 
Strain PAβN (25 µg/ml) Ertapenem MIC (µg/ml) 
K. pneumoniae − 0.016 
NCTC9633 + 0.016 
Isolate 423 − 32 
K. pneumoniae + 64 
Isolate 433 − 8 
K. oxytoca + 64 
Isolate 472 − 64 
K. pneumoniae + 128 
Isolate 582 − 2 
K. pneumoniae + 8 
Isolate 664 − 8 
K. pneumoniae + 8 
−: Not added; +: Added; ND: Not determined; Bolded fonts denote significant 
increase in MIC values. Bolded fonts denote significant increase in MIC values. 
 
Where the strains showed a change in the MIC value of ertapenem in the presence of 
25 µg/ml PAβN, changes in the porin profile were also observed. Yellow arrows 
show the changes in the intensity of the porin bands. 
55 kDa 
35 kDa 
25 kDa 
15 kDa 
L - + - + - + - + - + - + L
423 433 472 582 NCTC 664 
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(Lavigne et al., 2012). However, the resistant isolate had no expression of OmpK35 and 
OmpK36 which are frequently associated with carbapenem resistance (Adams-Sapper et al., 
2015, Clancy et al., 2013a, Clancy et al., 2013b, Hernandez-Alles et al., 1999, Shields et al., 
2015). In another study, imipenem resistant mutants of E. aerogenes were selected by 
sequential sub-culturing of an ATCC13048 type strain in increasing concentration of 
imipenem. The mutants also showed increased expression of AcrA efflux protein (Bornet et 
al., 2003).  
A more recent study cloned and expressed the blaKPC gene on a plasmid in an E. coli 
N43 strain which does not produce the AcrA protein (Seecoomar et al., 2013). Compared to 
the parental strain, E. coli W4573 which carried the same carbapenemase-producing plasmid, 
the authors concluded that the AcrAB efflux pump is important for carbapenem resistance as 
there was a 32- and 16-fold increase in meropenem and imipenem MIC values, respectively in 
the parental strain (Seecoomar et al., 2013). Although the same blaKPC-2 in Tn4401 isoform ‘a’ 
and similar K-12 derived E. coli strains were used (Leavitt et al., 2010a, Nakamura, 1968, 
Seecoomar et al., 2013, Wanner et al., 1983), the AcrAB associated reduction in carbapenem 
susceptibility was not observed in this PhD study.  
The N43 strain carries a mutant allele of acrA termed acrA1 due to the insertion of an 
insertion element (IS2) close to the 5’ end of the acrA gene (Ma et al., 1993, Ma et al., 1995). 
Together with MIC data, it was assumed that N43 does not produce the functional AcrAB 
efflux pump as the susceptibility of the N43 strain could be restored to wildtype levels by 
introducing a wildtype acrA gene (Ma et al., 1993). It is important to note that this N43 strain 
is not an acrA null mutant and may carry other mutations with unknown effects on drug 
susceptibility (Ma et al., 1995). It is also not known whether there is any polar effect arising 
from the insertion element (Ma et al., 1993, Thanassi et al., 1997). If the AcrB protein is still 
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produced, the presence of other membrane fusion protein such as AcrE can complement the 
function of AcrA (Smith and Blair, 2014). Hence, the use of this N43 strain in the study does 
not provide a defined background to investigate the relationship of AcrAB efflux system with 
carbapenem resistance. 
On the contrary, the Salmonella strain used in this PhD study is different: the function 
of AcrAB has been completely abolished due to the inactivation method used which replaced 
the acrAB genes with a chloramphenicol resistance gene (cat) (Nishino et al., 2006). Similarly, 
the acrB efflux pump component has been completely removed from E. coli BW25113 (Baba 
et al., 2006). Hence, the data gathered from this PhD suggest that the AcrAB-TolC efflux 
system does not play a role in carbapenem resistance. This finding also corroborates a 
previous study which found no increase expression of acrB mRNA transcripts among 
carbapenem resistant isolates of Klebsiella spp. and Enterobacter spp. (Doumith et al., 2009). 
Moreover, to date, there is no study which clearly associates carbapenems (in particular, 
ertapenem) as a substrate of the AcrAB-TolC efflux system. Crystallisation and molecular 
docking studies have frequently centred on substrates, such as penicillins, cephalosporins, 
doxorubicin and minocycline (Collu et al., 2012, Eicher et al., 2012, Lim and Nikaido, 2010, 
Murakami et al., 2006, Nagano and Nikaido, 2009).  
Interestingly, although the functional AcrAB-TolC efflux system was not found to be 
required for the resistance of the carbapenemase-producing Salmonella strains, the loss of 
TolC function instead caused an increase in resistance towards a variety of carbapenem 
antibiotics (ertapenem, meropenem and doripenem) and a cephalosporin (ceftazidime). To 
investigate whether the plasmid (pKpQIL-UK) used was responsible for the reduced 
susceptibility observed in the TolC mutant, its variant (pKpQIL-D2), pNDM-HK and pUC18 
plasmids were also included in the experiment. The plasmid ca. 89 kb pNDM-HK is an 
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IncL/M plasmid which encodes for a blaNDM-1 carbapenemase (Ho et al., 2011). This plasmid 
shares no significant homology (≈4% Blastn alignment coverage) to the ca. 114 kb blaKPC-
encoding pKpQIL-UK and -D2 plasmids which belong to the IncF group of plasmids. Unlike 
the natural conjugative plasmids (pKpQIL-UK, -D2 and pNDM-HK), the much smaller (2.7 
kb) pUC18 is a laboratory generated plasmid (Norrander et al., 1983). Although as expected 
that the blaTEM-1-encoding pUC18 plasmid did not confer a clinically significant level of 
resistance to ertapenem in the TolC mutant, the fold increase in the ertapenem MIC value 
(when compared to the wildtype) was similar to those shown for strains containing the 
carbapenemase-producing plasmids. Taken together, these data suggest that the increase in β-
lactam (especially carbapenem) resistance in the Salmonella TolC mutant was not an effect of 
expression of other vector genes in the plasmids or chromosome of the strains used. Neither 
was it an effect of the carbapenemase or β-lactamase genes involved. This finding is similar to 
those that have been reported where clinical isolates harbouring different carbapenemases 
showed heteroresistance towards various carbapenem antibiotics (Jain et al., 2014, Pournaras 
et al., 2010, Tijet et al., 2013, Zavascki et al., 2014). The decrease in carbapenem 
susceptibility was not observed in the E. coli BW25113 TolC mutant. Instead, the E. coli 
TolC mutant carrying the pKpQIL-UK plasmid was more susceptible to various carbapenem 
antibiotics.  
It has been suggested previously that E. coli lacking TolC protein exhibit membrane 
stress (Dhamdhere and Zgurskaya, 2010). Hence, it was hypothesised that membrane damage 
from the loss of TolC might allow the diffusion of the carbapenemase into the extracellular 
environment allowing better tolerance to the carbapenem antibiotics tested. Possibly due to 
low expression of the carbapenemase (blaKPC) and/or low plasmid copy number of pKpQIL-
UK, a high amount of total protein was required to detect the hydrolysis of the nitrocefin dye. 
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This amount was not achievable using the supernatant of the culture medium. Hence, the 
passive release of the carbapenemase could only be assessed using the crude lysate of the 
bacterial pellet. As no significant difference in the initial hydrolysis of nitrocefin was 
observed between the wildtype Salmonella compared to the AcrAB and TolC mutant, it is 
unlikely that this hypothesis is correct. 
The effect of the well established efflux inhibitor PAβN in carbapenem susceptibility 
was also investigated. Of note, the addition of this efflux inhibitor increased the ertapenem 
MIC values of the wildtype S. Typhimurium 14028sRif and AcrAB mutant strain. The fold 
increase is similar to that observed in the Salmonella TolC mutant carrying the plasmids (in 
the absence of PAβN). It has been suggested that a low concentration of PAβN (20 µM ≈ 10.4 
µg/ml) will have efflux inhibitory effect, whereas a higher concentration (0.1 mM ≈ 51.9 
µg/ml) will enhance the efflux rate of cephalosporins via AcrB (Kinana et al., 2013). 
However, this phenomenon does not explain the observations of this PhD study as the 
increase in ertapenem resistance was also observed in the AcrAB Salmonella and AcrB E. coli 
mutants when treated with PAβN. Other studies have used PAβN to associate the role of 
efflux in carbapenem resistance when a decrease in carbapenem MIC value was observed in 
the presence of the inhibitor (Baroud et al., 2013, Szabó et al., 2006, Yang et al., 2012). The 
concentration of PAβN used in these studies ranged from 25 – 100 µg/ml. Unlike the data 
obtained from this PhD study, where 72 out of 86 clinical isolates showed at least 2-fold 
increase in ertapenem resistance, the previous studies reported reduction in carbapenem MIC 
values when the isolates were tested with PAβN (Baroud et al., 2013, Szabó et al., 2006, Yang 
et al., 2012). In one study, one of the E. coli isolate (E44) showed a 8-fold decrease in 
ertapenem susceptibility in the presence of 100 µg/ml PAβN (Baroud et al., 2013). However, 
the authors did not discuss this isolate further. 
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Previous studies have shown that efflux pump expression and repression of porin are 
closely regulated (Barbosa and Levy, 2000, De Majumdar et al., 2013). Microarray studies 
have also shown that the disruption of the acrB or tolC gene resulted in decreased expression 
of ompF (Webber et al., 2009). Recently RNA-sequencing from the Piddock Group which 
studied the impact of PAβN on S. Typhimurium SL1344 also showed decreased ompF mRNA 
transcript (Blair, J. & Piddock, L., Unpublished data). The ertapenem MIC values of the porin 
mutants carrying the pKpQIL-UK plasmid showed increased resistance to ertapenem, but the 
fold-change in MIC value after addition of PAβN decreases in the following order: OmpC, 
OmpF and OmpC/F double mutants. Taken together, these data suggested that altered porin 
production was associated with the observed reduction in ertapenem susceptibility in the 
strains carrying the various plasmids. This was supported by the SDS-PAGE gels which 
showed a decreased in Salmonella porin expression with an increasing concentration of PAβN. 
Similar changes in outer membrane protein profile were observed with the Enterobacteriaceae 
clinical isolates harbouring a variety of carbapenemases. These findings support a previous 
study which showed OmpC and OmpF or their orthologues play a role in carbapenem 
resistance among Enterobacter spp. and Klebsiella spp. (Doumith et al., 2009). 
To investigate whether the decrease in carbapenem susceptibility was specific to 
PAβN, MIC values were determined with two other efflux inhibitors (NMP and Compound 
A). The S. Typhimurium 14028sRif which carries the pKpQIL-UK plasmid was tested for its 
susceptibility towards ertapenem. This carbapenem was chosen as it showed the largest 
change in susceptibility. Independent of the presence of the functional AcrAB-TolC efflux 
system, PAβN and NMP reduced the susceptibility of the Salmonella and E. coli strains 
harbouring the pKpQIL-UK plasmid. Compound A had no impact on the carbapenem 
susceptibility of the strains. This may be due to the difference in the mechanism of action of 
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the efflux inhibitors. Since its discovery, PAβN has been known to have membrane 
permeabilising effects (Lomovskaya et al., 2001), but that the permeabilising effect was only 
apparent when efflux function was compromised. At up to 128 µg/ml PAβN, P. aeruginosa 
with a functional MexAB-OprM showed no significant membrane permeabilisation. However, 
more recently it has been suggested that the permeabilising effect of PAβN is stronger than 
previously reported (Lamers et al., 2013, Matsumoto et al., 2011). The membrane damaging 
effects occur also in wildtype Pseudomonas without efflux defects and the effects are stronger 
on the E. coli outer membrane compared to the former (Lamers et al., 2013, Matsumoto et al., 
2011). It may be possible that the membrane stress caused by PAβN is similar to that of the 
loss of the TolC physical protein and/or its function. The permeabilising effect of PAβN also 
explains the observation that most of the clinical isolates which showed a 4-fold increase in 
ertapenem MIC values at 25 µg/ml PAβN had only a 2-fold increase when 100 µg/ml PAβN 
was used. A previous study comparing the membrane permeabilising effects of PAβN and 
NMP also suggested a possible membrane permeabilising effect by NMP albeit less 
prominent than PAβN (Pannek et al., 2006). This suggests that NMP may have reduced the 
susceptibility of the Salmonella and E. coli strains via the same mechanism as PAβN. The 
effect of NMP via down-regulation of OmpF is also supported by the observation that the 
ertapenem MIC values were only increased in the SL1344 OmpC mutant but not when OmpF 
was absent. The regulation of porin expression is known to be complex and may differ 
between species (De La Cruz and Calva, 2010, Martínez-Flores et al., 1999). This may 
explain the differences observed between the K. pneumoniae, E. coli and S. Typhimurium 
efflux mutants’ susceptibility to the antibiotics tested. 
Previous studies have associated ESBL with carbapenem resistance (Doumith et al., 
2009, Woodford et al., 2007). Hence, the blaCTX-M-14 encoding pCT plasmid and its ESBL 
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inactivated plasmids were introduced into the set of Salmonella strains to study the effects of 
an ESBL on carbapenem susceptibility in the presence/absence of a functional AcrAB-TolC 
efflux system. Unlike the blaTEM-1-encoding pUC18, there was no obvious decrease in 
ertapenem susceptibility in the Salmonella TolC mutant. This was possibly due to the lower 
copy number of pCT and/or lower expression of blaCTX-M-14. However, in the presence of 
PAβN, an increase in ertapenem MIC values was observed for S. Typhimurium 
14028sRif/pCT and 14028sRif acrAB/pCT.  
Efflux systems has been well established for their contribution to antibiotic resistance 
and TolC forms the outer membrane channel of most efflux pumps found in Gram-negative 
bacteria. Hence, TolC has been suggested as a potential target for the design of efflux pump 
component inhibitors (Pagès and Amaral, 2009). From this work, it is suggested that PAβN 
which causes membrane stress and the loss of function of the TolC and/or its physical protein 
could increase the resistance of the bacteria against antibiotics which uses outer membrane 
porins as entry routes to their targets in the cell. Hence, TolC may not be an ideal drug target 
as the loss of TolC function and/or its protein may cause increase resistance via the down-
regulation of outer membrane proteins, especially OmpF. 
3.9 Future Work 
One main question arising from the data obtained is whether the down-regulation of the 
porins resulted from the physical loss of the TolC protein or from the loss of function of the 
protein. This could be addressed by expressing a non-functional TolC protein instead of using 
a deletion mutant. This could be done by introducing point mutations which affect the 
function of the TolC protein without affecting its expression or complex with the AcrAB 
components (Krishnamoorthy et al., 2013). Data arising from this experiment will be 
important for efflux inhibitor design. If the loss of TolC function was the trigger for the 
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adaptation in porin repression, a drug designed to inhibit the function of TolC may increase 
the resistance to certain antibiotics. The main antibiotics tested in this study were carbapenem 
antibiotics due to the carbapenemases encoded on the plasmids. However, other antibiotics 
which utilise OmpF as the major route of entry into the cells, such as quinolones, should also 
be tested (Marshall and Piddock, 1993).  
 From this study, it was observed that the inactivation of the efflux pump components 
had different effects in the different species (K. pneumoniae, E. coli and Salmonella). Hence, 
a TolC inactivated K. pneumoniae will be required to investigate whether the susceptibility of 
the carbapenemase producing strain would show similar susceptibility level as the E. coli or 
Salmonella strains. The inactivation of the TolC could be done as previously described by 
homologous recombination of chimeric PCR amplicons of antibiotic resistance gene (e.g. aph 
or cat) with flanking regions homologous to the tolC gene (Datsenko and Wanner, 2000). 
 It is hypothesised that the inactivation of TolC in Salmonella and the addition of 
PAβN (Salmonella and E. coli) represses porin production. This could be via at least two 
mechanisms: (1) the micF antisense pathway which inhibits OmpF translation and/or 
destabilisation of ompF mRNA transcript (Ramani et al., 1994) or (2) EnvZ-OmpR 
mechanism where EnvZ phosphorylates OmpR which then represses the transcription of 
ompF (Cai and Inouye, 2002). Hence, qRT-PCR could be used to assess the expression of 
micF and the porin genes in the TolC mutants and, when the wildtype Salmonella and E. coli 
strains are treated with PAβN. Another method to confirm that OmpF played a role in the 
carbapenem susceptibility observed in the Salmonella TolC mutant is by expression of OmpF 
in trans on a low copy plasmid in the strain. A low copy plasmid such as pUA66 can be used 
for the expression of OmpF with an inducible promoter (Zaslaver et al., 2004). If OmpF is 
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repressed in the TolC mutant, the expression of OmpF in trans would restore the carbapenem 
MIC values to wildtype levels. 
3.10 Key Findings 
 The AcrAB-TolC efflux system in K. pneumoniae, E. coli and S. Typhimurium is not 
essential for carbapenem resistance. 
 The loss of TolC protein and/or TolC function in S. Typhimurium reduces β-lactam 
antibiotic susceptibility. 
 The efflux inhibitor (PAβN) reduces β-lactam antibiotic susceptibility. 
 The decrease in carbapenem susceptibility in a Salmonella TolC mutant and, when 
Salmonella and E. coli are treated with PAβN, is likely due to OmpF repression. 
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CHAPTER FOUR: COMPARISON OF PLASMIDS pKpQIL-UK WITH pKpQIL-D2 
4.1 Background 
The blaKPC-encoding plasmid pKpQIL-UK has been found in bacteria isolated in various 
countries, including USA, Israel, Italy and Poland. Recently, this plasmid was also discovered 
in the UK (Woodford, N. Unpublished data). Interestingly, a variant of the plasmid i.e. 
pKpQIL-D2 was also isolated. A ca. 20 kb backbone region on the pKpQIL-UK has been 
substituted with a smaller ca. 16 kb in pKpQIL-D2. This variant plasmid was found in 
different species of Enterobacteriaceae, including E. cloacae and E. coli. However, it is not 
known whether the substituted region confers a general advantage to the dissemination and 
persistence of this variant plasmid in other species and so contributed to the hospital outbreak 
in the UK. 
4.2 Hypothesis and Aims 
It was hypothesised that the ca. 16 kb region in the pKpQIL-D2 plasmid confers a fitness 
advantage in the plasmid-carrying host. Therefore, the aims of the study were: 
i) To determine the conjugation frequencies of the pKpQIL-UK and -D2 from 
their original clinical isolates into representative species of Enterobacteriaceae. 
ii) To determine the ability of the plasmid-carrying hosts to form biofilm. 
iii) To study the differences in growth rate of the plasmid-carrying hosts. 
iv) To investigate the impact of the plasmids on host bacterium chromosomal gene 
expression. 
4.3 Comparison of the Genetic Sequence of pKpQIL-UK with that of pKpQIL-D2 
The pKpQIL-UK and pKpQIL-D2 plasmid DNA sequences were identical except for a ca. 20 
kb region in pKpQIL-UK which has been substituted with a ca. 16 kb region in pKpQIL-D2. 
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Both of these regions carry genes which are associated with resistance, mobile elements, 
replicon, plasmid genes (e.g. partition system) (Figure 1.8; On page 42). The majority of the 
open reading frames within the substituted region in pKpQIL-D2 encode for small 
hypothetical proteins (100 – 150 amino acids). Protein homology search by Blastp, conserved 
motif search by PROSITE (http://prosite.expasy.org/) and protein localisation prediction by 
PSORTb (http://www.psort.org/psortb/) were conducted but no significant hit was obtained 
for these hypothetical proteins. It is not known whether these were functional proteins. A 
blastn search (http://blast.ncbi.nlm.nih.gov/) using this region in pKpQIL-D2 showed 46% 
coverage with high sequence identity (98%) with a region in the plasmid pKPN5 found in the 
multidrug drug resistant K. pneumoniae MGH78578 (Figure 4.1). Among the isolates 
received by Public Health England, it was found that plasmid pKpQIL-D2 occurred more 
frequently than pKpQIL-D1. Moreover, pKpQIL-D2 was also found in E. cloacae, E. coli and 
non-ST258 K. pneumoniae. Therefore, all the fitness experiments conducted in this PhD study 
focused on the pKpQIL-UK and pKpQIL-D2 plasmids.   
4.4 Transfer of Plasmid into Different Species of Enterobacteriaceae 
Plasmids pKpQIL-UK and -D2 were large and could not be transferred by electroporation into 
new bacterial hosts. Hence, rifampicin-resistant mutants were selected from K. pneumoniae 
Ecl8, E. coli NCTC10418, S. Typhimurium (SL1344 and ATCC14028s), E. cloacae 
NCTC10005 and S. marcescens NCTC10211. A single amino acid substitution was found in 
the rpoB gene in representative mutants of all five strains. The amino acid substitution varied 
between the species. The frequency of mutation to resistance of each strain was typical of that 
of a mutation in a single gene (Table 4.1) (Miller et al., 2002).  
Plasmids pKpQIL-UK and -D2 were transferred by electroporation into highly 
electrocompetent ElectroMAXTM DH10BTM E. coli cells according to manufacturer’s  
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Figure 4.1 Alignment of pKpQIL-UK and -D2 with pKPN5  
 
The diagram was generated using Blast Ring Image Generator. From the inner most 
ring, (1) Size of the plasmid, (2) pKpQIL-UK (blue), (3) pKpQIL-D2 (green), (4) 
substituted region (orange) and (5) pKPN5 (pink). The 16 kb region in pKpQIL-D2 
which substituted the 20 kb region in pKpQIL-UK is highlighted in orange. It also 
shows that about 46% of this substituted region (orange) shares about 98% DNA 
sequence identity with pKPN5 plasmid from K. pneumoniae MGH78578. The genes 
shared between pKPN5 with the substituted region in pKpQIL-D2 include the repB 
replicon, parAB partitioning system and umuCD DNA damage control (Figure 1.8). 
Substituted region 
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Table 4.1 Rifampicin-resistant mutants of five species of Enterobacteriaceae  
 
 
Bacteria (Rifampicin-
Resistant) 
Code Mutation 
(Substitution) 
Mutation 
Frequency 
K. pneumoniae Ecl8 Ecl8Rif His537Leu 8.6 x 10-9 
E. coli NCTC10418 10418Rif Ser531Phe 2.2 x 10-8 
S. Typhimurium ATCC14028s 14028sRif Ser522Tyr 7.3 x 10-10 
S. Typhimurium SL1344 SL1344Rif Ser522Phe 1.1 x 10-9 
E. cloacae NCTC10005 EcloacaeRif Ser328Ala 1.3 x 10-8 
S. marcescens NCTC10211 SerratiaRif Asp516Gly 6.0 x 10-9 
 
The table shows the substitution found in each of the rifampicin-resistant strains used and the 
frequency at which these mutants were selected at. These strains were used as the host for the 
pKpQIL-UK and -D2 plasmids in the fitness experiments. 
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instructions. This E. coli strain was chosen as it is known to be plasmid-free and possesses a 
high transformation efficiency with a good ability to maintain large plasmids (Durfee et al., 
2008). To verify that the transformants contained the plasmids, PCR was used to detect the 
blaKPC gene. The PCR amplicon was purified and DNA sequenced; this showed that the 
DH10B transformants carried the blaKPC-2 variant carbapenemase. The DH10B/pKpQIL-UK 
and DH10B/pKpQIL-D2 strains were used to transfer the plasmids into the respective 
Enterobacteriaceae species (Figure 4.2).   
 The DH10B/pKpQIL-UK and DH10B/pKpQIL-D2 strains were used as the donor 
strains of the plasmids into the rifampicin-resistant recipient strains of E. coli, Salmonella, E. 
cloacae and S. marcescens in filter conjugation experiments. The plasmids were also 
transferred into K. pneumoniae ST258 which was naturally kanamycin resistant. All of the 
transconjugants obtained were checked for the presence of the blaKPC gene and for the 
plasmid backbone fragment which differentiates the two plasmids (Figure 4.3 – 4.7). For the 
SerratiaRif/pKpQIL-UK transconjugants, it was shown by PCR to contain the blaKPC gene 
(Figure 4.5a, Lane 7-9). However, the PCR to check for the presence of a pKpQIL-UK 
backbone region was unsuccessful (Figure 4.5b, Lane 4-6). Hence, the PCR was repeated 
(Figure 4.6).  
4.5 Growth Rates of Enterobacteriaceae pKpQIL-UK and -D2 
Growth kinetics was one of the aspects of fitness which was investigated to determine the 
impact of the plasmids on its host. It was hypothesised that bacteria carrying the variant 
plasmid, pKpQIL-D2 grew faster than strains containing pKpQIL-UK. It was further 
hypothesised that this attribute allowed the pKpQIL-D2 plasmid to spread and persist in the 
UK. The difference of growth rates was identified by calculating the generation time of each 
strain/plasmid combination during the logarithmic phase of growth. Under the conditions 
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Figure 4.2 PCR verification of the E. coli DH10B transformants for the 
presence of pKpQIL-UK and -D2  
The plasmids pKpQIL-UK and -D2 provided by Woodford, N. was electroporated into E. coli 
DH10B to be used as donor strains for conjugation experiments. The transformants were 
verified by PCR for the presence of the blaKPC gene. M: Hyperladder I (Bioline); Lane 4: 
pKpQIL-UK plasmid (Positive control); Lane 5: DH10B genomic DNA (Negative control); 
Lane 6: Water (Contamination control); Lane 10: pKpQIL-D2 plasmid (Positive control); Lane 
11: DH10B genomic DNA (Negative control); Lane 12: Water (Contamination control); 
Primers: KpQIL-KPC-F/R; Expected amplicon: 1580 bp. 
 
M 1 2 3 4 5 6 
2000 bp 
1500 bp 1580 bp 
DH10B/pKpQIL-UK 
Transformants 
M 7 8 9 10 11 12 
(a) PCR check for the presence of blaKPC 
DH10B/pKpQIL-D2 
Transformants 
M 1 2 3 4 5 6 
DH10B/pKpQIL-UK 
Transformants 
M 7 8 9 10 11 12 
DH10B/pKpQIL-D2 
Transformants 
(b) PCR check for the presence of pKpQIL-UK 
600 bp 
400 bp 
600 bp 
383 bp 
The plasmids pKpQIL-UK and -D2 provided by Woodford, N. was electroporated into E. coli 
DH10B to be used as donor strains for conjugation experiments. The transformants were verified 
by PCR for the presence of the respective plasmid backbone gene. 
Key to lanes: 
M: Hyperladder I (Bioline) 
Lane 4: pKpQIL-UK plasmid (Positive control) 
Lane 5: DH10B genomic DNA (Negative 
control) 
Lane 6: Water (Contamination control) 
 
Primers: pQIL-F/R 
Expected amplicon: 383 bp  
Lane 10: pKpQIL-D2 plasmid (Positive 
control) 
Lane 11: DH10B genomic DNA (Negative 
control) 
Lane 12: Water (Contamination control) 
 
Primers: pMan-F/R 
Expected amplicon: 600 bp  
151 
 
Figure 4.3 PCR verification of the Salmonella SL1344Rif transconjugants 
carrying pKpQIL-UK and -D2 
The transconjugants of Salmonella SL1344 carrying pKpQIL-UK & -D2 were verified by PCR 
for the presence of the blaKPC gene. M: Hyperladder I (Bioline); Lane 4: pKpQIL-UK plasmid 
(Positive control); Lane 5: SL1344Rif genomic DNA (Negative control); Lane 6: Water 
(Contamination control); Lane 10: pKpQIL-D2 plasmid (Positive control); Lane 11: SL1344Rif 
genomic DNA (Negative control); Lane 12: Water (Contamination control); Primers: KPCg-
colpcr-F/R; Expected amplicon: 785 bp. 
  
*New PCR primers giving a smaller amplicon to detect blaKPC gene was designed. These 
primers are used hereafter. 
M 1 2 3 4 5 6 
800 bp 
600 bp 
785 bp 
M 7 8 9 10 11 12 
SL1344Rif/pKpQIL-UK 
Transconjugants 
SL1344Rif /pKpQIL-D2 
Transconjugants 
(a) PCR check for the presence of blaKPC 
(b) PCR check for the presence of the specific plasmids 
M 1 2 3 4 5 6 M 7 8 9 10 11 12 
SL1344-Rif/pKpQIL-
UK Transconjugants 
SL1344-Rif /pKpQIL-
D2 Transconjugants 
600 bp 
400 bp 
600 bp 
383 bp 
Lane 10: pKpQIL-D2 plasmid (Positive control) 
Lane 11: pKpQIL-UK plasmid (Negative 
control) 
Lane 12: Water (Contamination control) 
 
Primers: pMan-F/R 
Expected amplicon: 600 bp  
Key to lanes 
M: Hyperladder I (Bioline) 
Lane 4: pKpQIL-UK plasmid (Positive control) 
Lane 5: pKpQIL-D2 plasmid (Negative control) 
Lane 6: Water (Contamination control) 
 
Primers: pQIL-F/R 
Expected amplicon: 383 bp  
The transconjugants of Salmonella SL1344 carrying pKpQIL-UK & -D2 were verified by PCR 
for the presence of the respective plasmid backbone gene.  
152 
 
Check for the presence of blaKPC 
Primers: KPCg-colpcr-F/R 
Postive control: pKpQIL-UK plasmid 
Expected amplicon: 785 bp  
 
Check for the presence of pKpQIL-UK 
Primers: pQIL-F/R 
Postive control: pKpQIL-UK plasmid 
Expected amplicon: 383 bp  
 
Check for the presence of pKpQIL-D2  
Primers: pMan-F/R 
Postive control: pKpQIL-D2 plasmid 
Expected amplicon: 600 bp  
 
 
 
 
Figure 4.4 PCR verification of the E. coli 10418Rif transconjugants carrying 
pKpQIL-UK and -D2 
Key to lanes 
M: Hyperladder I (Bioline) 
Lane 1: 10418Rif/pKpQIL-UK transconjugant 
Lane 2: 10418Rif/pKpQIL-D2 transconjugant 
Lane 3: Positive control 
Lane 4: 10418-Rif genomic DNA (Negative control) 
Lane 5: Water (contamination control) 
 
M 1 2 3 4 5 
1000 bp 
800 bp 785 bp 
Check for KPC gene 
400 bp 
200 bp 
M 1 2 3 4 5 M 1 2 3 4 5 
Check for pKpQIL-UK Check for pKpQIL-D2 
600 bp 
383 bp 
The transconjugants of Salmonella SL1344 carrying pKpQIL-UK & -D2 were verified by PCR 
for the presence of the blaKPC and respective plasmid backbone gene.  
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Lane 15: Water (Contamination control) 
 
Primers: KPCg-colpcr-F/R 
Expected amplicon: 785 bp  
 
 
Figure 4.5 PCR verification of the Rifampicin-resistant E. cloacae and S. 
marcescens transconjugants carrying pKpQIL-UK and -D2 
Key to lanes 
M: Hyperladder IV (Bioline) 
Electrophoresis was done using 2% (w/v) agarose 
 
Lane 13: pKpQIL-UK plasmid (Positive control) 
Lane 14: EcloacaeRif/SerratiaRif genomic DNA 
(Negative control) 
Key to lanes 
M: Hyperladder IV (Bioline) 
Electrophoresis was done using 2% (w/v) 
agarose 
 
Lane 7: pKpQIL-UK plasmid (Positive control) 
Lane 8: pKpQIL-D2 plasmid (Negative control) 
Lane 9: Water (Contamination control) 
 
Primers: pQIL-F/R 
Expected amplicon: 383 bp 
Key to lanes 
M: Hyperladder IV (Bioline) 
Electrophoresis was done using 2% (w/v) 
agarose 
 
Lane 7: pKpQIL-D2 plasmid (Positive control) 
Lane 8: pKpQIL-UK plasmid (Negative control) 
Lane 9: Water (Contamination control) 
 
Primers: pMan-F/R 
Expected amplicon: 600 bp  
 
M 1 2 3 4 5 6 
800 bp 785 bp 
EcloacaeRif/ 
pKpQIL-UK 
7 8 9 10 11 12 13 14 15 
EcloacaeRif/ 
pKpQIL-D2 
SerratiaRif/ 
pKpQIL-UK 
SerratiaRif/ 
pKpQIL-D2 
(a) PCR check for the presence of blaKPC 
M 1 2 3 4 5 6 
EcloacaeRif/ 
pKpQIL-UK 
SerratiaRif/ 
pKpQIL-UK 
7 8 9 
400 bp 
(b) PCR check for the presence of pKpQIL-UK 
M 1 2 3 4 5 6 
EcloacaeRif/ 
pKpQIL-D2 
SerratiaRif/ 
pKpQIL-D2 
7 8 9 
600 bp 
(c) PCR check for the presence of pKpQIL-D2 
The transconjugants of E. cloacae and S. marcescens carrying pKpQIL-UK & -D2 were verified 
by PCR for the presence of the blaKPC gene.  
The transconjugants of E. cloacae and S. marcescens carrying pKpQIL-UK & -D2 were verified 
by PCR for the presence of the respective plasmid backbone gene.  
154 
 
Figure 4.6 Repeat PCR verification of the Rifampicin-resistant S. marcescens 
transconjugants carrying pKpQIL-UK 
The transconjugants of S. marcescens carrying pKpQIL-UK were verified by PCR for 
the presence of the plasmid backbone gene. M: Hyperladder I (Bioline); Lane 4: 
pKpQIL-UK plasmid (Positive control); Lane 5: pKpQIL-D2 plasmid (Negative 
control); Lane 10 – 12: Water (Contamination control); Primers: pQIL-F/R; Expected 
amplicon: 383 bp. 
 
M 1 2 3 4 5 6 
400 bp 383 bp 
SerratiaRif/ 
pKpQIL-UK 
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Lane 10: pKpQIL-D2 plasmid (Positive control) 
Lane 11: ST258 genomic DNA (Negative 
control) 
Lane 12: Water (Contamination control) 
 
Primers: KPCg-colpcr-F/R 
Expected amplicon: 785 bp  
Figure 4.7 PCR verification of the K. pneumoniae ST258 transconjugants 
carrying pKpQIL-UK and -D2 
Key to lanes 
M: Hyperladder I (Bioline) 
Lane 4: pKpQIL-UK plasmid (Positive control) 
Lane 5: ST258 genomic DNA (Negative control) 
Lane 6: Water (Contamination control) 
(b) PCR check for the presence of the specific plasmids 
Lane 10: pKpQIL-D2 plasmid (Positive control) 
Lane 11: pKpQIL-UK plasmid (Negative 
control) 
Lane 12: Water (Contamination control) 
 
Primers: pMan-F/R 
Expected amplicon: 600 bp  
 
Key to lanes 
M: Hyperladder I (Bioline) 
Lane 4: pKpQIL-UK plasmid (Positive control) 
Lane 5: pKpQIL-D2 plasmid (Negative control) 
Lane 6: Water (Contamination control) 
 
Primers: pQIL-F/R 
Expected amplicon: 383 bp  
M 1 2 3 4 5 6 
800 bp 
400 bp 
785 bp 
M 7 8 9 10 11 12 
ST258/pKpQIL-UK 
Transconjugants 
ST258/pKpQIL-D2 
Transconjugants 
(a) PCR check for the presence of blaKPC 
M 1 2 3 4 5 6 M 7 8 9 10 11 12 
ST258/pKpQIL-UK 
Transconjugants 
ST258/pKpQIL-D2 
Transconjugants 
600 bp 
400 bp 
600 bp 
383 bp 
The transconjugants of K. pneumoniae ST258 carrying pKpQIL-UK & -D2 were verified by 
PCR for the presence of the respective plasmid backbone gene.  
The transconjugants of K. pneumoniae ST258 carrying pKpQIL-UK & -D2 were verified by 
PCR for the presence of the blaKPC gene.  
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tested, E. cloacae and S. marcescens carrying pKpQIL-UK grew significantly more slowly 
than when carrying pKpQIL-D2. S. Typhimurium 14028s containing pKpQIL-D2 had a 
significantly slower generation time (Figure 4.8 & Table 4.2). In all other host strains, no 
difference in the generation time was observed in strains carrying pKpQIL-D2.  
4.6 Plasmid Persistence 
It was hypothesised that the substituted region in the pKpQIL-D2 allowed the plasmid to 
persist better than pKpQIL-UK in bacterial host strains, thus allowing it to persist in different 
bacterial populations. The stability of plasmid carriage among the Enterobacteriaceae species 
was also assessed by consecutive growth of the plasmid (pKpQIL-UK and -D2) carrying 
strains over a period of 20 days (ca. 140 generations) without antibiotic selection (Figure 4.9). 
For the original clinical isolates carrying the plasmids (K. pneumoniae ST468/pKpQIL-UK 
and ST321/pKpQIL-D2) (Figure 4.9a) and the K. pneumoniae ST258 transconjugants (Figure 
4.9b), both plasmids were able to persist within their hosts over 20 days without detectable 
loss. However, in both strains of Salmonella, it was found that the pKpQIL-D2 plasmid was 
rapidly lost from the population (Figure 4.9c & d). On day 5, more than half of the population 
of Salmonella has lost pKpQIL-D2 (Figure 4.9c & d). However, pKpQIL-UK was able to 
persist within the population of Salmonella over the duration of time tested (ca. 140 
generations). Interestingly, both plasmids were gradually lost from the E. coli population 
(Figure 4.9e). On the 20th day, most of the E. coli within the population were plasmid-free. 
Similar to K. pneumoniae, both plasmids were able to persist within the E. cloacae population 
(Figure 4.9f). It was not possible to assess the percentage of the S. marcescens population 
which retained or lost the plasmids as carbapenem-resistant, but plasmid-free, Serratia were 
selected during the course of the experiment.  
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Figure 4.8 Growth kinetics of various Enterobacteriaceae carrying pKpQIL-
UK vs -D2 
(a) (b) 
(c) (d) 
(e) (f) 
Growth kinetics was one of the aspects of fitness which was investigated to determine the impact of the 
plasmids on its host. All absorbance values were recorded as mean ± standard deviation of three 
independent experiments. 
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Table 4.2 Generation time of various Enterobacteriaceae carrying pKpQIL-UK vs -
D2 
 
 
Species Strain Generation Time 
(min) 
Student’s 
t-test 
K. pneumoniae ST258 
ST258 32.7 ± 4.2 - 
ST258/pKpQIL-UK 32.9 ± 4.8 0.91 
ST258/pKpQIL-D2 33.9 ± 5.0 0.44 
E. coli NCTC10418 
10418Rif 45.1 ± 7.2 - 
10418Rif/pKpQIL-UK 51.3 ± 7.4 0.05 
10418Rif/pKpQIL-D2 50.7 ± 7.3 0.07 
S. Typhimurium ATCC14028s 
14028sRif 39.3 ± 1.0 - 
14028sRif/pKpQIL-UK 41.6 ± 3.4 0.06 
14028sRif/pKpQIL-D2 44.4 ± 4.9 0.01* 
S. Typhimurium SL1344 
SL1344Rif 52.3 ± 4.9 - 
SL1344Rif/pKpQIL-UK 53.7 ± 5.4 0.57 
SL1344Rif/pKpQIL-D2 56.6 ± 3.9 0.10 
E. cloacae NCTC10005 
EcloacaeRif 40.8 ± 3.2 - 
EcloacaeRif/pKpQIL-
UK 
51.2 ± 5.0 <0.001* 
EcloacaeRif/pKpQIL-D2 38.3 ± 2.3 0.05 
S. marcescens NCTC10211 
SerratiaRif 43.1 ± 4.5 - 
SerratiaRif/pKpQIL-UK 50.8 ± 4.7 0.001* 
SerratiaRif/pKpQIL-D2 45.5 ± 4.5 0.22 
The generation time of each strain was used as a measure for the fitness impact of the 
plasmids on their hosts. Generation times were recorded as mean ± standard deviation of three 
independent experiments. Asterisk (*) denotes significant differences observed by Student’s t-
test. 
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Figure 4.9 The percentage of pKpQIL-UK vs -D2 carrying cells in growth 
over a period of 20 days without antibiotic selection 
(a) (b) 
(d) 
(e) (f) 
The persistence of the plasmids in various Enterobacteriaceae species in LB broth without antibiotic 
selection over a 20-day period was investigated to determine the stability of the plasmids in their 
respective hosts. The percentages of cells which retain the plasmids were recorded as mean ± standard 
deviation of three independent experiments.
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4.7 Pairwise Competition of K. pneumoniae Ecl8 carrying pKpQIL-UK and -D2 
It was hypothesised that the K. pneumoniae carrying pKpQIL-D2 has a competitive advantage 
against pKpQIL-UK in a bacterial population. Hence, a pairwise competition assay was 
carried out to study the percentage of bacteria carrying the plasmids within a bacterial 
population over a period of 20 days. The pKpQIL-UK plasmid has been typically associated 
with K. pneumoniae ST258 (Chen et al., 2014a, Leavitt et al., 2010a). Hence, the competition 
assay was carried out with K. pneumoniae. In order to differentiate the two plasmids pKpQIL-
UK and -D2, the blaKPC gene was replaced with the kanamycin resistance gene, aph. The 
inactivated blaKPC was verified by PCR (Figure 4.10). Although ST258 is the ideal host to use 
for the competition experiment, the ST258 strain obtained from USA was kanamycin resistant. 
The strain was also resistant to chloramphenicol which the resistant marker is commonly used 
for gene inactivation. Hence, K. pneumoniae Ecl8 was used. The four plasmids (pKpQIL-UK, 
pKpQIL-UK blaKPC::aph, pKpQIL-D2 and pKpQIL-D2 blaKPC::aph) were transferred into K. 
pneumoniae Ecl8Rif by filter conjugation. The transconjugants were verified by PCR (Figure 
4.11).  
 In order to exclude the possibility of the kanamycin resistance gene (aph) affecting the 
outcome of the competition experiment, two experiments were carried out, i.e. pKpQIL-UK 
vs -D2 blaKPC::aph and pKpQIL-UK blaKPC::aph vs -D2. It was observed that pKpQIL-D2 
out-competed pKpQIL-UK over the 20-day period (Figure 4.12a & b). For the pKpQIL-UK 
blaKPC::aph vs -D2 competition, pKpQIL-UK was almost completely loss from the population 
at the 20th day of the experiment. However, the trend in the loss of the pKpQIL-UK vs -D2 
blaKPC::aph competition was different as the population of K. pneumoniae carrying pKpQIL-
UK dropped to ca. 15% on Day-5 and maintained throughout the duration of the experiment. 
Hence, the percentage of the population carrying the plasmids (pKpQIL-UK vs -D2 
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Figure 4.10 PCR verification of the E. coli DH10B transformants for the 
presence of blaKPC inactivated pKpQIL-UK and -D2  
The plasmids pKpQIL-UK which the blaKPC gene had been inactivated was 
electroporated into E. coli DH10B. M: Hyperladder I (Bioline); Lane 5: pKpQIL-UK 
plasmid (Positive control); Lane 6: DH10B genomic DNA (Negative control); Lane 7: 
Water (Contamination control); Primers: KPCg-colpcrF/R; Expected amplicon: 785 bp 
(WT); 1844 bp (+aph). 
M 1 2 3 4 5 6 
2000 bp 
1500 bp 
785 bp 
DH10B/pKpQIL-UK  blaKPC::aph 
Transformants 
7 
(a) PCR check for the presence of blaKPC 
(b) PCR check for the presence of pKpQIL-D2 
The plasmids pKpQIL-D2 which the blaKPC gene had been inactivated was 
electroporated into E. coli DH10B. M: Hyperladder I (Bioline); Lane 5: pKpQIL-D2 
plasmid (Positive control); Lane 6: DH10B genomic DNA (Negative control); Lane 7: 
Water (Contamination control); Primers: KPCg-colpcrF/R; Expected amplicon: 785 bp 
(WT); 1844 bp (+aph).  
 
800 bp 
2000 bp 
1500 bp 
800 bp 
M 1 2 3 4 5 6 
785 bp 
DH10B/pKpQIL-D2 blaKPC::aph 
Transformants 
7 
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Figure 4.11 PCR verification of the K. pneumoniae Ecl8 transconjugants for the 
presence of blaKPC inactivated pKpQIL-UK and -D2  
The rifampicin-resistant K. pneumoniae Ecl8 transconjugants carrying the wildtype and blaKPC-
inactivated pKpQIL-UK & -D2 plasmids were verified by PCR for the presence of the 
inactivated blaKPC and respective plasmid backbone genes. 
 
Key to lanes 
M: Hyperladder I (Bioline) 
 
Lane 1: K. pneumoniae Ecl8Rif 
Lane 2: Ecl8Rif/pKpQIL-UK 
Lane 3: Ecl8Rif/pKpQIL-UK blaKPC::aph 
Lane 4: Ecl8Rif/pKpQIL-D2 
Lane 5: Ecl8Rif/pKpQIL-D2 blaKPC::aph 
Lane 6: Water (Contamination control) 
 
Check for wildtype and inactivated blaKPC 
Primers: KPCg-colpcrF/R 
Expected amplicon: 785 bp (WT); 1844 bp (+aph) 
 
Check for the presence of pKpQIL-UK 
Primers: pQIL-F/R 
Expected amplicon: 300 bp  
 
Check for the presence of pKpQIL-D2 
Primers: pMan-F/R 
Expected amplicon: 600 bp  
 
M 1 2 3 4 5 6 
2500 bp 
400 bp 
785 bp 
Check for wildtype and 
inactivated blaKPC 
800 bp 600 bp 
300 bp 
1844 bp 
1 2 3 4 5 6 
Check for the presence of 
pKpQIL-UK 
1 2 3 4 5 6 
Check for the presence of 
pKpQIL-D2 
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Figure 4.12 Pairwise competition of pKpQIL-UK vs -D2  
Pairwise competition was done to study the competition of rifampicin-resistant K. pneumoniae 
Ecl8 carrying (a) pKpQIL-UK vs pKpQIL-D2 marked with an aph gene, and (b) pKpQIL-UK 
marked with an aph gene vs pKpQIL-D2. This was done to assess whether the plasmids 
conferred a competitive advantage to their hosts relative to the other. Percentage of plasmid 
carrying bacteria was recorded as mean ± standard deviation of three independent 
experiments. Competition index at the end of the experiment (a) was 0.62, (b) was 0.96. The 
positive values of the competition index indicated pKpQIL-D2 was fitter than pKpQIL-UK in 
the experiment. (c) The graph shows that pKpQIL-UK was rapidly displaced from the 
population by pKpQIL-D2 marked with an aph gene within the first five days of the 
competition. (d) Both plasmids were found to be stable within their host in LB broth without 
antibiotic selection over a period of 20 days. 
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blaKPC::aph) was determined from the first to the fourth day of the experiment to determine 
whether the initial input inoculum was equal. It was observed that for the pKpQIL-UK vs -D2 
blaKPC::aph competition, there was a rapid loss of pKpQIL-UK from Day 1 (Figure 4.12c) and 
the percentage of pKpQIL-UK in the population maintained at ca. 15% after Day 4. To assess 
whether pKpQIL-UK was stable in the K. pneumoniae Ecl8 strain, plasmid persistence assay 
without antibiotic selection was carried out for the Ecl8 strains carrying the plasmids. Unlike 
E. coli and Salmonella, both plasmids were able to persist without detectable loss in K. 
pneumoniae Ecl8 over a period of 20 days without antibiotic selection (Figure 4.12d). 
 It was hypothesised that the pKpQIL-UK plasmid had a slower generation time than 
its variant plasmid. Hence the generation time for the K. pneumoniae Ecl8 carrying the 
plasmids were determined (Figure 4.13, Table 4.3). There was no difference in generation 
times of K. pneumoniae Ecl8 carrying the various plasmids. The kanamycin resistance gene 
(aph) also had no detectable impact upon the growth rate of the plasmids.  
4.8 Conjugation Frequencies of the Plasmids into Various Enterobacteriaceae  
In addition to K. pneumoniae, the plasmid pKpQIL-D2 was also found in E. cloacae and E. 
coli in the UK outbreaks, whereas pKpQIL-UK was generally found in K. pneumoniae 
(Woodford, N. Unpublished data). Hence, it was hypothesised that pKpQIL-D2 possessed a 
higher transfer rate from its K. pneumoniae ST321 host compared to the K. pneumoniae 
ST468 carrying pKpQIL-UK. The transfer potential of the plasmids from their original 
clinical isolate host strains into four Enterobacteriaceae species was assessed using filter 
conjugation. pKpQIL-UK showed an 18-fold and 30-fold higher conjugation frequency into K. 
pneumoniae ST258 and E. coli, respectively (Figure 4.14a & b, Table 4.4). Both plasmids 
transferred at similar rates into S. Typhimurium (14028s and SL1344) (Figure 4.14c & d) and  
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Figure 4.13 Growth rates of rifampicin-resistant K. pneumoniae Ecl8 carrying 
pKpQIL-UK & -D2 in the presence & absence of blaKPC 
Growth kinetics for the various plasmid-carrying strains were determined to study the fitness 
impact of the plasmids and its blaKPC genes on their hosts. Generation times were recorded as 
mean ± standard deviation of three independent experiments. No difference in growth was 
observed between the K. pneumoniae Ecl8 carrying the wildtype plasmids and its corresponding 
blaKPC-inactivated plasmids.  
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Table 4.3 Generation times of rifampicin-resistant K. pneumoniae Ecl8 carrying 
pKpQIL-UK & -D2 in the presence & absence of blaKPC 
 
Strain Generation Time (min) Student’s t-test 
K. pneumoniae Ecl8Rif 33.2 ± 3.6 - 
Ecl8Rif/pKpQIL-UK 31.8 ± 5.7 0.54 
Ecl8Rif/pKpQIL-UK blaKPC::aph 33.2 ± 3.1 0.99 
Ecl8Rif/pKpQIL-D2 33.9 ± 5.6 0.76 
Ecl8Rif/pKpQIL-D2 blaKPC::aph 33.5 ± 3.2 0.84 
 
The generation time of each strain was used as a measure for the fitness impact of the 
plasmids in their hosts. Generation times were recorded as mean ± standard deviation of three 
independent experiments. Compared to the K. pneumoniae Ecl8Rif, no difference was 
observed in the generation time of the various plasmid carrying strains. 
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(a) (b) 
(c) (d) 
(e) 
Figure 4.14 Conjugation frequencies of pKpQIL-UK and -D2 from their 
respective clinical isolates into Enterobacteriaceae species 
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Conjugation frequencies were determined by filter mating to assess the differences in the transfer 
of the plasmids from their respective clinical isolates into different Enterobacteriaceae species. 
The values were recorded as mean ± standard deviation of three independent experiments. 
Significant difference (p<0.05) was determined by Student’s t-test. The values were recorded in 
Table 4.4. 
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Table 4.4 Conjugation frequencies of pKpQIL-UK and -D2 into various 
Enterobacteriaceae  
 
 
Strain 
Conjugation Frequency (per donor cell) Fold 
DifferencepKpQIL-UK pKpQIL-D2 
K. pneumoniae ST258 3.3 x 10-4 1.8 x 10-5 0.05* 
E. coli NCTC10418 1.4 x 10-5 4.5 x 10-7 0.03* 
S. Typhimurium ATCC14028s 1.7 x 10-5  2.7 x 10-5 1.6 
S. Typhimurium SL1344 3.9 x 10-4 3.1 x 10-4 0.8 
E. cloacae NCTC10005 6.0 x 10-4 6.4 x 10-3 11* 
S. marcescens NCTC10211 1.9 x 10-5 1.4 x 10-4 7 
Filter mating was used to determine whether the substituted region in pKpQIL-D2 conferred 
the plasmid with higher conjugation frequency from its original host into the various species. 
Asterisk (*) denotes significant difference (p<0.05) by Student’s t-test. Apart from K. 
pneumoniae ST258 which was kanamycin-resistant, all strains used were rifampicin-resistant. 
Fold difference was calculated as the ratio of conjugation frequency of pKpQIL-D2 relative to 
-UK. 
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S. marcescens (Figure 4.14f). In E. cloacae, pKpQIL-D2 transferred at 11 times higher rate 
from its original host (K. pneumoniae ST321) than did pKpQIL-UK (Figure 4.14e).  
4.9 Biofilm Formation 
4.9.1 Biofilm Formation on Plastic 
The fitness of the plasmid carrying strains was also assessed by measuring the ability of the 
strains to form a biofilm in comparison to the plasmid-free parental strain. No difference in 
biofilm formation was observed between K. pneumoniae ST258 carrying either plasmid 
(Figure 4.15a). Both plasmids increased biofilm formation in E. coli NCTC10418 (p<0.001) 
(Figure 4.15b). In S. Typhimurium ATCC14028s, the carriage of pKpQIL-D2 was associated 
with significantly (p<0.001) lower biofilm formation (Figure 4.15c). However, pKpQIL-UK 
significantly increase the biofilm formation in S. Typhimurium SL1344 (Figure 4.15d) but the 
variant plasmid had no detectable impact on biofilm formation. In E. cloacae, the variant 
plasmid was found to increase the biofilm formation significantly (p<0.05) (Figure 4.15e). 
However, in S. marcescens the opposite was observed: pKpQIL-UK reduced biofilm 
production whereas pKpQIL-D2 increased production significantly (Figure 4.15f).  
4.9.2 Biofilm Formation under Constant Flow of Medium 
The formation of a biofilm was also monitored under constant flow of LB broth (without salt) 
at various time points over a period of 48 hours using the BioFluxTM microfluidic channel 
system. LB broth without salt was used as it has been reported that biofilm formation is 
inhibited in the presence of salt (Zalewska-Piątek et al., 2013). S. Typhimurium SL1344 
carrying the plasmids was omitted from this study as SL1344 is weak at forming biofilm 
(García et al., 2004). Compared to the parental strain and K. pneumoniae ST258 carrying 
pKpQIL-D2, the carriage of pKpQIL-UK increased biofilm formation after 48 hours in this 
system (Figure 4.16a). The E. coli, E. cloacae and S. marcescens strains formed biofilm  
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(c) (d) 
Figure 4.15 Biofilm formation on plastic for the various plasmid carrying 
Enterobacteriaceae strain 
The impact of the plasmids on its hosts’ ability to form biofilm was investigated using the microtitre tray 
and crystal violet dye method. Percentage fold change was recorded as mean ± standard deviation of three 
independent experiments. Student’s t-test was used to analyse significant changes and shown with asterisk 
(*) p<0.05 and (**) p<0.001. Y-axis was not drawn to similar scale due to the large differences in fold 
change between species. 
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Figure 4.16 Images of biofilm formation in microfluidic channel at various time 
points 
Images were taken at a magnification of 400X. 
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Figure 4.16 Images of biofilm formation in microfluidic channel at various time 
points (Continued) 
Images were taken at a magnification of 400X. 
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Figure 4.16 Images of biofilm formation in microfluidic channel at various time 
points (Continued) 
Images were taken at a magnification of 400X. 
 
The ability of the plasmid-carrying hosts to form biofilm was determined under constant 
flow of LB broth (without salt) using the BioFlux microfluidic system. Images of the 
biofilm formed were captured at both ends and the middle of the channel. Representative 
images are shown in this figure. 
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equally well in the microfluidic channel after 48 hours (Figure 4.16b, d & e). Both E. coli and 
E. cloacae (with and without plasmids) started forming microcolonies as early as the 12 hours 
after the attachment of the cells in the microfluidic channel (Figure 4.16b and d). Relative to 
E. cloacae with and without pKpQIL-D2, carriage of pKpQIL-UK conferred the production 
of a denser biofilm, filling the entire flow channel after 48 hours (4.16d). However, S. 
marcescens carrying pKpQIL-UK formed biofilm slower than the plasmid-free parental strain 
or when carrying pKpQIL-D2 after 24 hours (Figure 4.16e). 
 The area in the microfluidic channel which was covered by the plasmid carrying 
strains relative to the parental strain with no plasmid was also determined (Figure 4.17). The 
plasmids had different impact on the biofilm forming ability of the K. pneumoniae ST258 in 
the BioFlux system (Figure 4.17a). Plasmid pKpQIL-UK was associated with a higher area of 
coverage relative to the plasmid-free strain while K. pneumoniae with pKpQIL-D2 had lower 
coverage. Relative to plasmid-free strain, no significant difference was observed for the E. 
coli and E. cloacae carrying both pKpQIL-UK and -D2 (Figure 4.17b and d). S. Typhimurium 
ATCC14028s carrying the pKpQIL-UK plasmid had significantly lower coverage compared 
to the plasmid-free strain and the pKpQIL-D2 counterpart (Figure 4.17c). In S. marcescens, 
both plasmid carrying strains showed significantly higher coverage compared to the plasmid-
free strain (Figure 4.17e).  
4.10 Infection of Galleria mellonella by Plasmid Carrying K. pneumoniae ST258  
Another aspect of fitness that was investigated in this PhD was the virulence of the plasmid-
carrying hosts in an infection model. It was hypothesised that the substituted region in 
pKpQIL-D2 conferred a difference in virulence of the plasmid carrying K. pneumoniae 
compared to the pKpQIL-UK carrying strain in the G. mellonella model. K. pneumoniae 
ST258 was used as the host of the plasmids in the virulence experiment as the plasmids were 
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The coverage of biofilm formed on the surface of the microfluidic channel was estimated using ImageJ 
software. The percentage coverage relative to the parental strain was recorded as mean ± standard 
deviation of three independent experiments. Student’s t-test was used to analyse significant changes which 
are shown with asterisk (*) p<0.05 and (**) p<0.001. 
(a) (b) 
(c) (d) 
(e) 
Figure 4.17 Percentage area of coverage by biofilm in microfluidic channel after 
48 hours under constant flow of LB broth (without salt) 
Pe
rc
en
ta
ge
 C
ov
er
ag
e 
(%
)
Pe
rc
en
ta
ge
 C
ov
er
ag
e 
(%
)
104
18
Rif
104
18
Rif /pK
pQI
L-U
K
104
18
Rif /pK
pQI
L-D
2
S. Typhimurium ATCC14028s
Pe
rc
en
ta
ge
 C
ov
er
ag
e 
(%
)
140
28s
Rif
140
28s
Rif /pK
pQI
L-U
K
140
28s
Rif /pK
pQI
L-D
2
0
50
100
150
*
Pe
rc
en
ta
ge
 C
ov
er
ag
e 
(%
)
S. marcescens
Ser
rati
aR
if
Ser
rati
aR
if /pK
pQI
L-U
K 
Ser
rati
aR
if /pK
pQI
L-D
2 
0
50
100
150
**
*
176 
 
originally found in this species. No difference was observed between the two populations of 
G. mellonella infected by either of the plasmid carrying K. pneumoniae ST258 (Figure 4.18). 
4.11 Minimum Inhibitory Concentration of Antibiotics for Various Plasmid-bearing 
Hosts 
It was hypothesised that the pKpQIL-D2 conferred higher antibiotic resistance in its hosts 
than pKpQIL-UK and this allow it to persist in other Enterobacteriaceae and frequently occur 
in the hospital outbreaks in the UK. Hence, susceptibility of the strains to various β-lactam 
antibiotics, ciprofloxacin and tigecycline was determined. Generally, there was no difference 
in the MIC values of the different species of Enterobacteriaceae carrying the plasmids (Table 
4.5). However, S. marcescens carrying pKpQIL-UK was more resistant to carbapenem 
antibiotics than pKpQIL-D2. Interestingly, there was no difference in the susceptibility of 
these two strains for the cephalosporins tested. The reverse was observed for K. pneumoniae 
Ecl8 carrying pKpQIL-UK, which was more resistant to cephalosporins than pKpQIL-D2 but 
not to carbapenem antibiotics. 
 Based upon this susceptibility data, it was hypothesised that the differences observed 
in S. marcescens and K. pneumoniae Ecl8 were due to differences in porin expression. 
However, no difference was observed in the porin profile of the parental strain and the 
plasmid-bearing strains (Figure 4.19, Table 4.6). 
It was hypothesised that the K. pneumoniae ST258 carrying pKpQIL-D2 would grow 
better than pKpQIL-UK in the presence of a carbapenem. To test this, the strains were grown 
in LB medium supplemented with 16 µg/ml doripenem (Figure 4.20a). The strains were also 
challenged with 16 µg/ml doripenem after they have reached OD600~0.6 (Figure 4.20b). In 
both cases, there was no difference in the growth between the two plasmid carrying strains. 
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Percentage of G. mellonella which survived after infection was recorded as mean ± 
standard deviation of three independent experiments at a 24-hour interval for five days. 
Each experiment consisted of a group of 10 Galleria larvae. Log-rank (Mantel-Cox) 
test was used to analyse the differences in survival of the two populations infected 
with plasmid carrying K. pneumoniae ST258 compared to the wildtype host. No 
difference was observed (p = 0.79) among the populations. 
Figure 4.18 Virulence assay of Galleria mellonella infected by pKpQIL-UK and -
D2 carrying K. pneumoniae ST258 
Survival of Galleria mellonella infected
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Table 4.5 Minimum inhibitory concentration of pKpQIL-UK and -D2 carrying hosts 
 
Strains ETP IMI MER DOR BIA FAR CAZ CTX CFX PIP CIP ATM TIG 
K. pneumoniae ST258 
ST258 0.12 0.12 0.03 0.03 0.12 2 256 16 64 512 >16 512 0.5 
ST258/UK 32 16 16 8 16 256 512 32 1024 1024 >16 1024 1 
ST258/D2 32 8 8 4 8 256 256 32 1024 1024 >16 1024 0.5 
K. pneumoniae Ecl8 
Ecl8 0.015 0.12 0.015 0.03 0.03 0.12 0.03 0.008 0.12 0.5 0.008 0.008 0.12 
Ecl8Rif 0.008 0.12 0.015 0.03 0.03 0.12 0.03 0.008 0.12 1 0.008 0.008 0.12 
Ecl8Rif/UK 4 2 2 2 4 64 16 4 256 256 0.03 64 0.12 
Ecl8Rif/D2 2 4 1 2 4 32 0.25 0.5 64 256 0.008 0.5 0.12 
E.coli NCTC10418 
10418 0.015 0.12 0.015 0.03 0.03 1 0.12 0.03 2 2 0.008 0.03 0.12 
10418Rif 0.015 0.25 0.03 0.06 0.06 1 0.12 0.03 2 2 0.015 0.03 0.12 
10418Rif/UK 0.5 4 0.5 1 2 64 1 1 128 128 0.015 8 0.12 
10418Rif/D2 0.5 4 0.5 1 2 64 1 1 64 128 0.015 8 0.12 
E. coli DH10B 
DH10B 0.008 0.12 0.015 0.03 0.03 1 0.25 0.03 4 2 0.002 0.06 0.12 
DH10B/UK 0.25 1 0.12 0.5 0.5 64 4 1 128 64 0.002 16 0.12 
DH10B/D2 0.25 1 0.12 0.5 0.5 64 4 1 128 64 0.002 16 0.12 
Continued overleaf. 
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Table 4.5 (Continued) Minimum inhibitory concentration of pKpQIL-UK and -D2 carrying hosts  
 
Strains ETP IMI MER DOR BIA FAR CAZ CTX CFX PIP CIP ATM TIG 
S. Typhimurium SL1344 
SL1344 0.015 0.12 0.015 0.03 0.06 0.5 0.25 0.12 8 4 0.015 0.06 0.25 
SL1344Rif 0.008 0.12 0.015 0.03 0.03 0.25 0.25 0.25 16 4 0.03 0.03 0.25 
SL1344Rif/UK 1 2 0.5 1 4 64 16 16 512 256 0.03 16 0.25 
SL1344Rif/D2 0.5 2 0.25 0.5 2 32 16 16 512 256 0.03 16 0.25 
S. Typhimurium ATCC14028s 
14028s 0.015 0.12 0.015 0.03 0.06 0.5 0.25 0.12 4 2 0.015 0.06 0.25 
14028sRif 0.008 0.12 0.015 0.03 0.03 0.25 0.25 0.12 8 2 0.015 0.03 0.25 
14028sRif/UK 2 2 0.5 1 2 64 8 8 512 256 0.015 16 0.25 
14028sRif/D2 1 2 0.5 1 2 64 8 8 512 256 0.015 16 0.25 
E. cloacae NCTC10211 
Ecloacae 0.5 0.5 0.06 0.12 0.12 4 1 2 256 2 0.008 1 0.12 
EcloacaeRif 0.5 0.25 0.06 0.06 0.06 4 1 1 128 2 0.008 0.12 0.12 
EcloacaeRif/UK 16 2 2 2 2 256 16 8 512 256 0.008 32 0.12 
EcloacaeRif/D2 16 4 4 4 4 256 16 16 1024 512 0.008 64 0.06 
S. marcescens NCTC10005 
Serratia 0.03 0.5 0.03 0.12 0.25 8 0.12 0.25 64 2 0.06 0.12 1 
SerratiaRif 0.015 0.5 0.06 0.12 0.5 8 0.25 0.12 32 2 0.06 0.06 1 
SerratiaRif/UK 32 16 32 64 64 512 16 32 1024 256 0.06 64 1 
SerratiaRif/D2 8 4 4 4 8 512 16 32 1024 128 0.06 64 1 
‘UK’ denotes pKpQIL-UK while ‘D2’ denotes variant plasmid pKpQIL-D2. Bolded fonts denote significant increase in MIC values. ETP: 
Ertapenem; IMI: Imipenem; MER: Meropenem; DOR: Doripenem; BIA: Biapenem; FAR: Faropenem; CAZ: Ceftazidime; CTX: Cefotaxime; 
CFX: Cefuroxime; PIP: Piperacillin; CIP: Ciprofloxacin; ATM: Aztreonam; TIG: Tigecycline. 
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Figure 4.19 Outer membrane profile of S. marcescens and K. pneumoniae Ecl8 
carrying pKpQIL-UK and -D2 
In order to determine whether the down-regulation of porins altered the MIC values of 
the antibiotics of the pKpQIL-UK carrying strains compared to the -D2 carrying strain. 
The outer membrane proteins were prepared and separated on a 10% SDS-PAGE gel. 
The relative abundance of the five outer membrane protein highlighted with the yellow 
boxes was analysed by densitometry (Table 4.6). 
 
L: PageRuler Plus Prestained Protein Ladder (Thermo Scientific) 
 
Lane 1: S. marcescens NCTC10005 
Lane 2: SerratiaRif/pKpQIL-UK 
Lane 3: SerratiaRif/pKpQIL-D2 
 
Lane 4: K. pneumoniae Ecl8Rif 
Lane 5: Ecl8Rif/pKpQIL-UK 
Lane 6: Ecl8Rif/pKpQIL-D2 
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Table 4.6 Relative abundance of the major outer membrane proteins in the plasmid-
carrying strains of S. marcescens and K. pneumoniae 
 
 
Bands 
(from 
top to 
bottom) 
Lane 1 Lane 2 Lane 3 Lane 4 Lane 5 Lane 6 
SerratiaRif SerratiaRif/UK SerratiaRif/D2 Ecl8Rif Ecl8Rif/UK Ecl8Rif/D2 
1 0.11 0.08 0.10 0.61 0.57 0.58 
2 0.54 0.60 0.50 0.15 0.19 0.19 
3 0.05 0.06 0.06 0.15 0.17 0.16 
4 0.14 0.14 0.20 0.02 0.02 0.02 
5 0.16 0.12 0.14 0.06 0.05 0.05 
Total 1.00 1.00 1.00 1.00 1.00 1.00 
‘UK’ denotes pKpQIL-UK, ‘D2’ denotes pKpQIL-D2 
 
Relative abundance of the major protein bands highlighted in the yellow box was determined 
by densitometry.  
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Figure 4.20 Growth kinetics of K. pneumoniae ST258/pKpQIL-UK vs -D2 in the 
presence of doripenem 
In order to determine whether the presence of pKpQIL-UK or -D2 affected the growth of 
its host in the presence of antibiotic, the growth kinetics of the strains were determined 
when the (a) LB broth was supplemented with 16 µg/ml doripenem and (b) 16 µg/ml 
doripenem was injected into the LB broth after the strains had achieved mid-logarithmic 
phase. Absorbance readings were recorded as mean ± standard deviation of three 
independent experiments. 
(a) 
(b) 
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4.12 Summary of Phenotypes Conferred by Carriage of pKpQIL-UK vs -D2 
The spread and persistence of pKpQIL-D2 in different species of Enterobacteriaceae in the 
UK was hypothesised to be associated to the fitness advantage conferred by the plasmid. 
However, compared to the pKpQIL-UK, no obvious fitness advantage was observed in the 
pKpQIL-D2 carrying bacterial hosts in the various experiments (Table 4.7). In general, 
depending on the fitness assay used, both plasmids affected their hosts in different ways. 
4.13 Gene Expression Profiling of Plasmid Carrying K. pneumoniae ST258 with RNA 
Sequencing 
4.13.1 Determination of Growth Phase for RNA Extraction 
Compared to the K. pneumoniae host carrying pKpQIL-UK, it was hypothesised that genes 
expressed in the pKpQIL-D2 substituted region conferred biological difference in its host as 
summarised in Table 4.7. In order to identify the genetic determinants conferring the 
differences, RNA sequencing was used to investigate the gene expression of the K. 
pneumoniae ST258 host in the presence of the pKpQIL-UK and -D2 plasmids. In order to 
ensure that the results from the study were reproducible, the K. pneumoniae ST258 and its 
isogenic strains carrying the plasmids (pKpQIL-UK and -D2) were grown in defined MOPS 
minimal medium for RNA preparation. The growth kinetics of the strains showed that the 
early, mid and late logarithmic phase were at an OD600 of 0.2, 0.4 and 0.6, respectively 
(Figure 4.21a, Table 4.8). Using ST258/pKpQIL-UK as a representative, the total RNA was 
prepared from the three growth phases to assess the expression level of the blaKPC gene by 
qRT-PCR. Across the logarithmic phase, it was found that the carbapenemase gene was 
highly expressed at the early phase (OD600 = 0.2) compared to the other phases (Figure 4.21b). 
 
 
Table 4.7 Summary of the fitness experiments for the various plasmid carrying Enterobacteriaceae 
 
Species Code Plasmid Growth Persistence Biofilm (Plastic) 
Biofilm 
(Flow) Transfer
ϯϯ MIC 
K. pneumoniae ST258 ST258 
pKpQIL-UK = = = ↑ = 
pKpQIL-D2 = = = ↓ ↓ = 
E. coli NCTC10418 10418Rif 
pKpQIL-UK = ↓ ↑ = = 
pKpQIL-D2 = ↓ ↑↑ = ↓ = 
S. Typhimurium ATCC14028s 14028sRif 
pKpQIL-UK = = = ↓ = 
pKpQIL-D2 ↓ ↓ ↓ = = = 
S. Typhimurium SL1344 SL1344Rif 
pKpQIL-UK = = ↑ ND = 
pKpQIL-D2 = ↓ = ND = = 
E. cloacae NCTC10005 EcloacaeRif 
pKpQIL-UK ↓ = = = = 
pKpQIL-D2 = = ↑ = ↑ = 
S. marcescens NCTC10211 SerratiaRif 
pKpQIL-UK ↓ ND ↓ ↑ ↑ * 
pKpQIL-D2 = ND ↑ ↑ = = * 
‘=’, no difference; ‘↓’, significantly lower; ‘↑’, significantly higher; ND, not determined 
 ‘ϯϯ’, conjugation frequency was recorded as a comparison of pKpQIL-D2 relative to -UK plasmid 
‘*’, S. marcescens carrying pKpQIL-UK was more resistant to carbapenem than -D2, no difference was observed for other β-lactam 
antibiotics tested 
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Figure 4.21 Growth kinetics of K. pneumoniae ST258 and plasmid carrying 
isogenic strains in MOPS minimal medium, and blaKPC expression 
(a) Growth kinetics of K. pneumoniae ST258 and plasmid carrying ST258 
(a) The growth kinetics of the plasmid-carrying strains of K. pneumoniae ST258 were 
determined to estimate the approximate early-, mid- and late-logarithmic phase of the 
strains in MOPS minimal medium. Compared to the ST258, no difference in generation 
time was observed for the plasmid carrying strains. (b) The blaKPC expression was 
determined for the various growth phases in MOPS minimal medium and results were 
recorded as fold change relative to the early growth phase (OD600 = 0.2). All values were 
recorded as mean ± standard deviation of three independent experiments. Student’s t-test 
was used to analyse the data for significant changes which is shown with an asterisk (*) 
p<0.05. 
 
(b)  
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Table 4.8 Generation times of plasmid carrying K. pneumoniae ST258 in 
MOPS minimal medium 
 
Strain Generation Time (min) Student’s t-test 
ST258 41.4 ± 3.3 - 
ST258/pKpQIL-UK 43.2 ± 4.4 0.26 
ST258/pKpQIL-D2 44.1 ± 3.8 0.08 
Generation time and growth kinetics were determined for the plasmid carrying K. 
pneumoniae ST258 to determine the early-, mid- and -late logarithmic phase of the 
growth in MOPS minimal media. Generation time was recorded as mean ± standard 
deviation of three independent experiments. Student’s t-test was used to analyse the data 
for significant changes. 
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4.13.2 Optimisation of Total RNA Extraction 
From the qRT-PCR data, it was found that the carbapenemase gene was highly expressed in 
the early stage of the logarithmic phase. Hence, the RNA from the early logarithmic phase 
was used to study the difference in the transcriptome of the K. pneumoniae ST258, 
ST258/pKpQIL-UK and ST258/pKpQIL-D2. Initially, the RNA preparation was carried using 
the SV Total RNA Isolation System (Promega, Wisconsin, USA, Catalogue No.: Z3105). 
This kit was used as it is frequently used to prepare RNA from S. Typhimurium in the 
Piddock Group. However, white precipitate (possibly debris from the Klebsiella capsule) was 
observed repeatedly at the final step where the RNA was eluted from the spin column. This 
white precipitate was also observed in the total RNA extracted for assessing the blaKPC 
expression in the different growth stages. As RNA sequencing involves many preparation 
steps and the sequencing reaction is sensitive to contaminants, the RNA preparation 
conditions were optimised before proceeding to the sequencing stage. The RNA extraction kit 
used was changed to TRIzol® Plus RNA Purification Kit (Life Technologies, California, USA, 
Catalogue No.: 12183-555). Using the ‘Total RNA Isolation’ protocol in the manufacturer’s 
manual, this kit yielded no detectable RNA when quantified by Qubit® RNA HS Assay Kit. 
Hence, the ‘Total Trancriptome Isolation’ method (designed to include small RNA during 
RNA extraction) in the manufacturer’s manual was used and yielded about 5 – 7 µg RNA. 
The eluted RNA was not contaminated with the previously observed white precipitate.  
When separated by electrophoresis, the 16S and 23S rRNA could be observed (Figure 
4.22a). Although the total amount of RNA extracted was high (5 – 7 µg), but the ribosomal 
RNA (16S and 23S) bands were relatively faint and possibly suggested a low amount of 
messenger RNA (mRNA) was present. The RNA samples were analysed using Agilent 2100 
Bioanalyzer. However, the RNA samples consisted of mostly of small RNA species (Figure 
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Figure 4.22 Purification of RNA from K. pneumoniae ST258 in the presence 
and absence of pKpQIL-UK and -D2  
(a) The total RNA samples extracted from the various plasmid-carrying K. pneumoniae 
ST258 strains using different commercial kits were compared in a 1% agarose gel by 
observing the intensity of the 16 and 23S rRNA bands. A representative image of Agilent 
2100 Bioanalyzer (b) electropherogram trace and (c) gel photo, for the RNA samples 
extracted using TRIzol® Plus Kit and Quick-RNATM Kit. The RNA samples consisted of 
mostly small RNA species as the 16 and 23S RNA peaks were very small on the 
electropherogram. 
 
M: Hyperladder I (Bioline) 
Lane 1 – 2: ST258 
Lane 3 – 4: ST258/pKpQIL-UK  
Lane 5 – 6: ST258/pKpQIL-D2 
Lane 7 – 8: ST258 (Quick-RNATM, Zymo Research Kit) 
M 1 2 3 4 5 6 
1500 bp 
1000 bp 
23S rRNA 
TRIzol® Plus 
7 8 
Zymo Research 
16S rRNA 
Small RNA 
(a) Purified total RNA separated on agarose gel 
(b)  Lower 
Marker 
Small 
RNA 
Ribosomal 
RNA 
(c)  
Lower 
Marker 
Small 
RNA 
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4.22b & c). A different kit (Quick-RNATM, Zymo Research, California, USA) was also used 
to prepare total RNA from ST258. A similar pattern of total RNA composition was observed 
in the electrophoresis gel (Lane 7 – 8, Figure 4.22a). The composition of RNA obtained from 
the two different kits suggested that it was not an artefact of the RNA extraction kit but the 
amount of mRNA at the early logarithmic phase was very low. Hence, a greater volume of 
culture was use for RNA extraction with the previous ‘Total RNA Isolation’ protocol in the 
manufacturer’s guide. This protocol was chosen instead of the ‘Total Transcriptome Isolation’ 
because the latter omits one of the washing buffers which was needed for on-column DNAse-
treatment. The removal of the on-column DNAse-treatment step would result in highly DNA 
contaminated RNA samples. 
Using an increasing volume of culture (30, 90, 120 and 150 ml) for RNA extraction, it 
was observed that there was an increase in the intensity of the ribosomal RNA and the smear 
of mRNA along the electrophoresis lanes (Figure 4.23a). Although the higher volume of 
culture used for RNA extraction indicated the possibility of increased mRNA transcripts in 
the samples, the Bioanalyzer analysis showed that the RNA samples still comprised of mostly 
small RNA species (Figure 4.23b and c). Moreover, the white precipitate was again observed 
using the larger culture volume. Hence, extraction of RNA using another method (i.e. glass 
beads) was attempted with the RiboPureTM RNA Purification Kit. The extraction was also 
carried out using a culture from the late logarithmic phase (OD600 = 0.6) to overcome the 
lower mRNA transcript production at the early growth phase. This kit produced a sufficient 
amount of total RNA (including mRNA) (ca. 15 – 20 µg) for sequencing. From the 
Bioanalyzer analyses, the 16S and 23S rRNA peaks were discreet suggesting a good quality 
of total RNA without obvious degradation (Figure 4.24a and b). The smear on the background 
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Figure 4.23 Purification of RNA from increasing volume of K. pneumoniae 
ST258 culture  
M: Hyperladder I (Bioline) 
Lane 1: ST258 (Total Transcriptome Isolation as positive control) 
Lane 2: ST258 (30 ml) 
Lane 3: ST258 (90 ml) 
Lane 4: ST258 (120 ml) 
Lane 5: ST258 (150 ml) 
M 1 2 3 4 5 
1500 bp 
1000 bp 
23S rRNA 
Total RNA 
Isolation
16S rRNA 
Small RNA 
(a) Purified total RNA separated on agarose gel 
Total Transcriptome 
Isolation 
Total RNA 
Isolation 
(a) The total RNA samples extracted from the various plasmid-carrying K. pneumoniae 
ST258 strains using different culture volumes were compared in a 1% agarose gel by 
observing the intensity of the 16 and 23S rRNA bands. A representative image of Agilent 
2100 Bioanalyzer (b) electropherogram trace and (c) gel photo, for the RNA samples 
extracted from 150 ml of culture using TRIzol® Plus Kit (Total RNA Isolation Protocol). 
The RNA samples consisted of mostly small RNA species as the 16 and 23S RNA peaks 
were very small on the electropherogram. 
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Ribosomal 
RNA 
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Ribosomal 
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(Figure 4.24a) and the elevated signal (Figure 4.24b) around the ribosomal RNA peaks 
showed that mRNA was present in the samples.  
4.13.3 Ribosomal RNA Depletion and Library Preparation 
The total RNA in a bacterial cell comprises of mostly ribosomal RNAs with messenger RNA 
only contributing to about 1 – 5% of the pool of RNA (Giannoukos et al., 2012, He et al., 
2010). To increase the sensitivity of detecting an mRNA transcript during sequencing, the 
depletion of ribosomal RNA was carried out before the sequencing stage. All RNA samples 
were DNAse-treated to remove DNA contamination as DNA will reduce the ribosomal RNA 
depletion efficiency. The DNAse-treated RNA samples were then verified by PCR for the 
gyrB gene to be free of DNA contamination (Figure 4.25). The DNA-free RNA samples were 
then subjected to ribosomal RNA depletion. All samples (Figure 4.26a & b) were successfully 
depleted of ribosomal RNA as shown by the reduction in the two major ribosomal RNA peaks 
(16S and 23S) in the Bioanalyzer electropherogram trace (Figure 4.26c & d). The rRNA-
depleted RNA samples were used for preparation of the cDNA library for sequencing. Before 
the library was sequenced, all library preparations were analysed by the Agilent 2200 
TapeStation (Figure 4.27a). All the cDNA libraries had an average fragment size of about 260 
bp, the recommended fragment size for RNA sequencing (Figure 4.27b).  
4.13.4 RNA Sequencing 
The sequencing obtained approximately 1.3 to 2.0 million reads per sample. The probability 
of a base being incorrectly assigned during sequencing was low for most of the length of the 
reads (Figure 4.28). The sequencing reads were initially mapped on to the published K. 
pneumoniae ST258 chromosome as the reference sequence (Accession No.: CP006923). 
However, in the subsequent analysis where the gene annotation file for the chromosome 
sequence was required, the software in GalaxyProject was unable to recognise the gene 
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Figure 4.24 Purification of RNA using RiboPureTM RNA Purification Kit 
(b) Representative of Agilent 2100 Bioanalyzer electropherogram trace  
Lower 
Marker 
Ribosomal 
RNA 
Messenger 
RNA 
(a) Agilent 2100 BioAnalyzer electrophoresis gel 
M: Molecular marker (Agilent) 
M 1 2 3 4 5 
23S rRNA 
16S rRNA 
6 7 8 9 10 11 12 
Lower Marker 
ST258 
ST258/ 
pKpQIL-UK
ST258/ 
pKpQIL-D2
A representative image of Agilent 2100 Bioanalyzer (a) electropherogram trace and (b) 
gel photo, showing the total RNA samples extracted from the various K. pneumoniae 
ST258 strains using RiboPure RNA Purification Kit. All the samples contained mRNA 
and the discreet 16 and 23S rRNA peaks suggest good RNA integrity with minimal 
degradation. 
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Figure 4.25 Validation of DNA contamination in DNAse-treated RNA samples 
The DNAse-treated RNA samples were checked by PCR (40 cycles) for the presence of 
the gyrB gene. The presence of DNA contamination would allow the gene to be 
amplified and the amplicons would be visible in the agarose gel. M: HyperLadder IV 
(Bioline); Lane 16: K. pneumoniae ST258 genomic DNA; Lane 17: Water; Primer: 
gyrB-F/R; Expected amplicon: 373 bp. 
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Figure 4.26 Depletion of ribosomal RNA 
(a) 
A representative Agilent 2100 Bioanalyzer (a) electropherogram trace and (b) gel 
photo of DNA-free RNA sample (ST258) before rRNA-depletion. 
Lower 
Marker 
Ribosomal 
RNA 
Small 
RNA 
Messenger 
RNA Lower 
Marker 
Ribosomal 
RNA 
(b) 
A representative Agilent 2100 Bioanalyzer (c) electropherogram trace and (d) gel 
photo of DNA-free RNA sample (ST258) after rRNA-depletion. After the rRNA-
depletion step, the 16 and 23S rRNA peaks were clearly reduced. 
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Figure 4.27 Validation of cDNA libraries 
M: Molecular ladder (Agilent) 
cDNA 
Library 
The DNase-treated and rRNA-depleted RNA samples were converted into cDNA. The 
average length of the fragments in these cDNA libraries were determined by the Agilent 
2200 TapeStation. (a) The gel photo shows the average length of the cDNA libraries of 
all samples. (b) A representative electropherogram shows a majority of the cDNA 
fragment are at the recommended size of about 260 bp for sequencing. 
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cDNA 
Library 
(a) Agilent 2200 TapeStation gel photo of all library preparation for sequencing 
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bp M 1 2 3 4 5 6 7 8 9 10 11 12 
ST258 
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pKpQIL-UK
ST258/ 
pKpQIL-D2 
(b) A representative Agilent 2200 TapeStation electropherogram for a cDNA 
library sample 
196 
 
Figure 4.28 Quality check of RNA sequencing reads 
The sequencing reads of each sample were analysed using the FASTQC analysis 
software. A representative FASTQC analysis shows the majority of the length of 
the sequencing reads obtained from the MiSeq Sequencer was of good quality 
i.e. the probability of a base being incorrectly assigned was low. 
 
Good  Poor 
197 
 
annotation. This was probably due to incorrect annotation in the original ST258 file. Hence, 
the chromosome sequence of K. pneumoniae MGH78578 (ST38) (Accession No.: CP000647) 
was used as the reference sequence for the analysis. The MGH78578 shares 91-92% coverage 
with 99% identity with the other published ST258 chromosome sequence (CP006923 & 
CP006918) (Figure 4.29).  
 The difference in K. pneumoniae ST258 chromosomal gene expression was studied in 
the presence of pKpQIL-UK and -D2 (Table 4.9). The genes were categorised according to 
cluster of orthologous groups (COG). Generally, both plasmids did not significantly alter the 
gene expression in the K. pneumoniae ST258 host. Interestingly, with the exception of four 
genes, pKpQIL-UK and -D2 affected the expression of two different sets of chromosomal 
genes. The four genes which were affected by both plasmids were carbon starvation gene 
(yjiY), transcriptional regulator (ycgE), short chain dehydrogenase and a gene encoding for a 
hypothetical protein. Twenty four genes were differentially expressed due to the presence of 
the plasmid. These were broadly categorised into genes related to cellular processes and 
signalling (n = 2, Table 4.9a), information storage and processing (n = 4, Table 4.9b), 
metabolism (n = 9. Table 4.9c) and genes of poorly characterised functions (n = 9, Table 4.9d). 
Most of the genes which were affected by the plasmids were related to transporters involved 
in metabolic functions (n = 5, Table 4.9c). 
 Expression of the pKpQIL-UK and -D2 plasmidic genes were also compared. 
However, only the genes located in the substituted regions were found to be expressed 
differently (Table 4.10). By mapping the sequencing reads of K. pneumoniae ST258 carrying 
the plasmids on to the substituted region of the individual plasmids, it was found that 
pKpQIL-UK’s substituted region was transcriptionally more active than the -D2 plasmid 
(Figure 4.30 – 4.33). Although both parA and parM genes were found on the substituted  
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Figure 4.29 Chromosome alignment of K. pneumoniae ST258 chromosome 
sequences with MGH78578 
The K. pneumoniae chromosome sequence alignment was generated using Blast Ring 
Image Generator software. From the inner most ring, (1) Size of the chromosome, (2) 
ST258-1 (Accession No.: CP006923) (pink), (3) ST258-2 (Accession No.: CP006918) 
(orange), and (4) MGH78578 (blue). The chromosomes of the three K. pneumoniae 
share about 91% coverage which has 99% DNA sequence identity. 
 
 
 
 
Table 4.9 Differentially expressed chromosomal genes in the presence of pKpQIL-UK vs -D2 
 
(a) Cellular Processes and Signaling 
Gene ID Gene Name Strand Putative Function 
Fold Changes BlastP 
Identity 
(%) 
COG ID COG Group COG Definition pKpQIL
-UK 
pKpQIL
-D2 
KPN_00443 acrB - Multidrug resistant efflux system 1.8 NS 100 COG841 V Defense mechanisms 
KPN_04776 yjiY - Carbon starvation protein 0.7 0.7 100 COG1966 T 
Signal transduction & 
mechanisms 
 
(b) Information Storage and Processing 
Gene ID 
Gene 
Name Strand Putative Function 
Fold Changes BlastP 
Identity 
(%) 
COG ID 
COG 
Group COG Definition pKpQIL
-UK 
pKpQIL
-D2 
KPN_01003 appY + AraC family transcriptional regulator NS 0.5 100 COG2207 K Transcription 
KPN_01374 dbpA + ATP-dependent RNA helicase NS 0.7 99 COG513 L,K,J 
Replication, recombination 
& repair; Transcription; 
Translation, ribosomal 
structure & biogenesis 
KPN_01535 cynR + LysR type transcriptional regulator 1.9 NS 100 COG583 K Transcription 
KPN_04733 ycgE - MerR family transcriptional regulator 0.1 0.1 100 COG789 K Transcription 
Continued overleaf. 
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(c) Metabolism 
Gene ID Gene Name Strand Putative Function 
Fold Changes BlastP 
Identity 
(%) 
COG ID COG Group COG Definition pKpQIL
-UK 
pKpQIL
-D2 
KPN_00640 xylG - ABC sugar transporter 1.8 NS 99 COG1129 G Carbohydrate transport & metabolism 
KPN_00801 bioF + 
Biotin metabolism (8-
amino-7-oxononanoate 
synthase) 
NS 1.7 100 COG156 H Coenzyme transport & metabolism 
KPN_01007 oppA + Oligopeptide transport system NS 0.5 99 COG4166 E 
Amino acid transport & 
metabolism 
KPN_02229 chaA + Calcium/sodium:proton antiporter 0.5 NS 100 COG387 P 
Inorganic ion transport & 
metabolism 
KPN_02235 hemA - Glutamyl-tRNA reductase 0.5 NS 100 COG373 H 
Coenzyme transport & 
metabolism 
KPN_02333 manX + 
PTS mannose 
transporter subunit 
IIAB 
0.7 NS 99 COG3444 G Carbohydrate transport & metabolism 
KPN_03184 cobQ - Cobyric acid synthase NS 0.8 100 COG1492 H Coenzyme transport & metabolism 
KPN_03259 yesO + Oligogalacturonate-binding protein OgtD NS D2 100 COG1653 G 
Carbohydrate transport & 
metabolism 
KPN_03375 metK + S-adenosylmethionine synthetase NS 1.4 100 COG192 H 
Coenzyme transport & 
metabolism 
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(d) Poorly Characterised 
Gene ID Gene Name Strand Putative Function 
Fold Changes BlastP 
Identity 
(%) 
COG ID COG Group COG Definition pKpQIL
-UK 
pKpQIL
-D2 
KPN_01536 smrA + DNA endonuclease 1.9 NS 100 COG2840 S Function unknown 
KPN_01888 yddH + Flavin reductase-like protein 2.6 NS 100 COG1853 R 
General function 
prediction only 
KPN_04023 ycnE + Hypothetical protein 0.6 0.4 100 COG1359 S Function unknown 
KPN_04732 sdh - 
Short chain 
dehydrogenase/ 
reductase 
0.1 0.1 99 COG300 R General function prediction only 
KPN_00439 ylaC - Hypothetical protein 1.8 NS 99 Unclassified Unclassified Unclassified 
KPN_01031 - + 
Hypothetical 
transmembrane 
protein 
2.0 NS 100 Unclassified Unclassified Unclassified 
KPN_01110 bhsA + Multiple stress resistance protein NS 1.4 100 Unclassified Unclassified Unclassified 
KPN_01149 yciG + Hypothetical protein NS WT 98 Unclassified Unclassified Unclassified 
KPN_02999 alaE + Hypothetical protein NS 0.6 100 Unclassified Unclassified Unclassified 
‘NS’ denotes non-significant changes in gene expression based on q-value. ‘WT’ denotes the gene was only expressed in the absence of the 
plasmids. ‘D2’ denotes the gene was only expressed in the presence of the pKpQIL-D2 plasmid. The genes were categorised according to the 
cluster of orthologous group (COG). ‘Red’ denotes increased in expression whereas ‘Blue’ denotes the opposite. 
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Table 4.10 Differentially expressed plasmidic genes 
 
Gene Name Strand Putative Function Plasmid 
BlastP 
Identity 
(%) 
xerC + Resolvase pKpQIL-UK 100 
parM + Plasmid segregation pKpQIL-UK 100 
parA - Plasmid segregation pKpQIL-UK 99 
parA + Plasmid segregation pKpQIL-D2 100 
parB + Plasmid segregation pKpQIL-D2 100 
parM + Plasmid segregation pKpQIL-D2 99 
- - Hypothetical protein pKpQIL-D2 100 
- - Transposase pKpQIL-D2 99 
The genes were located within the substituted regions of the respective plasmids. Hence, relative expression was not available. 
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Figure 4.30 Alignment of RNA sequencing reads from K. pneumoniae ST258 carrying pKpQIL-UK on to substituted region on 
pKpQIL-UK DNA sequence 
 
 
The figure was generated using Artemis (www.sanger.co.uk) by mapping the sequencing reads of ST258/pKpQIL-UK on to the substituted 
region in pKpQIL-UK plasmid sequence. The region highlighted in pink is the substituted region in pKpQIL-UK. From Figure 4.30-4.33, the 
mapping results suggest that all samples from the plasmid carrying strains were correct. Relative to pKpQIL-D2’s substituted region (Figure 
4.32), the corresponding region in pKpQIL-UK (pink) was found to be more transcriptionally active (based on the number of reads mapped on 
to this region). 
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Figure 4.31 Alignment of RNA sequencing reads from K. pneumoniae ST258 carrying pKpQIL-UK on to substituted region on 
pKpQIL-D2 DNA sequence 
 
 
The figure was generated using Artemis (www.sanger.co.uk) by mapping the sequencing reads of ST258/pKpQIL-UK on to the substituted 
region in pKpQIL-D2 plasmid sequence. The region highlighted in pink is the substituted region in pKpQIL-D2. As the substituted region in 
pKpQIL-D2 is completely different from the corresponding region in pKpQIL-UK, no sequencing reads were mapped on to the reference 
sequence. From Figure 4.30-4.33, the mapping results suggest that all samples from the plasmid carrying strains were correct. 
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Figure 4.32 Alignment of RNA sequencing reads from K. pneumoniae ST258 carrying pKpQIL-D2 on to substituted region on 
pKpQIL-D2 DNA sequence 
 
 
The figure was generated using Artemis (www.sanger.co.uk) by mapping the sequencing reads of ST258/pKpQIL-D2 on to the substituted 
region in pKpQIL-D2 plasmid sequence. The region highlighted in pink is the substituted region in pKpQIL-D2. From Figure 4.30-4.33, the 
mapping results suggest that all samples from the plasmid carrying strains were correct. Relative to pKpQIL-UK’s substituted region (Figure 
4.30), the corresponding region in pKpQIL-UK (pink) was found to be more transcriptionally active (based on the number of reads mapped on 
to this region). 
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Figure 4.33 Alignment of RNA sequencing reads from K. pneumoniae ST258 carrying pKpQIL-D2 on to substituted region on 
pKpQIL-UK DNA sequence 
 
 
The figure was generated using Artemis (www.sanger.co.uk) by mapping the sequencing reads of ST258/pKpQIL-D2 on to the substituted 
region in pKpQIL-UK plasmid sequence. The region highlighted in pink is the substituted region in pKpQIL-UK. As the substituted region in 
pKpQIL-UK is completely different from the corresponding region in pKpQIL-D2, only non-specific sequencing reads were mapped on to the 
reference sequence. From Figure 4.30-4.33, the mapping results suggest that all samples from the plasmid carrying strains were correct. 
 
 
 206 
207 
 
region of pKpQIL-UK and -D2, and were highly expressed, these genes shared low amino 
acid sequence identity to each other (Figure 4.34 & 4.35). 
4.14 Discussion 
Bacterial fitness is a complex phenomenon which can be broadly defined as the ability of 
bacteria to alter their metabolism to adapt to the environmental conditions, in order for its 
genetic trait to compete, survive and reproduce within itself or to transfer across different 
hosts (Binet and Maurelli, 2005, Pope et al., 2010). For this study, the fitness of the plasmid-
bearing strains was investigated in various ways, such as growth rates, biofilm formation, 
conjugation frequency, antibiotic susceptibility and pairwise competition.  
 Plasmid carriage has been previously reported to incur a fitness cost, most often 
translated into slower growth rates (Bouma and Lenski, 1988, Dahlberg and Chao, 2003, 
Lenski and Bouma, 1987, Ow et al., 2006). In this PhD study, the growth rates of pKpQIL-
UK and -D2 were indistinguishable from their parental strains (K. pneumoniae ST258, S. 
Typhimurium SL1344 and E. coli NCTC10418). Although SL1344 and ATCC14028s are 
generally regarded as closely related pathogenesis models for Salmonella (Brown et al., 2011), 
pKpQIL-D2 carriage in S. Typhimurium ATCC14028s conferred a significantly slower 
growth rate. These data suggest that minor differences in the host played a role in the 
differences in fitness impact of the plasmids. pKpQIL-UK, but not -D2, negatively affected 
the growth rate of S. marcescens and E. cloacae. Although both plasmids are very similar 
with 85% coverage at 99% sequence identity, the differences in the substituted region could 
have contributed to the differences in observed growth rates. Although a large plasmid size 
has been implicated with slower growth rates (Smith and Bidochka, 1998, Zünd and Lebek, 
1980), such a correlation was not observed in this study (pKpQIL-UK=113 kb; -D2=111 kb).  
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Figure 4.34 Amino acid alignment of ParA pKpQIL-UK vs -D2 
 
pKpQIL-UK-parA      MKRDYGGVGSIARRAGILLESMSRDIEDQRKEFNLTEYFQTFTRNAVAKLPKLSRRIVEQ 60 
pKpQIL-D2-parA      -MDNIEQLRKVATRAGKLLTSLSESIRQQKEELKLTEFYQEYSKAALYKLPKLSKGSVEY 59 
                       :   : .:* *** ** *:*..*.:*::*::***::* ::: *: ******:  **  
 
pKpQIL-UK-parA      AIKEMEDAGYDFNKKRVGNVEQYALTVQNVIDIYAHRKIPKYREIHQSPYVIFVVNLKGG 120 
pKpQIL-D2-parA      AVSEMEAGGYIFKKKPSGNTMKYAMTIQNVIDLYNHRKVPKYRDRFDKAFTIFVCNLKGG 119 
                    *:.*** .** *:**  **. :**:*:*****:* ***:****: .:..:.*** ***** 
 
pKpQIL-UK-parA      VSKTVSTVTLAHALRVHQDLLRHDLRILVIDLDPQASSTMFLDHTHSIGSILETAAQAML 180 
pKpQIL-D2-parA      GSKTVTTASLSHAFRAHPQLLFEDLRILAIDFDPQASLTMFLSHENSVGLVENTAAQAML 179 
                     ****:*.:*:**:*.* :** .*****.**:***** ****.* :*:* : :******* 
 
pKpQIL-UK-parA      NDVDAETLRNEVIRPTIIPGVDVIPASIDDGFVASAWKELVSEHLPGVNQYEVLRKIIID 240 
pKpQIL-D2-parA      QNVSREELLSDFIVPSIIPGVDVIPASIDDAFLAEGWKGLCEEHLPGKNIHAVLKENIID 239 
                    ::*. * * .:.* *:**************.*:*..** * .***** * : **:: *** 
 
pKpQIL-UK-parA      RVADDYDFILIDTGPHLDPFLLNGLAASDLILTPTPPAQVDFHSTLKYLTRLPEMLETLE 300 
pKpQIL-D2-parA      KLQHDYDFIFLDSGPHLDAFLKNCIGAADLMLTPLPPATVDFHSSLKFVASLPALIDSIE 299 
                    :: .*****::*:*****.** * :.*:**:*** *** *****:**::: ** :::::* 
 
pKpQIL-UK-parA      EEGIEPRLAASIGFMSKMTGKPDHLVSHSLAREVYTSSILDSSLPRLDGFERCGETFDTI 360 
pKpQIL-D2-parA      MDGHTCNLIGNVGFMSKILNKSDHKICHSQAKEVFGADMLDMVLPRLDGFERCGETFDTV 359 
                     :*   .* ..:*****: .*.** :.** *:**: :.:**  ****************: 
 
pKpQIL-UK-parA      ISANPASYPGSNDALKKARTEAEHFTKAVFDRIEFLRSQSA- 401 
pKpQIL-D2-parA      ISANPATYDGSTEALKSAKSAAEDFAKAVFDRIEFIRTNGGM 401 
                    ******:* **.:***.*:: **.*:*********:*::..  
 
 
Both substituted region in pKpQIL-UK and -D2 contain genes which have been annotated as 
the ParA protein involved in plasmid segregation. However from BlastP, both ParA proteins 
share 97% coverage with only 57% amino acid sequence identity. 
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Figure 4.35 Amino acid alignment of ParM pKpQIL-UK vs -D2 
 
 
 
pKpQIL-UK-parM      ------MATISTISQPLRGEFIRTAATAGAVVY-QVDARLPALIPVFFAGQLSAVRLCAV 53 
pKpQIL-D2-parM      MNIYCDDGSTNVKLAWFEGDELQTRVSANSFRHGWKVAEFSAATFNYQVGTLKYTWDSVS 60 
                           .: ..    :.*: ::* .:*.:. :    *.:.*    : .* *. .  ..  
 
pKpQIL-UK-parM      MALVSGT-----WSSL-----------TGLPDEPENGGAALPVSP---------ETEYQR 88 
pKpQIL-D2-parM      RDAIPTTNVEYQYGDLNLLAVHHALLNSGLEPQPVSLTVTLPLSEYYDGDCQRNEENIRR 120 
                       :. *     :..*           :**  :* .  .:**:*          * : :* 
 
pKpQIL-UK-parM      RR----YTLTLQNGRSG---------ERVESVLTEASSRLRGDLLRNLIITG----LALH 131 
pKpQIL-D2-parM      KRENLMRELVLNKGRAFTVTDVKVMPESLPAAFSRLAELKPGPAETTLIIDLGGTTLDAG 180 
                    :*      *.*::**:          * : :.::. :.   *    .***      *    
 
pKpQIL-UK-parM      TTAPELPRLLASMPVPPTSVSELQALVQQMAGTAD------------------------- 166 
pKpQIL-D2-parM      VIVGQFDDISAVHGNPSVGVSQVTRAAAGALRAADSETSALIADTIIRNRNDRQYLQRVI 240 
                    . . ::  : *    *...**::   .     :**                          
 
pKpQIL-UK-parM      -----VNRAAAAVPDTPTASAAPVS---------------GSDTREIKKNMRRAFGD--- 203 
pKpQIL-D2-parM      NDAGKIDEVRNKITEAITSLGARVTSELTAFRNVNRVFLVGGGASLIEEAIRQAWPLAPD 300 
                         ::..   :.:: *: .* *:               *..:  *:: :*:*:      
 
pKpQIL-UK-parM      ----------------------- 
pKpQIL-D2-parM      RIEVIGDPQMALAREIALYNKED 323 
 
 
Both substituted region in pKpQIL-UK and -D2 contain genes which have been annotated as 
the ParM protein involved in plasmid segregation. However, both ParM proteins share only 
26% coverage and 45% identity. 
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Bacterial growth rates have also been implicated to impact upon drug susceptibility 
(Costerton et al., 1999, Gilbert et al., 1990, Lewis, 2001). However, this was not observed in 
this study. All strains carrying the two plasmids were inhibited by similar MIC values for the 
antibiotics tested.  
S. marcescens carrying pKpQIL-UK which was found in this PhD study to be more 
resistant than S. marcescens carrying pKpQIL-D2 towards carbapenem antibiotics. A 
previous study implicated the loss of OmpF and/or OmpC with the overproduction of AmpC 
β-lactamase as a cause for β-lactam resistance in S. marcescens (Weindorf et al., 1998). 
However, no difference in porin expression was observed in my study. Derepression of 
AmpC β-lactamase in the presence of antibiotic inducers has been previously reported. Some 
β-lactam antibiotics such as imipenem, cefoxitin and cefotetan are known to be strong AmpC 
β-lactamase inducers whilst third generation cephalosporins such as cefotaxime and 
ceftazidime have poor inducing properties (Sanders et al., 1997, Stapleton et al., 1995). 
Therefore in S. marcescens NCTC10211 carrying the pKpQIL-D2 plasmid, the phenotype 
maybe caused by incomplete derepression of the chromosomal AmpC β-lactamase.  
The high rate of loss of both plasmids from the E. coli population was probably due to 
high fitness cost incurred by the presence of the plasmids. The general fitness cost of plasmid 
carriage may be attributed to a variety of factors including cytotoxic effect resulting from 
misfolded proteins, additional usage of cellular resources for physiological processes and 
alteration of metabolic flux due to introduction of homologues (Baltrus, 2013). The loss of 
pKpQIL-D2 but not pKpQIL-UK from the S. Typhimurium SL1344 and ATCC14028s 
populations suggests that the fitness cost most probably originated from the substituted region 
in pKpQIL-D2. The stability of large low copy plasmids within a bacterial population is 
generally facilitated by post-segregational killing and active partitioning mechanisms encoded 
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by the plasmids (Sengupta and Austin, 2011). The pKpQIL-UK plasmid is known to encode 
genes involve in plasmid maintenance, such as the parA/parB and stbA/stbB (Leavitt et al., 
2010a). The variant plasmid, pKpQIL-D2 also carries the same stbA/stbB genes but a variant 
of parA/parB genes. It is possible that these genes were not able to function efficiently in 
maintaining the plasmids in some of the genetic backgrounds tested. Although it has been 
reported that genetic adaptation, which ameliorates the fitness cost of plasmid carriage can 
reduce the rate of loss of the plasmid (San Millan et al., 2014), this was not observed under 
the conditions tested. The plasmids exhibited a complete, rather than a delayed loss in the 
persistence assay. Both plasmids had similar conjugation frequencies into the two Salmonella 
strains, but pKpQIL-D2 was unable to persist. This may suggests that lateral gene transfer 
play little role in the maintenance of these two plasmids. Previous studies have shown strong 
correlation between antibiotic usage and the emergence of resistance (Van De Sande-
Bruinsma et al., 2008). The reduction in antibiotic consumption has also led to the decrease in 
resistance (Anonymous, 2008, Seppälä et al., 1997). However, where the genes encoding for 
antibiotic resistance are found on successful plasmid such as pKpQIL-UK or its variant, the 
reduction in resistance is unlikely.  
Interestingly, it was observed that the percentage of K. pneumoniae ST258 and Ecl8 
carrying the pKpQIL-UK plasmid dropped at the early stages of the persistence experiment 
(Figure 4.9b and Figure 4.12d). However, the plasmid carrying population recovered after day 
5 (ca. 35 generations). A similar observation was noted with the original clinical isolate (K. 
pneumoniae ST321) carrying the pKpQIL-D2. This may indicate a slight fitness cost of the 
plasmids in their respective hosts which was rapidly abrogated. A study has shown that 
chromosomal adaptation could alleviate the fitness cost of the plasmids after 100 generations 
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of co-existence of the plasmid and its host (San Millan et al., 2014). However, it is unclear 
whether a similar adaptation had occurred with the persistence experiments in this PhD.  
Relative to the host bacterial strain with no plasmid (i.e. before introduction of 
pKpQIL-UK and -D2), both plasmids affected the ability of various Enterobacteriaceae hosts 
to form a biofilm on plastic in different ways. Biofilm formation is an important phenomenon 
as most bacteria (99%) in the natural environment exist in biofilms (Potera, 1996). The 
establishment of a biofilm by a single or a mixture of bacterial species plays an important role 
in various infections and resistance to antimicrobial agents (antibiotics and biocides) 
(Costerton et al., 1999). Conflicting data associating conjugation to biofilm formation have 
been previously reported (Ghigo, 2001, Reisner et al., 2006, Røder et al., 2013). The carriage 
of F-plasmids has been previously shown to confer the ability to form biofilm in the E. coli 
host (Ghigo, 2001). When plasmid carrying strains which do not form thick biofilm on their 
own were co-cultured with the plasmid-free E. coli MG1655, the author observed a significant 
increase in biofilm formation. Moreover, when the traA gene involved in pilus formation on 
the plasmid was inactivated, the ability to form a biofilm was abolished (Ghigo, 2001). This 
also suggested that the cell-to-cell and/or cell-to-surface contact promoted by the conjugation 
pilus can influence biofilm formation (Ghigo, 2001). A similar observation was made in 
another study investigating the effects of co-culturing clinical isolates with plasmid-free E. 
coli on biofilm formation (Reisner et al., 2006). However, a recent study on IncP-1 plasmid 
carriage in different species showed a reduction in biofilm formation (Røder et al., 2013). In 
contrast, the inactivation of traF gene involved in the conjugation machinery increased the 
biofilm formation of the host bacterium (Røder et al., 2013). However, as the conjugation 
machinery involves a large number of genes, it is likely that there is a complex interaction 
between this machinery with that of biofilm formation. From my study, it was observed that 
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the bacterial species also contributed to the difference in ability to form a biofilm in the 
presence of the plasmids.   
The pairwise competition assay between the pKpQIL-UK and -D2 in K. pneumoniae 
Ecl8 showed that pKpQIL-D2 conferred a competitive advantage over pKpQIL-UK in this 
host. Over the 20-day period, the majority of pKpQIL-UK carrying Ecl8 strain was displaced 
from the population. All the strains used in this competition had comparable growth rates 
discounting growth rate as the factor for the plasmid loss from the population. Unlike in S. 
Typhimurium, both pKpQIL-UK and -D2 were able to persist within the population of K. 
pneumoniae over a period of 20 days (ca. 140 generation). This suggested that the pKpQIL-
D2 plasmid had a competitive advantage over pKpQIL-UK when both plasmid carrying K. 
pneumoniae Ecl8 hosts were grown in the same population. In the competition of pKpQIL-
UK vs -D2 blaKPC::aph, it was observed that pKpQIL-UK was not completely cleared from 
the population. It is possible that the kanamycin resistance gene (aph) had a fitness impact on 
the pKpQIL-D2 plasmid reducing its ability to displace the pKpQIL-UK plasmid. However, 
the aph gene was used extensively in our previous work and no apparent fitness cost was 
observed (Cottell et al., 2014, Cottell et al., 2012). The plasmids pKpQIL-UK, -D2 and their 
blaKPC-inactivated plasmids were conjugative as the tra locus was still present. As both 
plasmids were of the same incompatibility group, the transfer of pKpQIL-D2 into pKpQIL-
UK-carrying Ecl8Rif was unlikely as both plasmids could not coexist in the same host. The 
possibility of the transfer of pKpQIL-D2 into plasmid-free Ecl8Rif (from the loss of pKpQIL-
UK) and displacing the pKpQIL-UK-carrying host from the population was minimal as both 
plasmids persisted equally well in K. pneumoniae Ecl8Rif without any significant loss and all 
the plasmid carrying strains used in the competition had equal generation times (Figure 4.12d 
& Figure 4.13 & Table 4.3). Moreover, pKpQIL-UK was found to have a higher conjugation 
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frequency than pKpQIL-D2. As pKpQIL-UK was out-competed by pKpQIL-D2, it was 
unlikely that conjugation played a significant role in this experiment.   
Another method to assess fitness of the plasmid carrying hosts is by studying the 
bacteria using infection models. A simple model involving Galleria mellonella has been 
established to study infection by K. pneumoniae (Insua et al., 2013, Wand et al., 2013). In this 
model, there was no detectable difference in virulence between the two plasmid carrying K. 
pneumoniae ST258 under the conditions tested. It is possible that this infection model is not 
sufficiently sensitive to detect the subtle differences contributed by the plasmids. Hence, 
additional virulence assays such as murine infection model, serum resistance and 
macrophage-mediated killing assays are needed to assess the virulence of the pKpQIL-UK 
and -D2 carrying K. pneumoniae ST258 (Diago-Navarro et al., 2014).   
The RNA sequencing data revealed a minimal influence of both plasmids on the host 
chromosomal gene expression. Those chromosomal genes with altered transcription were 
related to metabolic functions. However, there was no clear association of these pathways 
with the fitness or virulence of the host. Interestingly, pKpQIL-UK was found to up-regulate 
the multidrug efflux pump component gene, acrB. The up-regulation of this gene did not 
translate into obvious changes in antibiotic susceptibility of the host for the antibiotics tested. 
However, acrB is also known to affect virulence of the host and biofilm formation (Piddock, 
2006b). However, there were no detectable changes in biofilm formation or Galleria infection 
for K. pneumoniae ST258 carrying pKpQIL-UK vs -D2. However, the lack of observed 
difference may also be caused by the poor biofilm forming ability of the ST258 strain used. 
The lack of many changes in gene expression of the host in the presence of the plasmids may 
imply that the plasmids are well adapted to K. pneumoniae. Hence, they do not significantly 
change the gene expression of their host resulting in excessive (if any) fitness cost. The 
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pKpQIL-UK plasmids have been generally found in K. pneumoniae since its discovery (Chen 
et al., 2014a, Leavitt et al., 2010b, Villa et al., 2013). Moreover, the pKpQIL-UK is 
essentially comprised of pKPN4 with the Tn4401 harbouring the blaKPC-2 gene (Leavitt et al., 
2010a). The pKPN4 plasmid was found in the multidrug-resistant K. pneumoniae MGH78578 
(ATCC700721) isolated from the sputum of a 66-year-old ICU patient with Klebsiella caused 
pneumonia in 1994. The pKpQIL-UK plasmid is relatively stable with less than 10 nucleotide 
substitution detected in sequenced plasmids (Chen et al., 2014a, Leavitt et al., 2010b). 
Although deletion or variations of the plasmid have been reported, the significance of these 
variants is unclear (Chen et al., 2014a, Villa et al., 2013). In the RNA sequencing analysis, it 
was found that the plasmid segregation genes parA and parM were highly expressed in both 
plasmids. However, the genes found on both plasmids share low amino acid sequence identity. 
It is unclear whether these proteins function differently in the individual plasmids. 
The RNA sequencing data suggested no significant difference in the transcriptome 
profile of the plasmid carrying K. pneumoniae ST258. Similarly, the presence of both 
plasmids in K. pneumoniae did not show a significant difference in phenotype under the 
conditions tested. Taken together, these may suggest that the plasmids are well adapted to the 
K. pneumoniae host. Hence, both plasmids do not confer significant fitness cost on their host, 
allowing them to thrive in K. pneumoniae. However, this is different to the observations with 
an IncH plasmid commonly found in S. Typhimurium (Paytubi et al., 2013). The study found 
that the IncHI1 plasmid affected different categories of genes to assist its Salmonella host to 
adapt to environmental stresses. A recent study also found that the introduction of a ca. 5 kb 
plasmid (pNUK73) had tremendous impact on the transcriptional profile of its P. aeruginosa 
PAO1 host (San Millan et al., 2015). This shuttle vector was rapidly loss from its host due to 
its high fitness cost (San Millan et al., 2014). The fitness cost was a result of the expression of 
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the Rep plasmid replication protein (San Millan et al., 2015). After 300 generations of co-
existence with its host, chromosomal mutations in the helicase or kinase gene successfully 
reverted the transcriptome profile of the plasmid-carrying strains to that of the plasmid-free P. 
aeruginosa PAO1, reducing the cost of plasmid carriage and stabilising the plasmid in the 
bacterial population (San Millan et al., 2014, San Millan et al., 2015). These studies suggest 
that different plasmid incompatibility groups may affect their host differently.  
Due to its isolation in many Enterobacteriaceae species in the outbreaks in UK, it was 
hypothesised that pKpQIL-D2 was more successful than pKpQIL-UK. The data obtained 
from the competition experiment suggest that the variant plasmid is able to displace pKpQIL-
UK from the population under the conditions tested. However, outbreaks in the UK were 
found to involve both plasmids, suggesting that both plasmids are able to persist equally in the 
clinical environment.  
4.15 Future Work 
It has been shown that plasmid copy number can affect the metabolic flux of the plasmid 
carrying host possibly due to increase gene expression (Adler et al., 2014, Wang et al., 2006). 
Determination of the plasmid copy number of pKpQIL-UK and -D2 in the various 
Enterobacteriaceae bacteria could provide more insights to some of the observations made in 
this study. For example, the loss of pKpQIL-D2 from the Salmonella host strains during the 
20-day plasmid persistence assay may be due to low plasmid copy number. The information 
on the plasmid copy number after the inactivation of the blaKPC gene with the kanamycin 
resistance gene (aph) will also exclude the plasmid copy number factor in the interpretation of 
the competitive advantage observed in pKpQIL-D2. Also, it can be hypothesised that the 
difference in the plasmid segregation proteins (ParA and ParM) in conjunction with low 
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plasmid copy number have contributed to the advantage observed in pKpQIL-D2 during the 
competition experiment or its inability to persist in a S. Typhimurium host.  
 Real time PCR could also be used to determine the expression of the plasmid 
maintenance genes (parAB and stbAB) in the Salmonella and E. coli hosts where the loss of 
plasmids from the population was significant. The plasmid persistence assay involved daily 
sub-culturing of the plasmid-carrying bacteria. Hence, bacteria constantly undergo the lag, log 
and stationary phases of growth. It is hypothesised that both plasmid-carrying bacteria 
perform differently in the different growth phases leading to the subsequent displacement 
from the population. Using a chemostat, the growth rate can be kept constant to reduce the 
variability in the experiment. The same could be done with the pairwise competition assay to 
determine the competitiveness of the plasmid-carrying strains.  
 Although pKpQIL-UK has been reported to have crossed the sequence type barrier 
and is found in other ST strains of K. pneumoniae (Chen et al., 2014a), a pairwise competition 
assay should ideally be done using a carbapenem susceptible ST258 which is the predominant 
K. pneumoniae clone and host of the plasmid. In order to use the current antibiotic resistance 
gene for inactivation/tagging of the blaKPC gene on the plasmid, a kanamycin or 
chloramphenicol susceptible ST258 strain will be needed. Otherwise, an alternative resistance 
marker (e.g. tellurite resistance gene) could be used instead to differentiate the plasmids 
during competition. However, the alternative marker will need to be tested to confirm that it 
does not confer any significant cost to the plasmid-carrying host. 
 The RNA sequencing showed that the presence of either plasmid had little influence 
on chromosomal gene expression. Nonetheless, the difference in the gene expression in the 
presence of both plasmids needs to be confirmed by using qRT-PCR. Another study also 
showed that different culture conditions and growth phases can affect the influence of the 
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plasmids on their host (Paytubi et al., 2013). It is hypothesised that pKpQIL-UK and -D2 may 
regulate host gene expression under stress to allow their persistence within the bacterial 
population. Hence, the RNA sequencing could be repeated using total RNA extracted from 
stationary phase to investigate the effects of the plasmids on their host under stress (e.g. 
limited nutrients).  
4.16 Key Findings 
 Contrary to the hypothesis, pKpQIL-D2 does not confer an obvious fitness advantage to 
its host over pKpQIL-UK. 
 Both pKpQIL-UK and pKpQIL-D2 plasmids influenced their host differently in the 
various fitness experiments done. 
 The pKpQIL-D2 plasmid was found to out-compete pKpQIL-UK in a pairwise 
competition assay. 
 RNA-sequencing suggests that both plasmids have a minimal effect on host chromosomal 
gene expression. 
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CHAPTER FIVE: OVERALL DISCUSSION 
The continuous spread and persistence of carbapenemase-producing Enterobacteriaceae and 
deleterious impact on the treatment of infections have attracted increasing attention in the 
recent years (Otter, 2014). The spread of these carbapenemases and other major β-lactamases 
is promoted by plasmids (Harris et al., 2015). In addition to antibiotic resistance, plasmid 
carriage also promotes evolution of the bacterial host via acquisition of new beneficial traits 
associated with virulence, resistance to heavy metals and additional metabolic functions 
(Bennett, 2008). It is a widely viewed that the acquisition of plasmids incurs a significant 
fitness cost upon the bacterial host, which results in plasmid-bearing bacteria to be out-
competed by the plasmid-free strains (Bouma and Lenski, 1988, Lenski, 1998, Lenski and 
Nguyen, 1988). 
 In this PhD study, the impact of a globally disseminated blaKPC carbapenemase 
encoding plasmid (pKpQIL-UK) and its variant (pKpQIL-D2) on various Enterobacteriaceae 
host strains was investigated. The pKpQIL-D2 variant has not been described in the published 
blaKPC-encoding plasmids to date (31st March 2015). The majority of the pKpQIL-like  
plasmids (i.e. pKpQIL-UK) investigated (Chen et al., 2014a) do not carry the substituted 
region observed in the pKpQIL-D2 isolated in the UK. Since the discovery of the pKpQIL 
plasmid in Israel, the plasmid has since been isolated in various continents including North 
America, Europe and Asia (Chen et al., 2013, Leavitt et al., 2010a, Richter et al., 2012, Tang 
et al., 2014, Hrabák et al., 2013, Lee et al., 2014). Variants of the plasmid have also been 
isolated (Chen et al., 2014a, Villa et al., 2013). The variations in the plasmids obtained can be 
very drastic. Although the original pKpQIL plasmid was approximately 114 kb, deletion, 
insertion and fusion events have been observed which resulted in the generation of variant 
plasmids ranging from 49 kb to 115 kb (Chen et al., 2014a, Villa et al., 2013). The presence 
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of multiple insertion elements (e.g. IS26) on the plasmid is believed to have contributed to the 
plasticity of this plasmid (Partridge, 2014, Villa et al., 2013). 
 The historical events leading to the emergence of the pKpQIL-D2 variant plasmid are 
unclear. The pKpQIL-UK (or referred to as pKpQIL in the literature) plasmid is essentially of 
pKPN4 plasmid of K. pneumoniae MGH 78578 (Accession No.: GCA_000016305) carrying 
the blaKPC containing Tn4401 transposon (Leavitt et al., 2010a). As the host K. pneumoniae 
strain MGH 78578 carries five plasmids (pKPN3, 4, 5, 6 and 7), it is possible that the D2 
substituted region was a result of recombination of the pKPN4 and pKPN5 plasmids (Figure 
1.8 & 4.1). The region between the repB and umuD (Figure 1.8) in the pKpQIL-D2 16 kb 
substituted region shares 98% DNA sequence identity with the corresponding region in 
pKPN5. However, it is unclear whether the blaKPC containing transposon was inserted in 
pKpQIL-D2 before or after the additional fragment of the substituted region was introduced. 
The source of the additional fragment is also unclear as Blastn search of the fragment did not 
provide any significant homology hits apart from pKPN5.   
Previous reports have studied the association of blaCTX-M ESBL with specific 
genotypes of E. coli (Branger et al., 2005, Deschamps et al., 2009). Although no conclusive 
correlation was observed between the type of blaCTX-M-encoding plasmids with the genotype 
of the E. coli host, it was suggested that adaptation between the ESBL gene and the host 
genotype resulted in increased fitness of the resistant strains which aided in the dissemination 
of the ESBL gene within the host bacterial genotype (Deschamps et al., 2009). This has been 
found to be true for blaCTX-M-15 which has been reported to be highly associated with the E. 
coli ST131 causing frequent outbreaks around the world (Coque et al., 2008, Mathers et al., 
2015, Peirano and Pitout, 2010). Although the blaKPC carbapenemase was initially discovered 
in a K. pneumoniae, it has crossed species boundaries and can be found in various 
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Enterobacteriaceae including E. coli, S. marcescens, E. cloacae, A. baumannii and P. 
aeruginosa (Cai et al., 2008, Chen et al., 2012). In K. pneumoniae, this carbapenemase is 
predominantly associated with K. pneumoniae ST258 (Chen et al., 2014b, Chen et al., 2012). 
However, blaKPC can also be found with sequence type unrelated to ST258 (Giakkoupi et al., 
2011, Lavigne et al., 2013). Comparative genomics of published K. pneumoniae genome 
sequence of various sequence types have found high conservation among chromosomal 
sequences with differences mostly associated to mobile elements (Chen et al., 2014b). Due to 
the differences in the capsule polysaccharide gene clusters K. pneumoniae ST258 is 
categorised into two clades (DeLeo et al., 2014). The blaKPC-2 and blaKPC-3 carrying plasmids 
are associated with clade 1 and 2, respectively (DeLeo et al., 2014). The authors also 
suggested possible association of plasmid incompatibility groups with the clades (DeLeo et al., 
2014). The reason contributing to these associations is unknown. It is possible that factors 
encoded in the host and/or the plasmids have resulted in this close host-plasmid relationship.    
Antibiotic resistance has frequently been associated with a fitness cost incurred on the 
host bacterium (Andersson and Hughes, 2010). One study compared the fitness impact of a 
carbapenemase, blaSME-1 and a penicillinase, blaTEM-1 cloned into a pTrc99A- and pUC18-
based plasmids on a E. coli host (Marciano et al., 2007). Compared to the blaTEM-1 carrying E. 
coli, the authors found that the E. coli carrying the blaSME-1 gene had a significant slower 
growth rate, lower cell viability after 24 hours of culture and were unable to persist in the 
absence of antibiotic selection (Marciano et al., 2007). The lower cell viability was also 
observed when the blaSME-1 was cloned into the E. coli chromosome. Hence, the authors 
concluded that the fitness impact arose from the carriage of the carbapenemase gene 
(Marciano et al., 2007). Another study, on blaVIM-2 carbapenemase in S. Typhimurium, also 
found that the carbapenemase resulted in colony morphology deformity, slower growth, 
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decreased motility and reduction in invasion of Caco-2 cells (Cordeiro et al., 2014). However, 
a blaOXA-66 carbapenemase had no deleterious effects on the growth and morphology in the 
same experiment (Cordeiro et al., 2014). Recently, various blaKPC-2 containing plasmids of 
different incompatibility groups (IncN, IncL/M and IncFII) were transferred into a common K. 
pneumoniae ATCC10031 and the fitness impact of these plasmid carrying hosts were 
assessed using the Caenorhabditis elegans infection model (Lavigne et al., 2013). The authors 
found that the K. pneumoniae carrying plasmids isolated from clonal group 258 were more 
virulent than plasmids from non-ST258 related strains. The K. pneumoniae carrying a blaKPC-2 
cloned into a pBK-CMV expression plasmid was found to be unable to kill the C. elegans as 
efficiently as the plasmid-free host, suggesting the carbapenemase gene was the source of the 
fitness cost (Lavigne et al., 2013). This also suggested that the observed increase in virulence 
in the infection model was probably a result of the plasmid backbone. 
In this PhD study, the carriage of the pKpQIL-UK or -D2 plasmid showed no 
detectable adverse impact on the virulence of the K. pneumoniae ST258 in the Galleria 
infection model. This correlated to the other fitness experiments done with the K. pneumoniae 
ST258 as both plasmids did not have a significant impact in the generation time, ability to 
form biofilm and persistence of the plasmids in this strain. Further supporting these, the total 
transcriptome of both K. pneumoniae ST258 carrying pKpQIL-UK and -D2 also showed the 
plasmids had minimal impact in the host chromosomal gene expression. The carriage of 
blaKPC-2 inactivated pKpQIL-UK and -D2 plasmids in K. pneumoniae Ecl8 also showed no 
changes in generation times of the bacterial host strains. This suggested that the 
carbapenemase gene does not incur any fitness cost on the growth rate of the host. It was 
hypothesised that the pKpQIL-D2 plasmid with the new substituted region has a fitness 
advantage over the original pKpQIL-UK plasmid. However, there was no obvious advantage 
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across the panel of fitness experiments used to compare the two plasmids in the various 
Enterobacteriaceae. Of note, the pKpQIL-D2 plasmid was only found to confer a fitness 
advantage over the pKpQIL-UK plasmid in a pairwise competition experiment in K. 
pneumoniae Ecl8, where the variant plasmid carrying bacterial host strain displaced most of 
the pKpQIL-UK carrying K. pneumoniae Ecl8 after 20 days (ca. 140 generation). No 
correlation was observed between conjugation frequencies of the plasmids from their original 
clinical isolates into the various Enterobacteriaceae strains with the persistence of the 
plasmids in their new bacterial hosts. Virulence experiment using a representative K. 
pneumoniae ST258 isolate and a septicaemia mice model suggested that this sequence type is 
avirulent (Tzouvelekis et al., 2013). The strain was also prone to human serum killing and 
phagocytosis. Hence, the authors suggested that the K. pneumoniae ST258 generally acts as 
an opportunistic pathogen and the associated mortality rate with this epidemic strain is mostly 
by overwhelming of the host immune system with high bacterial load (Tzouvelekis et al., 
2013). Antibiotic resistance which leads to therapy failure may also allow the bacteria to 
achieve the numbers required for infection to occur (Tzouvelekis et al., 2013).  
The spread of carbapenemase producing Enterobacteriaceae has threatened one of the 
most efficacious antibiotics available, i.e. carbapenem for treatment of serious bacterial 
infections. Correct management of infections should depend on the antibiotic susceptibility of 
bacteria from patient specimens and epidemiological data. However, as reported, 
carbapenemase producing Enterobacteriaceae can appear susceptible to carbapenem 
antibiotics leading to false reports (Nordmann et al., 2012b). Where treatment options is 
guided by such information, it may lead to counter-productive outcome among patients with 
bacterial infections (Cortés et al., 2010, Kang et al., 2005, Lueangarun and Leelarasamee, 
2012, MacGowan, 2008, Zilberberg et al., 2014). The level of carbapenem resistance is 
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dependent on various factors including level of gene expression and number of 
carbapenemase genes, up-regulation of efflux pump and down-regulation of porins (Kitchel et 
al., 2010). Hence, inappropriate initial antibiotic therapy may select for high level resistant 
isolates during the course of treatment leading to serious consequences (Adams-Sapper et al., 
2015).  
Carbapenemase producing Enterobacteriaceae often carry other resistance determinant 
rendering other antibiotics such as fluoroquinolone and aminoglycosides ineffective (DeLeo 
et al., 2014, Ho et al., 2011). Hence, the combination therapy of efflux inhibitor and 
antibiotics may present an alternative option for the treatment of multidrug resistant bacteria 
(Lomovskaya and Bostian, 2006). The presence of the efflux inhibitor may sensitise the 
bacteria to a variety of antibiotics which are substrates to the efflux systems. However, data 
from this PhD study suggest that careful design and judicious use of efflux inhibitors are 
required to ensure that indirect effects of the inhibitor do not result in reduced susceptibility of 
bacteria carrying β-lactamase genes. Where the efflux inhibitor exerts an effect (such as 
down-regulation of porins), the inhibitor should only be used in combination with antibiotics 
that do not require porins as the main entry route into the bacterial cell.  
 The recent Review on Antimicrobial Resistance has acknowledged the increasing 
concerns of mortality and morbidity associated with antibiotic resistant E. coli and K. 
pneumoniae (O'Neill, 2014). The widespread prevalence of blaKPC carrying K. pneumoniae 
ST258-related clones poses a serious threat to medical treatment. At present, pKpQIL and its 
variant have played a significant role in the dissemination of this carbapenemase across 
various sequence type and species (Chen et al., 2014a). Although the reason for the successful 
spread and stability of this plasmid within a bacterial population still remains unclear, the 
findings of this PhD study has provided more evidence that these factors are found on the 
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plasmid. This work allows us to better understand the interaction of plasmid factor(s) with 
bacterial host background in determining the success of the plasmid. 
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